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The onset and progression of Alzheimer’s disease (AD) is characterised by 
increasing intracellular aggregation of hyperphosphorylated tau protein and the 
accumulation of amyloid beta (Aβ) in the neocortex. Despite recent success in 
identifying genetic risk factors for AD, the transcriptional and epigenomic 
mechanisms involved in disease progression are not fully understood. The main 
aim of this project was to evaluate transcriptional and epigenomic differences 
associated with the development of tau and amyloid pathology. To achieve this, 
I used transgenic mice harbouring human tau (rTg4510) and amyloid precursor 
protein (J20) mutations. I profiled transcriptional and epigenomic variation in 
brains from rTg4510 and J20 mice, collected at four time points carefully selected 
to span from early to late stages of neuropathology in each model. I identified 
robust gene expression and methylomic changes in both models, including genes 
associated with familial AD from genetic studies of human patients, and genes 
annotated to both common and rare variants identified in genome-wide 
association and exome-sequencing studies of late-onset sporadic AD. I 
quantified neuropathological burden across multiple brain regions in the same 
individual mice, identifying genomic changes paralleling the development of tau 
pathology in rTg4510 mice and amyloid pathology in J20 mice. Furthermore, I 
compared gene co-expression networks identified in my rTg4510 and J20 
samples to those identified in AD human brains, finding considerable overlap with 
disease-associated co-expression modules (or clusters of genes) identified in the 
human cortex. In summary, this project represents the most systematic analysis 
of transcriptional and methylomic variation in mouse models of tau and amyloid 
pathology, providing further support for an immune-response component in the 
accumulation of AD-associated neuropathology, and highlighting novel molecular 
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Chapter 1.  General Introduction 
 
This chapter represents a modified version of a soon-to-be published book 
chapter that I wrote during my PhD (Castanho and Lunnon, 2019). 
 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD), first described by the German psychiatrist Alois 
Alzheimer in 1898 (Alzheimer, 1898, Alzheimer, 1907), is the most common type 
of dementia. AD is characterised by memory loss, cognitive decline, behavioural 
changes and, ultimately, death (Blennow et al., 2006), which are consequences 
of progressive neurodegeneration and synaptic loss (Crews and Masliah, 2010, 
Selkoe, 2011). AD contributes significantly to the global burden of disease, 
affecting more than 850,000 people in the UK (Prince et al., 2014) and about 26 
million people worldwide (Prince et al., 2016). The high prevalence of AD is not 
only devastating for affected families, but also inflicts a high economic burden; 
the cost of caring for patients with AD was estimated to be £26.3 billion per year 
in 2014 in the United Kingdom alone (Prince et al., 2016, Prince et al., 2014). 
Although potentially promising new drugs are currently being tested in clinical 
trials, at present there are no available disease-modifying treatments, and 
existing medications only partially alleviate the symptoms of AD (Alzheimer's-
Association, 2018). 
People affected by AD display brain atrophy, restricted to cortical and limbic 
regions, accompanied by enlargement of the ventricles, reflecting differential 
neurodegeneration and presence of neuropathology; some regions of the brain 
are particularly affected by AD pathology, while other regions are relatively 
resistant (Blennow et al., 2006) (Figure 1.1). The hippocampus and the 
entorhinal cortex, for example, both involved in memory formation and recall, are 
particularly affected from the earliest stages of disease; in contrast, the 
cerebellum is relatively spared from pathology even in advanced AD (Serrano-
Pozo et al., 2011). Other characteristic features of AD include the activation of 




Figure 1.1 – Pathological hallmarks of Alzheimer’s disease. 
On a microscopic level, Alzheimer’s disease (AD) is characterised by the presence of extracellular amyloid beta (Aβ) plaques and intracellular 
neurofibrillary tangles (NFTs). On a macroscopic level the brain of an individual with AD is characterised by extensive brain atrophy across limbic and 
cortical regions, and ventricular enlargement. Figure from Castanho and Lunnon (2019).
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AD neuropathology is believed to start decades before the actual manifestation 
of clinical symptoms (Rajan et al., 2015), and is characterised by two key 
histopathological hallmarks: extracellular amyloid beta (Aβ) plaques, and 
intracellular neurofibrillary tangles (NFTs) (O'Brien and Wong, 2011, Wang and 
Mandelkow, 2016). Amyloid plaques are aggregates of Aβ peptides that result 
from the amyloidogenic cleavage of amyloid precursor protein (APP) (Figure 
1.1), a transmembrane protein highly expressed in the brain and involved in 
neurite outgrowth and synapse formation (O'Brien and Wong, 2011). APP is a 
single-pass transmembrane protein, with a large extracellular domain, and is 
metabolised in a rapid and highly complex fashion by a series of sequential 
proteases. The sequential cleavage of APP occurs by two pathways: 1) 
nonamyloidogenic, and 2) amyloidogenic. The amyloidogenic processing of APP 
involves β-secretase (or BACE1), followed by the γ-secretase complex, and 
results in the production of Aβ (Figure 1.1). NFTs are deposits of 
hyperphosphorylated and aggregated microtubule associated protein tau (MAPT) 
(Figure 1.1), a crucial protein for microtubule assembly and stabilization with 
important functions in neurons (e.g. axonal growth and transport). Aggregation of 
hyperphosphorylated tau into NFTs characterises a wide range of 
neurodegenerative diseases known as tauopathies, including AD. The longest 
tau isoform (2N4R) contains 85 potential phosphorylation sites (80 Ser or Thr, 
and 5 Tyr); in AD and other tauopathies 17 Thr-Pro or Ser-Pro motifs are targeted 
by several signal-transducing proline-directed serine/threonine kinases, and are 
abnormally hyperphosphorylated, with the phosphorylation sites of tau clustering 
in the flanking regions. Other phosphorylation sites in or near the repeat domain 
can be phosphorylated by alternative kinases (e.g. microtubule affinity-regulating 
kinases (MARKs; also known as PAR1 kinases), cyclic AMP-dependent protein 
kinase (PKA) and Ca2+- or calmodulin-dependent protein kinase II (CaMKII)). 
Tau can also be phosphorylated by tyrosine kinases such as lymphocyte-specific 
protein tyrosine kinase (Lck), spleen tyrosine kinase (Syk) and tyrosine-protein 
kinase Fyn (Fyn) (SRC family members) at Tyr18, and by Abelson-related gene 
enzyme (Arg, also known as ABL2) and Abelson murine leukemia viral oncogene 
homolog 1 (ABL1) (ABL family members) at Tyr394 (Wang and Mandelkow, 
2016). 
As neuropathology precedes clinical symptoms, AD can only be clinically 
diagnosed relatively late in the disease process, with a definitive diagnosis only 
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being possible post-mortem (Blennow et al., 2006). According to the microscopic 
presence of the aforementioned neuropathological hallmarks, AD can be 
categorised into different stages. Considering the spread of NFTs, AD can be 
classified into six groups known as Braak stages (Braak et al., 2006, Braak and 
Braak, 1991): tau pathology starts in the transentorhinal and entorhinal regions 
(Braak I and II), extending progressively to the limbic system (e.g. hippocampus) 
and adjoining neocortex (Braak III and IV), before later spreading to other 
neocortical regions (Braak V and VI) (Jouanne et al., 2017, Murphy, 2019) 
(Figure 1.2a). Similarly, according to the progressive deposition of Aβ, AD can 
also be categorised into five groups known as Thal stages (Thal et al., 2002): β-
amyloidosis spreads from the neocortex (Thal I), progresses into allocortical 
regions such as the entorhinal area, hippocampus, and striatum (Thal II and III), 
until it reaches subcortical structures, the brain stem and finally the cerebellum 







Figure 1.2 – Spatial-temporal progression of the pathological hallmarks of AD according to Braak and Thal. 
(a) Tau neurofibrillary tangles (NFTs) progression. (b) Amyloid (Aβ) progression. Figure and legend adapted from Jouanne et al. (2017). 
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1.2. Alzheimer’s disease: the genomic era 
AD can be divided into two subtypes: familial AD (FAD) and sporadic AD (SAD). 
FAD is usually early-onset (EOAD), generally occurring in individuals <65 years, 
while SAD is mainly late-onset (LOAD), affecting people >65 years (Figure 1.3). 
FAD accounts for less than 5% of disease incidence and is caused by one or 
more autosomal dominant mutations in the APP gene, or in the genes that 
encode for presenilin-1 or -2 (PSEN1 or PSEN2), which are components of the 
γ-secretase enzyme that is involved in the cleavage of APP (Guerreiro et al., 
2012). Although the role of genetic variation in SAD is less well-defined compared 
to FAD, it has been shown to be highly heritable, exemplified by the larger 
monozygotic twin concordance rate for the disease (probandwise concordance = 
~50%), compared to dizygotic twin concordance (probandwise concordance 
~30%) (Gatz et al., 2006, Plomin et al., 1994). 
 
To date, the most robust genetic risk factor identified for SAD is in the 
apolipoprotein E (APOE) gene, more specifically the presence of the ε4 allele 
(Corder et al., 1993, Strittmatter et al., 1993). However, many common, low 
penetrance genetic variants, and many rare but high penetrant genetic variants, 
have been shown to be involved in the disease, suggesting that SAD has a large 
polygenic component, where many variants influence disease. In addition to 
APOE, recent large genome-wide association studies (GWAS) and subsequent 
meta-analyses have identified numerous common single nucleotide 
polymorphisms (SNPs) that individually confer a relatively small risk for disease 
(Kunkle et al., 2019). Results from these studies have identified variants 
annotated to numerous genes, including clusterin (CLU), phosphatidylinositol 
binding clathrin assembly protein (PICALM), complement receptor 1 (CR1) 
(Carrasquillo et al., 2010, Corneveaux et al., 2010, Harold et al., 2009, Jun et al., 
2010, Lambert et al., 2009, Zhang et al., 2010), bridging integrator 1 (BIN1), 
cluster of differentiation 2-associated protein (CD2AP), cluster of differentiation 
33 (CD33), erythropoietin-producing hepatoma receptor A1 (EPHA1), and ATP-
binding cassette subfamily A member 7 (ABCA7), amongst others (Hollingworth 
et al., 2011, Lambert et al., 2013). With advances in genomic sequencing 
technology, researchers have also identified a number of rarer variants conferring 
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a moderate increase in disease risk, including variants annotated to the genes 
for triggering receptor expressed on myeloid cells 2 protein (TREM2) (Guerreiro 
et al., 2013, Jonsson et al., 2013, Sims et al., 2017), and phospholipase D3 
(PLD3) (Cruchaga et al., 2014). The variants identified from genetic studies 
suggest specific biological pathways are altered in AD, including synaptic 
pathways, immune regulation, cholesterol transport and lipid metabolism, 
endocytosis, ubiquitination, and protein folding (Smith et al., 2016a). Recently, 
three large studies (GWAS and meta-analyses) have provided further support for 
a role of the immune system and lipid metabolism in AD by confirming the 
association of previously identified loci with AD. More importantly, these reports 
collectively identified 15 novel loci, of which one, ADAM metallopeptidase domain 
10 (ADAM10), was common to all three studies (Jansen et al., 2019, Kunkle et 
al., 2019, Marioni et al., 2018). 
 
Of note, very few of the risk variants identified in GWAS of AD directly alter protein 
structure, with the majority residing in noncoding regions of the genome 
(Guerreiro et al., 2012); Kunkle et al., for example, reported only 2% of AD-
associated variants in their study to be located in exons, with the majority (58%) 
being located in introns (Kunkle et al., 2019). AD risk variants are predicted to 
influence gene regulation rather than directly affect the coding sequences of 
transcribed proteins, emphasising the importance of studying transcriptional 





Figure 1.3 – AD subtypes and their genetics. 
FAD accounts for <5% of AD cases and is caused by autosomal dominant mutations in the APP, PSEN1 or PSEN2 genes. SAD accounts for >95% 





Figure 1.4 – Different levels of gene regulation. 
From the set of genes present in an organism (genome) to the observable characteristics of an individual (phenotype), there are several levels of 
gene regulation, including the epigenome and transcriptome, which can also be influenced by factors in the environment. The epigenome 
corresponds to the set of chemical modifications and regulatory RNA molecules that can control gene activity. The transcriptome refers to all RNA 




1.3. Evidence for differential gene expression in the 
Alzheimer’s disease brain 
The transcriptome refers to the complete set of RNA transcripts expressed in a 
specific type of cell or tissue, at a given time. A number of studies have quantified 
patterns of gene expression in brain tissue identifying messenger RNA (mRNA) 
changes associated with AD pathological processes. The majority of these 
genome-wide gene expression studies have used microarrays to investigate 
gene expression alterations in AD (Blalock et al., 2004, Bossers et al., 2010, 
Emilsson et al., 2006, Hokama et al., 2014, Horesh et al., 2011, Katsel et al., 
2007, Miller et al., 2008, Miller et al., 2013, Tan et al., 2010, Xu et al., 2006, Youn 
et al., 2007, Zhang et al., 2013), and the results of these studies are summarised 
in Table 1.1. Of note, many of these studies are characterised by design 
limitations; they have often been performed on relatively small numbers of 
samples and there are a number of potential confounding effects in these 
analyses that make the results generally hard to interpret. More recently, the 
advent of highly-parallel RNA sequencing (RNA-seq) (Table 1.2) has enabled 
more systematic AD expression studies to be performed, profiling larger sample 
cohorts, and using more sophisticated bioinformatic approaches (Logsdon et al., 
2019, Mostafavi et al., 2018, Raj et al., 2018). One issue is that these analyses 
generally assess ‘bulk’ brain tissue comprising a mix of different cell-types; a few 
studies have used laser capture microdissection (LCM) to isolate and profile 
neurons or astrocytes from AD brain tissue (Dunckley et al., 2006, Liang et al., 





Table 1.1 – Gene expression studies in AD using array-based technologies. 
 
Reference Tissue Samples Method Key findings 




22 AD (varying severity) 
versus 9 controls 
Microarrays 
Altered biological processes included: 
• Up-regulation of genes involved in proliferation and differentiation, 
including tumour suppressors, oligodendrocyte growth factors, and 
protein kinase A modulators (correlated with incipient AD); 
• Up-regulation of adhesion, apoptosis, lipid metabolism, and initial 
inflammation processes; 
• Down-regulation of protein folding/metabolism/transport and some 
energy metabolism and signalling pathways. 




16 AD versus 4 controls 
 
5 AD APOE ε4/ε4 versus 5 
AD APOE ε3/ε3 
Microarrays 
AD versus controls 
• Genes with increased expression were associated with negative 
regulation of cell proliferation, signal transduction, stress response, 
regulation of transcription, regulation of cell cycle, modulation of the 
cytoskeleton, immune response, and iron ion homeostasis (e.g. 
NDUFC2, NDUFA1, COX6C, COX6B, COX7C, COX8, ATP5J2, 
ATP5L, ATP5H, ATP5A1, ATP5G2, ATP5B, MXI1, BS69, DUSP1, 
NSEP1, GNB1, EDG2, WASF3, SNX3, HSP90AA1, DNAJA1, 
DNAJB1, SOD3, PGF, GTF2I, RGC32, ACTR3, SPTBN1, MYO10); 
• Genes with reduction in expression were involved in mitochondrial 
function, cytoskeletal structure, synaptic plasticity, neuronal cell 
adhesion, neurogenesis, and vesicle neurotransmission (APOE, C3, 
TUBB2, TUBB4, TUBB5, TUBA1, TUBB, TUBA3, TUBA6, VAMP2, 
BIN1, NRGN, PLD3). 
AD APOE ε4/ε4 versus AD APOE ε3/ε3 
• Genes with increased expression were associated with cell growth 
suppression, signal transduction, myelinogenesis, cell adhesion and 
migration, heavy metal metabolism and detoxification (BIN1, 
RASSF2, FYN, ITPKB, S100A1, MYO10); 
• Genes with reduction in expression were involved in mitochondrial 







Frontal cortex 61 AD versus 53 controls 
Microarrays 
and RT-PCR 
Three genes showing large and consistent expression differences: ITPKB 
(increased), RAB3A (decreased), and RGS4 (decreased). 
Younet al. 
(2007) 
Hippocampus 19 AD versus 15 controls Microarrays 
Decreased expression of ITPKB and KALRN; increased expression of 
RGS4. 
No significant differences between AD and control specimens for 
cerebellum. 
Katsel et al. 
(2007) 
17 brain regions 
19 controls, 34 mild AD, 16 
moderate AD, 48 severe AD 
Microarrays 
Dysregulation of lipid metabolism, including expression changes of key 
enzymes involved in sphingolipid metabolism, particularly in temporal and 
frontal cortices. 









AD progression-associated gene modules related to mitochondrial 
metabolism (‘hub’ genes: VDAC1, VDAC3, ATP5F1), and synaptic 
processes (‘hub’ genes: WDR7, SYNJ1, STXBP1, SNAP91). 
Tan et al. 
(2010) 
Temporal cortex 
12 AD (Braak III/IV-V/VI) 




AQP1 as the transcript with the highest increase in expression by fold-
change; other gene expression changes included reduction in expression of 
RPH3A, NRN1, SV2A, SV2B, SYT11, SYT12, SYT13, suggestive of 




7 AD individuals for each 
Braak stage (6 Braak stages) 
versus 7 controls 
Microarrays 
Gene expression changes associated with AD progression (Braak staging), 
with the most significant changes identified between Braak stages II and III: 
• Increased expression of genes involved in the exocytosis of 
neurotransmitters, and potassium voltage-gated channels (SNAP25, 
CPLX1, VAMP7, SYT1, SYT3, SYT4, NAPB, SV2C, KCNS3, 
KCNB1, KCNA1 and KCNAB1); 
• Decreased expression of SYT6 in Braak stage II. 
In late Braak stages: 
• Increased expression of HSPA2, HSPB2, MT1B, and MT1G; 
• Reduction of expression of SST. 




55 AD, 28 schizophrenia, 22 
controls 
Microarrays 
Common transcriptomic changes in AD and schizophrenia, particularly in 
genes involved in regulation of autophagy (e.g. ULK2, ATG3) and inositol 








visual cortex, and 
cerebellum 
376 LOAD versus 173 






Constructed multi-tissue co-expression networks and compared gene 
connectivity, identifying an immune- and microglia-specific (with increased 
expression) as the top-ranked module: 
• TYROBP as key causal regulator; 
• Other genes exhibiting increased expression: CTSC, HCK, 
SERPINA1, S100A11, LY86, DOCK2, FCER1G. 




17 LOAD (moderate and 





AD progression-associated genes: 
• initial enrichment of increase in expression of genes in CA1 (over-
represented genes related to signal transduction, immune response, 
and cell motility); 
• initial enrichment of genes with decreased expression in CA3 
(overrepresented genes relevant for synaptic transmission, 
cytoskeletal protein binding, and cholesterol biosynthesis). 
More dramatic differences in CA1 than CA3. 
CA1-only gene expression changes: 
• genes with increased expression related to cell death and cell 
proliferation (top genes: S100A6, PFKFB3, SERPINA3); 
• genes with reduction in expression involved in synaptic transmission 
and cell-cell signalling processes (top genes: SEPT5, 5CS, WFDC1, 
KCNIP1). 
Co-expression network analysis identified a microglia-associated module 






26 AD (Braak I-VI) versus 62 
non-AD 
Microarrays 
Expression changes in genes: 
• Involved in noninsulin-dependent diabetes mellitus and obesity; 
• Previously associated with AD and other psychiatric disorders, both 
in AD brains and hippocampal samples from an AD mouse model 
(see Table 1.7). 
The most significant changes identified in the hippocampus: 
• Reduction in expression of transcripts associated with neuronal 
dysfunction (MET, PCSK1, PTPN3, SERPINF1, VEGFA, GABRA1, 
GABRA4, GABRA5, GABRG2, SYT4, SYT5, SYT7, STX1B, 
KCNJ6, RGS4, RGS7); 
• Increased expression: AEBP1, TXNIP, VCAM1, ANGPT1. 
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Table 1.2 – Gene expression studies in AD using RNA-seq. 
 
Reference Tissue Samples Method Key findings 
Magistri et al. 
(2015)  
Hippocampus 
4 LOAD (Braak V-VI) versus 
4 controls (Braak I-II) 
RNA-seq 
Reduction in expression of TAC1; increase in expression of SERPINE1. 
 
Pathway analysis: dysregulation in neural communication, cerebral 
vasculature, and Aβ clearance. 




268 AD,182 controls 
(total of 450 individuals from 
2 aging cohorts) 
RNA-seq 
Expression changes identified in: 
• Novel transcripts (e.g. AP2A1, AP2A2, FUS, MAP1B, TBC1D7); 






478 individuals from 2 
longitudinal cohorts 
(280 with pathological AD; 




Identified modules of co-expressed genes associated with both cognitive 
decline and AD neuropathology (amyloid pathology). 
 
The module (increased expression) most strongly associated was enriched 
for genes involved in regulation of the cell cycle and chromatin modification 





2114 samples across 7 brain 





Five consensus clusters consistent across studies, methods, and samples. 
AD genetic associations, previously studied AD-related biological 
processes: 
• AD targets under active investigation were enriched in only three of 
these five clusters; 
• The remaining two clusters demonstrated strong heterogeneity 





Table 1.3 – Gene expression studies in AD at the single cell level. 
 





19 AD, 14 controls 
 
AD neurons with NFT versus 
adjacent non-NFT-bearing 
neurons (from 19 AD) 
Microarrays 
225 differentially expressed genes exhibiting progressively increased or 
decreased expression from AD NFT neurons, AD non-NFT neurons, and 
controls. 
 
NFT-associated elevated gene expression levels included APOJ, TIMP3, 
and IRAK1. 




from multiple brain 
regions 
34 AD, 14 controls Microarrays 
Regional differential expression in AD compared to controls, including in 
genes previously implicated in AD: 
• Increased expression of ITPKB in neurons from the entorhinal 
cortex and reduction in expression of GSK3B in hippocampal 
neurons; 
• Decreased expression of MAPT in neurons from the entorhinal 






6 Braak 0–II, 6 Braak III–IV, 
6 Braak V–VI 
Microarrays 
Altered biological pathways in early versus late stages of AD: 
• Actin cytoskeleton, proliferation, apoptosis, and ubiquitin-mediated 
proteolysis dysfunction at Braak stages I–II; 
• Dysregulation of intracellular signalling pathways such PI3K/MAPK 
pathways associated with Braak stages V-VI; in individuals with 
APOE ε4 these pathways were already altered in Braak I–II. 










Changes in the expression of mitochondria-related genes (e.g. TRMT61B, 








6 AD, 6 controls RNA-seq 
Increased expression of ANK1 in AD microglia, but not in neurons or 




Taken together, the transcriptomic studies of AD performed to date nominate the 
dysregulation of genes involved in various pathways including synaptic and 
neural function, calcium signalling, neuroinflammation, lipid and cholesterol 
metabolism, and mitochondrial dysfunction. One issue with these studies is that 
they have largely focused on identifying differential gene expression but have 
largely ignored looking at different transcript variants, isoforms and alternative 
splicing; these analyses require ultra-deep sequencing and are unfeasible for 
large studies. In the future, it will be important to examine whether specific 
transcript variants are altered in AD, particularly since changes at the level of total 
gene expression do not always result into changes at the protein level. Some 
research has been conducted to assess this (Malik et al., 2013, Raj et al., 2018, 
Raj et al., 2014, Tollervey et al., 2011), including reported AD-associated splicing 
alterations in several genes, including CD33 (Malik et al., 2013, Raj et al., 2018, 




1.4. Alzheimer’s disease from an epigenetic perspective 
Despite the increased understanding of the role of genetic variation in AD, recent 
studies have highlighted that common variants only explain about 30% of disease 
incidence (Ridge et al., 2013), with much of the remaining heritability for disease 
still being unclear. A number of features of AD are suggestive of an epigenetic 
contribution to disease aetiology, for example monozygotic twin discordance 
(Mastroeni et al., 2009, Plomin et al., 1994) for both the development of disease 
(Gatz et al., 2006) as well as age of onset (Nee and Lippa, 1999). Aging, 
considered the greatest risk factor for AD, has been shown to be associated with 
significant epigenetic changes (Pal and Tyler, 2016, Sen et al., 2016), including 
in the APP and MAPT genes (Tohgi et al., 1999a, Tohgi et al., 1999b). 
Furthermore, many of the non-genetic risk factors identified for AD are related to 
lifestyle and/or the environment, including low education levels, hypertension, 
obesity, smoking, depression and/or stress, physical inactivity, social isolation, 
and diabetes (Alzheimer's-Association, 2018, Prince et al., 2016); of note, these 
exposures may influence gene regulation via so-called ‘epigenetic’ alterations 
(Figure 1.4). Taken together, it has been hypothesised that a combination of both 
genetic and epigenetic factors is likely involved in AD. 
Epigenetic processes that control gene regulation can be divided into three major 
categories: 1) DNA modifications, 2) histone modifications, and 3) RNA-based 
mechanisms (Figure 1.5), which together comprise the ‘epigenome’. Epigenetic 
mechanisms regulate gene activation/repression in a dynamic and reversible 
fashion, independently of genetic variation, and have been widely hypothesised 
to play a role in AD (Chouliaras et al., 2010, Lunnon and Mill, 2013, Mill, 2011). 
Because epigenetic changes are potentially reversible, targeting disease-
associated epigenetic changes makes them potentially attractive therapeutic 
options for the treatment of AD. Although, previous and ongoing studies in AD 
have investigated many types of epigenetic modifications in AD, most of the 
research has looked at DNA modifications (Section 1.4.1), which are one focus 







Figure 1.5 – Epigenetic processes hypothesised to play a role in AD. 
There are three broad categories of epigenetic processes influencing gene regulation: DNA modifications, histone modifications and RNA-based 
mechanisms. Figure from Castanho and Lunnon (2019). 
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1.4.1. DNA modifications 
Methylation of DNA at the 5th carbon of the cytosine nucleotide is the most‐
studied epigenetic modification, mainly due to its relative stability as an epigenetic 
modification and because numerous robust methods have been developed for its 
quantification across the genome. Accordingly, it has been the primary focus of 
most AD-related epigenetic studies to date (Smith and Lunnon, 2017). DNA 
methylation is established and maintained by DNA‐methyltransferases (DNMTs) 
resulting in the formation of 5-methylcytosine (5mC). It can be demethylated by 
oxidation into 5-hydroxymethylcytosine (5hmC), another DNA modification, via 
the action of the ten-eleven translocation (TET) family of enzymes (Yong et al., 
2016). 
 
1.4.1.1. Global DNA modification changes in AD 
Several early epigenetic studies of AD used immunoreactive approaches to 
evaluate ‘global’ variation in DNA methylation, with varying results. Some studies 
identified disease-associated hypomethylation, other studies reported 
hypermethylation, and others found no changes in AD samples (Bradley-
Whitman and Lovell, 2013, Chouliaras et al., 2013, Condliffe et al., 2014, 
Coppieters et al., 2014, Lashley et al., 2015, Mastroeni et al., 2010, Mastroeni et 
al., 2009) (Table 1.4). These discrepancies potentially reflect the fact that 
different studies explored distinct brain regions and/or different subtypes of AD, 
with a very limited number of samples being evaluated. It is important to note that 
these immunoassay approaches can only evaluate DNA modifications at a global 
level; as such, it provides they no insight into the exact biological pathways or 
specific loci that are epigenetically altered in disease. Furthermore, 
immunostaining-based methods are not very sensitive for the detection of DNA 





Table 1.4 – Global DNA modification studies in AD using immunostaining. 
 





1 pair of monozygotic twins, 
discordant for AD 
Hypomethylation (5mC) in the twin with AD. 
Mastroeni et 
al. (2010) 
Entorhinal cortex 20 AD, 20 controls 









7 late-stage AD, 5 preclinical 
AD, 5 controls 
Hypermethylation (5mC and 5hmC) in late-stage AD and preclinical AD 
compared to age-matched controls. 
Coppieters et 
al. (2014) 
Middle frontal gyrus 
and middle 
temporal gyrus 





13 AD, 8 controls 
Decreased 5hmC levels in AD compared to controls in both brain regions; 
however, no differences in 5mC detected. 
Lashley et al. 
(2015) 





1.4.1.2. Methylation changes in AD candidate genes 
A number of studies have investigated DNA methylation across regulatory 
regions associated with specific AD candidate genes. The first published study 
assessing epigenetic dysregulation in the context of AD used an enzymatic 
digestion followed by southern-blotting to evaluate DNA methylation at the APP 
gene (West et al., 1995). In this study, West et al. compared an AD patient to a 
non-demented subject, reporting absent DNA methylation at a site in the APP 
gene in the temporal lobe of the AD individual. A more recent candidate-based 
study used bisulfite-pyrosequencing to measure aberrant CpG DNA methylation 
in the APP, MAPT and glycogen synthase kinase 3 beta (GSK3B) genes in post-
mortem AD brain samples (Iwata et al., 2014). Interestingly, in their report, Iwata 
et al. suggest that the hypermethylation and hypomethylation changes that they 
identified in APP and MAPT, respectively, were associated with increased 
expression of both genes. In another recent publication, gene specific DNA 
methylation in the vicinity of MAPT was evaluated by pyrosequencing in FAD 
brains from patients bearing a mutation in PSEN1 (which results in higher 
production and accumulation of Aβ), revealing no changes in DNA methylation in 
the visual cortex, but a significant decrease in methylation levels in the 
cerebellum of AD patients compared to age-matched controls (Coupland et al., 
2015). One study used real-time polymerase chain reaction (RT-PCR) to 
measure gene-specific changes in DNA methylation in post-mortem frontal cortex 
of AD patients when compared to age-matched controls (Rao et al., 2012). The 
authors assessed the methylation status of the promoter regions for a number of 
genes, reporting hypomethylation of cyclooxygenase-2 (PTGS2) and nuclear 
transcription factor kappa B (NF-kB), and hypermethylation of brain-derived 
neurotrophic factor (BDNF), transcription factor cAMP response element-binding 
protein (CREB) and synaptic protein synaptophysin (SYP) in AD. 
 
DNA methylation changes in transposable elements (repetitive elements) such 
as Alu sequences and long interspersed nuclear elements (LINEs) have also 
been suggested to be altered in AD (Bollati et al., 2011). However, studies 
exploring this relationship are very limited and further investigations are 
necessary, particularly in brain tissue.  
56 
 
1.4.1.3. Genome-wide DNA methylation studies in AD 
The first study to take a more systematic genome-wide approach used the 
Illumina 27K methylation array to assess DNA methylation at >27,000 CpG sites 
in the prefrontal cortex of LOAD patients compared to control individuals 
(Bakulski et al., 2012). The promoter region of transmembrane protein 59 
(TMEM59) was the CpG site most strongly associated with AD status, and gene 
ontology analysis suggested hypermethylation of genes related to transcription 
and DNA replication, with hypomethylation in regions annotated to membrane 
transporters. The authors also reported hypomethylation in one site of the PSEN1 
gene in AD cases compared to controls. 
The successor to the 27K array, the Illumina 450K methylation array, has more 
recently been used to assess DNA methylation at >485,000 CpG sites. Two 
independent epigenome-wide association studies (EWAS) were published 
together in 2014 and used this method to compare DNA methylation profiles in 
post-mortem brain samples from AD cases and low pathology controls (De Jager 
et al., 2014, Lunnon et al., 2014). Both studies highlighted neuropathology-
associated differential methylation in ankyrin 1 (ANK1), ribosomal protein L1 
(RPL13), rhomboid 5 homolog 2 (RHBDF2) and cadherin-related family member 
23 (CDH23) (Lord and Cruchaga, 2014). Disease-associated ANK1 
hypermethylation was observed in cortical samples from four independent study 
cohorts, and interestingly brain regions most affected in the disease (e.g. the 
entorhinal cortex, superior temporal gyrus and frontal cortex) showed robust 
differences, whilst the cerebellum and pre-mortem blood showed no alterations 
in ANK1 methylation (Lunnon et al., 2014). The study by de Jager and colleagues 
also highlighted two additional genes, ABCA7 and BIN1 that overlapped with 
previous genetic studies (De Jager et al., 2014). A follow up study assessing 
levels of DNA methylation in known AD risk genes within this data-set highlighted 
neuropathology-associated differential DNA methylation in sortilin-related 
receptor 1 (SORL1), ABCA7, major histocompatibility complex class II DR beta 5 
(HLA-DRB5), solute carrier family 24 member 4 (SLC24A4) and BIN1 (Yu et al., 
2015). Another follow-up study, using the Lunnon et al. (2014) data-set, 
highlighted AD-associated hypermethylation at a CpG site within the TREM2 
gene in the superior temporal gyrus, which was validated in two other cohorts 
(Smith et al., 2016b). More recently, other AD EWAS have been published; 
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Watson et al. (2016) identified 479 AD-associated differential methylated regions 
(DMRs) in the superior temporal gyrus, the majority of which were 
hypermethylated in AD cases compared to non-demented controls and enriched 
for brain-specific histone signatures and for binding motifs of transcription factors, 
finding a significant correlation between their data-set and the Lunnon et al. 
(2014) data-set (Watson et al., 2016), whilst Smith et al. (2018) highlighted AD-
associated hypermethylation within the homeobox A (HOXA) gene cluster in the 
frontal cortex and superior temporal gyrus, which spanned 48kb (Smith et al., 
2018). A recent study found that ANK1 DNA methylation changes in the 
entorhinal cortex are specific to certain neurodegenerative diseases, with 
hypermethylation observed in AD, Huntington’s disease (HD) and to a lesser 
extent Parkinson’s disease (PD). Interestingly, in individuals with vascular 
dementia (VaD) or dementia with Lewy bodies (DLB), disease-associated 
hypermethylation was only observed in individuals with co-existing AD pathology 
(Smith et al., 2019). Another recent study using fluorescence-activated cell 
sorting (FACS) investigated AD-associated DNA methylation changes in sorted 
neuronal and non-neuronal (glial) nuclei from post-mortem human occipital cortex 
samples, in addition to “bulk” tissue from the frontal and temporal cortex 
(Gasparoni et al., 2018). Gasparoni et al. provided evidence that sorting cells 
improves the detection of AD-associated DNA methylation changes and reported 
cell-type-specific DNA methylation signatures associated with Braak stage, 
including loci annotated to MCF.2 cell line derived transforming sequence like 
(MCF2L), ANK1, microtubule associated protein 2 (MAP2), volume-regulated 
anion channel subunit LRRC8B (LRRC8B), serine/threonine-protein kinase 32C 
(STK32C) and S100B. A meta-analysis combining the data of significant cell 
sorted differentially methylated regions from neuronal and glial populations 
identified Braak stage-associated changes in known AD genes including APP, 
HOXA3 and ADAM17 (Gasparoni et al., 2018). Notably, the study also validated 
DNA methylation changes previously identified in AD EWAS in genes such as 




1.4.1.4. DNA hydroxymethylation 
Recent studies have also started to profile site-specific variation in 5hmC in AD; 
of note, this modification has been shown to be enriched in the brain, particularly 
in synaptic genes (Khare et al., 2012), is found at different levels across different 
brain regions (Lunnon et al., 2016), and is altered during brain development 
(Spiers et al., 2017). To date, only one study has quantified DNA 
hydroxymethylation at the genome-wide level in AD brains (Zhao et al., 2017). 
This study used a biotin tag capturing method followed by high-throughput 
sequencing and reported both hyperhydroxymethylation and 
hypohydroxymethylation changes in the dorsolateral prefrontal cortex from 
patients with a high burden of AD pathology compared to individuals with low AD 
neuropathology. The study nominated ~300 loci at which variable 5hmC was 
associated with high amyloid burden, 50 loci that were associated with high tau 
neuropathology, and four genes that were associated with both amyloid and tau 
pathology: 4-aminobutyrate aminotransferase (ABAT), calcium/calmodulin 
dependent protein kinase (CAMK1D), high-temperature requirement factor A3 
(HTRA3), and leucine rich repeat neuronal 1 (LRRN1). Using network analyses 
to explore co-hydroxymethylation patterns, the authors identified dysregulation of 
modules containing genes involved in ion channel activity, neuron differentiation 
and development, neurotransmitter transport, glutamatergic synapse, and 
calcium ion-dependent exocytosis of neurotransmitter. Of note, the authors 
highlight that the low resolution of the sequencing used in their study means they 
might not have been able to fully discriminate 5hmC from 5mC (Zhao et al., 2017). 
As such, additional studies using other methodological approaches are hotly 




1.5. Modelling Alzheimer’s disease: mouse models as 
powerful tools 
Despite highlighting pathways potentially involved in the pathogenesis of AD, 
molecular epidemiological studies using human post-mortem tissue are 
potentially confounded by many secondary factors associated with the disease 
itself (including environmental exposures, medication effects, diet, potential 
stressors, and reverse causation); it may therefore be difficult to conclude much 
about underlying causal processes in disease pathology (Mill and Heijmans, 
2013). 
The use of mouse models over the last few decades has enabled researchers to 
better comprehend diseases at a molecular level, identifying important pathways 
affected by and/or involved in pathology, establishing and validating biomarkers, 
and identifying novel therapeutic targets (Gotz and Ittner, 2008, Sasaguri et al., 
2017, Gotz et al., 2018). Other key advantages of using mouse models include 
the tight control of potentially confounding factors (e.g. differential exposure to 
environmental factors, reverse causation, and genetic differences), easy access 
to specific regions of the brain, and the ability to investigate changes at multiple 
stages / across development (e.g. through the development of brain pathology). 
Age-related disorders, such as AD, for which disease-associated changes can 
take decades to manifest in humans, rarely occur spontaneously in animals used 
for research, mainly because their lifespan may not be long enough to observe 
them. Therefore, the most used animal models are genetically engineered mice 
that recapitulate many aspects of human diseases. Animal models in general, 
and mouse models in particular, represent valuable tools for probing the 
pathogenic mechanisms involved in a wide range of diseases, but especially 




1.5.1. Currently available AD mouse models 
A diverse range of mouse models have been used to study aspects of AD 
pathology. Most currently used mouse models (Figure 1.6) overexpress human 
APP, either alone (e.g. Tg2576, J20) or in conjunction with presenilin (PSEN) 
overexpression (e.g. APP/PSEN1, 5xFAD), bearing mutations identified in FAD 
(Table 1.5). These mice show some of the characteristics of AD, particularly the 
formation of Aβ plaques. 
 
Table 1.5 – Examples of AD mouse models overexpressing human APP. 
 
Mouse model Mutation(s) Reference(s) 








Borchelt et al. (1996) 







Oakley et al. (2006) 
 
A number of tau mouse models are also available (Figure 1.6), overexpressing 
human MAPT (e.g. hTau.P301S, rTg4510) and bearing mutations identified in 
people with familial frontotemporal dementia (FTD) (Table 1.6). These mice 
recapitulate NFT neuropathology. 
 
Table 1.6 – Examples of AD mouse models overexpressing human tau. 
 
Mouse model Mutation(s) Reference(s) 
hTau.P301S MAPT P301S Allen et al. (2002) 
rTg4510 MAPT P301L 
Santacruz et al. (2005) 
(Ramsden et al., 2005) 
 
Finally, mice that develop plaques and tangles due to overexpressing mutated 
APP, PSEN and MAPT (e.g. the 3xTg-AD mouse model with APP KM670/671NL, 
MAPT P301L, and PSEN1 M146V) (Oddo et al., 2003) are also widely used as 






Figure 1.6 – Most common AD mouse models. 
Most widely used AD mouse models either express 1) mutant human APP alone (examples: Tg2576, J20, APP knock-in mice) or 2) in conjunction 
with mutated PSEN (examples: APP/PSEN1, 5xFAD); 3) mutated human MAPT that codes for tau (examples: hTau.P301S, rTg4510); and 4) 




The insertion of the transgenes in these models has been shown to disrupt 
several endogenous mouse genes (Goodwin et al., 2017, Tosh et al., 2017). More 
recently, APP knock-in lines, such as the AppNL-G-F/NL-G-F (APP KM670/671NL, 
APP I716F, APP E693G) and AppNL-F/NL-F (APP KM670/671NL, APP I716F) 
mouse models (Saito et al., 2014, Sasaguri et al., 2017), have been developed, 
which are characterised by Aβ accumulation without some of the additional 
effects observed in first-generation APP over-expression models. 
It is important to note that the validity and credibility of different mouse models of 
AD sparks robust debate. Although no model fully recapitulates the pathology 
and symptoms of human AD and their pathology is driven by the introduction of 
human mutations identified in familial forms of AD or FTD, there are specific 
advantages and disadvantages to the various genetic models that are currently 
available. Despite the inherent limitations in many of the models, studying mouse 
models can still provide a means to understanding processes mediating the early 
changes and progression of AD pathology. Furthermore, the use of laboratory 
animals is highly regulated, including the control of their environment and the 
general conditions they are exposed to, allowing the exclusion of potential 
confounders common in human research. 
 
In my research for this thesis, I have used the rTg4510 and J20 mouse models, 
to specifically profile progressive changes in gene regulation associated with the 
development of either tau (rTg4510) or amyloid (J20) pathology. More details 





1.5.1.1. Modelling tau neuropathology: the rTg4510 mouse model 
rTg4510 mice (Ramsden et al., 2005, Santacruz et al., 2005) overexpress a 
human mutant (P301L) form of tau identified in familial FTD, under the calcium-
calmodulin-dependent kinase II (Camk2a) promoter, with transgene expression 
being largely restricted to the forebrain by the Camk2a promoter. Of note, the 
transgene also contains exons 2-3 of the mouse prion protein gene (Prnp) 
untranslated sequence. These mice develop age-dependent tauopathy, 
neurofibrillary tangle formation and associated neuron loss in the forebrain, as 
well as cognitive, behavioural and electrophysiological deficits (Blackmore et al., 
2017, Booth et al., 2016, Ramsden et al., 2005, Santacruz et al., 2005) (Figure 
1.7). Sex differences in the manifestation of these phenotypes have been 
reported, with females being affected earlier and more aggressively than males 
(Blackmore et al., 2017, Yue et al., 2011). 
 
 
Figure 1.7 – Phenotype characterisation of rTg4510 mice. 
Figure taken from Alzforum (www.alzforum.org; accessed 7th March 2019). LTP – long-




rTg4510 mice were originally described as developing pretangles around 2.5 
months of age, with neurofibrillary tangle pathology starting in the neocortex and 
progressing rapidly into the hippocampus and limbic structures with increasing 
age (Ramsden et al., 2005, Santacruz et al., 2005), a profile which has been 
replicated in more recent studies (Sahara et al., 2014). The spread of 
neuropathology in this mouse model recapitulates the Braak stages in human AD 
brains, classified according to the spread of NFTs (Braak et al., 2006, Braak and 
Braak, 1991) (see Figure 1.2). 
The “r” in rTg4510 refers to “regulatable”, as these mice result from crossing the 
4510 ‘responder’ line (carrying human MAPT P301L cDNA downstream of a 
tetracycline operon–responsive element), with an ‘activator’ line (expressing a 
tetracycline-controlled transactivator (tTA) under control of the Camk2a 
promoter) (see Chapter 2, Table 2.1). Bi-transgenic progeny (rTg4510 
carrier/carrier or CC, as homozygous mice are not viable) express human tau 
constitutively, which can be inactivated by administration of doxycycline, 
providing an option for temporal control of mutant tau transgene expression. 
Several studies have shown that neuronal death and cognitive decline can be 
stopped and even reversed following transgene suppression with doxycycline 
(Blackmore et al., 2017, Santacruz et al., 2005, Spires et al., 2006). 
Of note, the genome integration sites for both the Camk2a-tTA and MAPT 
transgenes have been shown to disrupt endogenous mouse genes, resulting in 





1.5.1.2. Modelling amyloid neuropathology: the J20 mouse model 
J20 mice overexpress a mutant form of the human amyloid precursor protein 
(hAPP) with two mutations identified in FAD – the Swedish (K670N/M671L) and 
Indiana (V717F) mutations – under control of the platelet-derived growth factor 
subunit B (PDGFB) promoter. These mice are characterised by progressive 
amyloid deposition in the forebrain, abnormal neuronal morphology and function, 
as well as cognitive deficits (Mucke et al., 2000, Palop et al., 2007). Specifically, 
progressive deposition of amyloid plaques in J20 mice has been described to 
occur in the hippocampus and neocortex at 5-7 months of age, with all transgenic 
mice exhibiting plaques by 8-10 months of age (Harris et al., 2010, Mucke et al., 
2000), resembling amyloid deposition in individuals with AD (Thal et al., 2002) 
(see Figure 1.2). Neuronal loss has been reported in J20 transgenic mice in the 
CA1 region of the hippocampus at 12, 24, and 36 weeks of age, with no neuronal 
loss observed in the CA3 region up to 36 weeks of age (Wright et al., 2013). The 
transgene integration site in the J20 model has been shown to disrupt the mouse 
Zbtb20 gene, affecting its expression in young J20 transgenic mice, with no 





Figure 1.8 – Phenotype characterisation of J20 mice. 
Figure taken from Alzforum (www.alzforum.org; accessed 7th March 2019). EPSP – 




1.5.2. Genomic alterations in mouse models of AD 
Even with the development of validated animal models of AD and the widespread 
utility of model organisms as a valuable tool for understanding the molecular 
processes involved in disease progression (Gotz and Ittner, 2008, Sasaguri et 
al., 2017), limited work has been undertaken to assess regulatory genomic 
changes associated with neuropathology in non-human models of AD. 
 
1.5.2.1. Transcriptomic studies in AD mouse models 
Recent studies have identified widespread gene expression differences in 
transgenic mice harbouring a diverse range of AD-associated mutations (Table 
1.7 and Table 1.8). Many of these studies have assessed individual brain regions 
from a single mouse model, with most analyses performed on relatively small 
numbers of animals. Furthermore, the vast majority of these studies have not 
directly related transcriptional alterations to the progressive burden of pathology 
in the same mice, and only limited attempts to relate observed variation to human 
AD data have been undertaken. 
Similarly to AD studies in human (see Section 1.3), initial gene expression 
studies in AD mouse models used microarray-based approaches (Table 1.7). 
One study in particular found that the progression of Aβ plaques in amyloid 
transgenic mice was associated with immune gene expression, and that the 
presence of neurofibrillary tangles was negatively correlated with the expression 
of synaptic genes, in cortical and hippocampal samples, with larger differences 
identified in the hippocampus (Matarin et al., 2015). In a follow-up study, Salih et 
al. (Salih et al., 2018) used RNA-seq to reanalyse these hippocampal mouse 
samples, reporting similar results to their previous study, particularly for genes 




Table 1.7 – Gene expression studies in bulk brain tissue from AD mouse models using microarray-based methods. 
 
Reference Model(s) Tissue Age(s) Key findings 
Hokama et 
al. (2014) 
3xTg-AD Hippocampus 14 months 
Significant expression alterations in genes involved in noninsulin-
dependent diabetes mellitus and obesity in both AD brains (see Table 1.1) 
and 3xTg-AD samples: 
• Transcripts with decreased expression included Srd5a1, Mlh1, 
Cdkn1b, Pcsk1, Camk2d, Cplx3, Vgf, Chrna4, Pygb, Pik3cg, and 
Pla2g16; 
• Transcripts with increased expression included Cst7, Ide, 
Apobec3b, Ldlr, and Il18bp. 





1, 4, 6 and 9 months 
Shift in gene expression patterns between 1 and 4 months of age. 
 
Region-specific variation in gene expression at 1 month (with 
hippocampus showing many more changes), but a large proportion of 
common gene expression changes in both brain regions in all other age 
stages (4, 6 and 9 months), after onset of plaque deposition. 
 
Common transcripts with increased expression in the two brain regions 
(e.g. Clec7a, Cst7, Itgax (or Cd11c)), were predominantly involved in 
inflammatory and immune processes, complement, major 
histocompatibility complexes, and toll-like receptors, and were suggestive 
of microglial activation. 
 
Other transcripts showing increased expression included Igf1, Osmr and 
Grn/Pgrn, suggestive of dysregulation of insulin signalling pathways. 





1.9, 4.7, to 6.1 months 
Used Camk2a-tTA transgenic mice instead of double negative wildtype 
mice as controls. Identified age-dependent (1.9, 4.7, to 6.1 months) 
changes in the expression of transcripts such as C4b, Gfap, Trem2, and 
Tyrobp, as well as Itgax and Cd68, further suggesting Tyrobp and Cd68 


















2, 4, 8 and 18 months 
Gene expression differences associated with amyloid and tau pathology, 
with larger effects identified in APP/PSEN1 mouse samples: 
• Changes of immune-related genes positively corelated with 
amyloid plaques; 
• The presence of neurofibrillary tangles was negatively correlated 
with the expression of synaptic genes. 





Cortex 12 months 
Expression changes in neuroinflammatory genes in cortex tissue from 12 
months-old mice highly correlated with amyloidosis, with higher changes 
in AppNL-G-F/NL-G-F compared to 3xTg mice. 
 
Transcripts with increased expression in AppNL-G-F/NL-G-F compared to 
control non-transgenic mice included C4a/C4b, Cd74, Ctss, Gfap, Nfe2l2, 
Phyhd1, S100b, Tf, Tgfbr2, Vim, Apoe, Abi3, and Cd33, Bin2, Ctsc, 
Dock2, Fcer1g, Frmd6, Hck, Inpp5D, Ly86, Plcg2, Trem2, and Tyrobp. 
 
Only Trem2 showed increased expression in both models, and Frmd6 






Table 1.8 – Gene expression changes in bulk brain tissue from AD mouse models using RNA-seq. 
 
Reference Model(s) Tissue Age(s) Key findings 
Lee et al. 
(2018) 
5xFAD/TREM2 5xFAD 2, 4, and 7 months 
Partial rescue of cortical transcriptional dysregulation with increased 
TREM2 gene dosage. 









Hippocampus 2, 4, 8 and 18 months 
A microglia-associated expression module was correlated with amyloid 
pathology and contained the mouse orthologs of AD-relevant 
previously identified loci, particularly from GWAs studies, such as 
Trem2, Spi1, Ms4a6d, Abi3, and Cd33, as well as Tyrobp, identified in 
gene expression studies in the human AD brain. Other transcripts that 
have been previously associated with amyloid pathology, such as 







3, 6, 9, 12, 15 months 
 
TgCRND8: 
1.5, 3, 4.5, 6, 10 months 
Age-dependent transcriptional changes when comparing transgenic 
male mice to wildtype age-matched littermate controls. Larger changes 
were found in TgCRND8 mice: 
• Increase in expression of Trem2, Tyrobp, Cd68, Clec7a, Tspo, 
Itgfax, and C4b. 
In laser captured plaque-enriched regions versus non-plaque regions 
from 6-months-old TgCRND8 mice the majority of transcriptional 
changes identified were enriched within plaques. 





brain stem, and 
cerebellum 
3 and 6 months 
Expression changes of the top genes with increased expression in the 
cerebellum had an opposite profile in the cortex. Using co-expression 
analysis, two modules were found to be correlated highly with 
phosphorylated tau in MAPT P301S mice: 
• One module, showind decreased expression at 6 months in all 
brain regions except the cerebellum, was enriched for synaptic 
pathways; 
• One module, with increased expression at 6 months in all brain 
regions except the cerebellum, was enriched for immune and 
inflammatory categories; 





At the single cell level, Keren-Shaul et al. (2017) identified a specific subset of 
microglia in 5xFAD transgenic individuals that was absent in wildtype animals, 
which they called disease-associated microglia (DAM). DAM were characterised 
by reduction in expression of microglia homeostatic genes (e.g. P2ry12/P2ry13, 
Cx3cr1, Tmem119) and increased expression of Apoe, Cst7, cathepsin D (Ctsd), 
lipoprotein lipase (Lpl), Tyrobp, and Trem2. Gene ontology analysis of DAM-
specific genes revealed a significant involvement of transcripts associated with 
lysosomal/phagocytic pathways, endocytosis, and regulation of the immune 
response. The authors further report that these DAM surround plaques and 
require TREM2 in order to be activated. Additional analysis by Keren-Shaul et al. 
identified DAM in a mouse model of amyotrophic lateral sclerosis (SOD1-G93A 
mice) (Keren-Shaul et al., 2017), and a similar microglia cell state was identified 
in a different mouse model of neurodegeneration (CK-p25 mice) at later stages 
of disease progression in another study (Mathys et al., 2017), with expression 
profiles of these late-response microglia characterised by increased expression 
of common genes to DAM described by Keren-Shaul et al. (e.g. Itgax, Clec7a, 
Ctsd, Cd63, Lpl, Cst7, Apoe). Together, the results from these two studies 
suggest that microglia expressing a core set of genes may respond to various 
causes of brain homeostasis disruption. In addition, a study looking at microglia 
isolated from the forebrain of rTg4510 mice reported temporal transcriptomic 
alterations in microglia from transgenic mice compared to controls (2, 4, 6, and 8 
months), including an increase in the expression of genes involved in innate 
immunity and a reduction in the expression of genes involved in the glutamatergic 




1.5.2.2. Epigenetic studies in AD mouse models 
Despite their widespread utility, limited work has been undertaken to assess 
epigenomic changes in AD-relevant mouse models. Most studies carried out to 
date have focused either on global levels of epigenetic modifications, particularly 
histone modifications, or at a small number of loci (Francis et al., 2009, Gstir et 
al., 2014, Marques et al., 2012, Sanchez-Mut et al., 2013, Walker et al., 2013, 
Zhang et al., 2014). 
 
Very few studies assessing DNA modifications in AD mouse models have been 
performed to date (Table 1.9). The first studies used genome-wide DNA 
methylation arrays (Cong et al., 2014, Sanchez-Mut et al., 2013), and two 
subsequent studies have assessed global methylation using 
immunohistochemistry (Cadena-del-Castillo et al., 2014, Lardenoije et al., 2018). 
Interestingly, hypomethylation of the Mapt promoter has been reported in 5-
month-old J20 transgenic mice, which display little or no plaque pathology at this 
time point (see Section 1.5.1.2), compared to controls (Coupland et al., 2014). 
All these studies have profiled a very low number of mice (1-5 animals per group), 
and it is currently difficult to make any firm conclusions about changes in DNA 




Table 1.9 – Studies of DNA modifications in AD mouse models. 
 
Reference Model(s) Tissue Method Key findings 
Sanchez-Mut 








mouse brain DNA 
methylation array 
(covering 384 genes), 
and pyrosequencing 
Hypermethylation of promoter CpG sites annotated to Tbxa2r, F2rl2, 
Sorbs3, and Sptbn4 in APP/PSEN1 transgenic mice compared to controls. 
This was related to increased promoter hypermethylation for TBXA2R, 
SORBS3 and SPTBN4 in AD human samples. 








Hypermethylation in 485 genes, with several differentially methylated 
genes from the same gene family (e.g. olfactory receptor (OLFR), solute 
carrier, interleukin, keratin, cytochrome P450, and nuclear receptor family 
members). Top hypermethylated genes included Serpinb10, Tgfb1, 








Lower DNA methylation in J20 transgenic mice compared to controls in 
the Mapt promoter. 
Cadena-del-
Castillo et al. 
(2014) 
3xTg-AD mice 




Increase in global 5hmC levels in the cortex of transgenic mice compared 





(5, 14, 17, 27 months) 
 
J20 
(4, 8, 16, 34 months) 
 
APP/PSEN1 
(6, 16, 17, 18, 34, 27 months) 
 Immunohistochemistry 
Age-associated increase in global 5mC in the DG and CA1-2 hippocampal 
sub-regions in 3xTg-AD mice (from 5 to 25 months old), with no 
differences in global 5hmC identified in this mouse model. Age-related 
decrease in 5mC in the DG, a decrease in the ratio of 5mC and 5hmC in 
the DG and CA3, and a negative correlation between plaque load and 
5mC in the DG, in J20 transgenic mice compared to controls. No 





1.6. Aims and objectives 
Considering the literature described in the previous sections, the overall 
hypothesis to be tested in my PhD was that the accumulation of tau and amyloid 
pathology in the brain is associated with progressive transcriptomic and 
epigenomic dysregulation in the entorhinal cortex. My goal was to describe 
transcriptional mechanisms involved in i) the accumulation of tau and amyloid, ii)  
managing the neuroinflammatory response to this pathology, as well as iii) the 
biological consequences of these toxic protein species. Using two well-
characterised rodent models of AD neuropathology, the rTg4510 (Section 
1.5.1.1) and J20 (Section 1.5.1.2) mouse lines, the aim of this project was to 
evaluate transcriptional and epigenomic consequences of progressive tau or 
amyloid pathology. 
 
The main objectives of my PhD project were: 
1) to characterise the neuropathological burden of tau and amyloid mice 
(Chapter 3); 
2) to identify changes in gene transcription associated with the 
progression of tau or amyloid pathology, integrating these changes 
with neuropathological information from the same mice (Chapter 4); 
3) to identify global changes in DNA modifications associated with the 
progression of tau or amyloid pathology (Chapter 5); 
4) to identify site-specific variation in DNA methylation associated with tau 
or amyloid pathology (Chapter 6). 
 
The overall study design for my thesis is shown in Figure 1.9, and the approach 
used to achieve my proposed objectives, including the methods used across this 





Figure 1.9 – Study design. 
(a) To investigate genomic signatures of tau pathology, I used the rTg4510 model, which overexpresses a human mutant (P301L) form of the 
microtubule-associated protein tau (MAPT). To investigate amyloid pathology, I used the J20 mouse line, which expresses a mutant (K670N/M671L 
and V717F) form of the human amyloid precursor protein (APP). Tissue was collected from transgenic (TG) and wildtype (WT) control mice at four 
time points. (b) From each mouse, the entorhinal cortex (ECX, dark green) and hippocampus (HIP, orange) were dissected from the left hemisphere 






Figure 1.10 – Approach. 
Levels of investigation, including genomic interrogation, and the methods used to profile them. 
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1.7. Originality and contribution of my PhD 
Our group and others have previously identified differences at the transcriptomic 
and epigenomic level in human post-mortem tissue from AD brains (see Section 
1.3 and Section 1.4). As discussed above (Section 1.5), despite highlighting 
pathways potentially involved in disease pathogenesis, studies using human 
post-mortem tissue are confounded by many secondary factors; the use of animal 
models can therefore play a major role in understanding the processes mediating 
the initial stages and progression of disease. Nonetheless, limited work has been 
undertaken to assess regulatory genomic changes associated with 
neuropathology in AD-relevant animal models (see Section 1.5.2). My PhD 
builds up on the literature described in the previous sections and develops our 
understanding about the brain response to the production of toxic protein species 
– Aβ or tau – and the gradual deposition of plaques or tangles, respectively. It 
provides information about the biological systems involved in fighting the 
accumulation of plaques and tangles (including microgliosis and 
neuroinflammatory responses in general, astrocytosis, autophagy, and lipid 
metabolism pathways), as well as the biological consequences of toxic protein 
species (neurotoxicity and apoptosis, for example) in the mouse brain. 
Additionally, using systems-level analyses, loci characterised by transcriptomic 
changes associated with the progression of amyloid and/or tau pathology have 
been subsequently explored in human brain data generated from ongoing studies 
of AD patients and matched controls. 
 
To my knowledge, this project represents the most systematic analysis of 
transcriptional and methylomic variation in mouse models of tau and amyloid 
pathology and is the first to specifically focus on changes in the entorhinal cortex, 
a key region of the brain implicated early in the pathogenesis of AD (see Section 
1.1). Compared to previous studies of transcriptional variation in transgenic 
mouse models of AD (see Section 1.5.2), I profiled a relatively large number of 
samples spanning multiple time-points selected to encompass the development 
of pathology; this study was therefore well powered to identify gene expression 
differences associated with both genotype and the progression of AD pathology. 
My detailed immunohistochemical analyses also allowed me to directly compare 
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transcriptional variation with measures of tau and amyloid pathology from the 




Chapter 2.  General Methods 
This chapter contains general methods used for the experiments and results 
described in multiple chapters (Chapters 3-6). Specific experimental procedures 
relevant to individual results chapters are described in detail in the methods 
section of each chapter. 
 
2.1. Animal models 
2.1.1. Brief overview 
Numerous mouse models of AD pathology have been described (see Section 
1.5 in Chapter 1 for an overview). To investigate changes in transcriptomic and 
epigenomic regulation associated with tau or amyloid pathology, in this thesis I 
used the rTg4510 (rTg(tet-o-TauP301L)4510) and J20 (B6.Cg-
Zbtb20Tg(PDGFB-APPSwInd)20Lms/2Mmjax) mouse models, respectively. 
rTg4510 mice overexpress a pathogenic human mutant form (TauP301L, with 
absence of an N-terminal segment, 4R0N) of the microtubule-associated protein 
tau (MAPT) under the Camk2a promoter. Transgene expression is highest in the 
forebrain, with mice characterised by an age-dependent formation of 
neurofibrillary tangles (Ramsden et al., 2005, Santacruz et al., 2005) (see 
Section 1.5.1.1). The J20 mouse line expresses a mutant form (with the Swedish 
K670N/M671L and Indiana V717F mutations) of the human amyloid precursor 
protein (APP) under the platelet-derived growth factor beta (PDGFB) promoter. 
These animals have an age-dependent distribution of amyloid pathology, which 
is highest in the hippocampus and neocortex (Harris et al., 2010, Mucke et al., 
2000) (see Section 1.5.1.2). Littermate female mice were used in this study 
(initial n = 9-10 animals per group). 
 
2.1.2. Breeding strategies 
All animal procedures were carried out at Eli Lilly where I did an industrial 
placement (~3.5 months) during my PhD (from May 2017 to August 2017), in 
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accordance with the UK Animals (Scientific Procedures) Act 1986 and with 
approval of the local Animal Welfare and Ethical Review Board. 
rTg4510 mice, licensed from the Mayo Clinic (Jacksonville, FL, United States), 
were bred on a mixed 129S6/SvEvTac + FVB/NCrl background (heterozygous 
tau responder x heterozygous tTA effector). Six breeding colonies are required 
to produce rTg4510 transgenic (bigenic) mice in addition to the stock colony: two 
parental inbred background lines (Background Line 1: 129S6/SvEvTac from 
Taconic, and Background Line 2: FVB/NCrl from Charles River); two transgenic 
parental lines (Parental line 1: Responder line tau P301L on a FVB/NCrl 
background, and Parental line 2: tTA Effector line Camk2a-tTa (Tetr transgenic 
carrier) on a 129S6/SvEvTac background); two heterozygous (HET) transgenic 
lines (offspring from Parental line 1: HET Tau Responder line (these mice express 
low levels of human tau), and offspring from Parental line 2: HET tTA Effector line 
(these animals only express tTa)) – Table 2.1. 
 

































































J20 mice, licensed from Gladstone Institute (San Francisco, California, United 
States), with founder mice purchased from MMRRC at The Jackson Laboratory 
(Bar Harbor, Maine, United States), were bred on a C57BL/6JOlaHsd 
background (parental generation: hemizygous male x C57BL/6J wild type 
female). Hemizygous (here identified as TG) females and littermate controls 
(WT), 6, 8, 10 and 12 months of age (n = 9-10 animals per group), were used for 
this study. 
All mice were bred and delivered to Eli Lilly and Company (Windlesham, UK) by 
Envigo (Loughborough, UK). 
 
2.1.3. Housing conditions 
At Eli Lilly, animals were housed under standard conditions (constant 
temperature and humidity) with a 12h light/dark cycle in individually ventilated 
cages (up to 5 animals per cage), with free access to food (Teklad irradiated 
global rodent diet (Envigo, United Kingdom)) and water. 
 
2.2. Genotyping 
To confirm identity and validate transgene status, all mice were genotyped 
following instructions from original suppliers. Briefly, genomic DNA was extracted 
from tail tip or ear biopsy using DNAeasy Tissue Kit (Qiagen) and subsequently 
genotyped by Envigo (Loughborough, UK). Genotyping of rTg4510 mice was 
achieved using two polymerase chain reaction (PCR) experiments to genotype 
the tau transgene (primers for Human Tau Exon 1, Human Tau Exon 5, and 
Mouse T-cell receptor as internal control), and Camk2a-tTA (primers for Camk2a-
tTa and T cell receptor delta chain as internal control), following instructions from 
the Mayo Clinic (Jacksonville, FL, USA). Genotyping of J20 mice was performed 
using PCR (with primers for the transgene and internal positive control) and 
quantitative PCR (qPCR) to distinguish hemizygous from homozygous transgenic 
animals, following instructions from the Jackson Laboratory (Bar Harbor, Maine, 
United States). Ear biopsy samples from mice that exhibited unexpected 
pathology (or unexpected lack of pathology) in my immunohistochemistry 
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analyses (see Chapter 3) were sent to Envigo to be re-genotyped; mice with 
genotype discrepancies were removed from further analyses. 
 
2.3. Study design and sample collection 
A more detailed overview of the study design (briefly described in Section 1.6 of 
Chapter 1) is shown in Figure 2.1. 
For the rTg4510 model, samples from bi-transgenic (CC, here referred as TG) 
female mice and littermate controls (WW, here identified as WT), 2, 4, 6 and 8 
months old (n = 9-10 animals per group), were collected –Figure 2.1a (blue). For 
J20 mice, samples from hemizygou (here identified as TG) females and littermate 
controls (WT), 6, 8, 10 and 12 months of age (n = 9-10 animals per group), were 
collected (Figure 2.1a (red)). 
Mice were terminally anaesthetised with pentobarbital (intraperitoneal injection) 
and transcardially perfused with phosphate-buffered saline (PBS). 
The whole brain was collected, weighed, and the two brain hemispheres were 
separated and processed as described below. 
 
2.4. Sample processing 
2.4.1. Left brain hemisphere 
The entorhinal cortex (ECX) and hippocampus (HIP) were dissected from the left-
brain hemisphere on wet ice as described by Heffner et al. (1980) (Figure 2.1b 
left). Dissected regions were snap-frozen, and transferred to Exeter on dry ice for 
subsequent nucleic acid extractions and downstream genomic assessments 





2.4.2. Right brain hemisphere 
The right hemisphere was immersed in 10% buffered formalin for fixation (7-8 
days) and processed for subsequent immunohistochemistry (Chapter 3 and 
Chapter 4) assessments (Figure 2.1b right). 
 
 
Figure 2.1 – An overview of the experimental design. 
(a) To investigate genomic signatures of tau pathology I used the rTg4510 model, and 
to investigate amyloid pathology I used the J20 mouse line. Tissue was collected from 
transgenic (TG) and wildtype (WT) control mice at four time points. (b) From each 
mouse, the entorhinal cortex (ECX, dark green) and hippocampus (HIP, orange) were 
dissected from the left hemisphere and used for RNA and DNA isolation. The right 





2.5. Nucleic acid isolation 
2.5.1. Selection of the optimal method for DNA and RNA 
isolation from mouse brain 
Given the limited amount of brain tissue available from each animal, and the 
desire to isolate both DNA and RNA from the same tissue sample, I compared 
several extraction protocols using ‘test’ samples (hippocampus) from control mice 
(Table 2.2). 
The optimal yield and quality for both DNA and RNA (see Section 2.5.3) were 
obtained using the AllPrep DNA/RNA Mini Kit (Qiagen) (highlighted in green in 
Table 2.2, Figure 2.5, Figure 2.9 and Figure 2.10), therefore the elected method 
for extraction of DNA and RNA from rTg4510 and J20 brain samples used in this 
study.  
 
2.5.2. Isolation of DNA and RNA from mouse brain samples 
Samples were labelled with anonymised ID codes and processed in batches, 
blinding me to genotype and age for individual samples. Tissue samples from 
each mouse model were processed separately and individual samples were 
randomised to ensure that each group was equally represented in each 
processing batch. 
Total genomic DNA and RNA from all samples was isolated from the entorhinal 
cortex (Chapter 4 and Chapter 6) and hippocampus (Chapter 5) in a laminar 
flow hood (class II), using the AllPrep DNA/RNA Mini Kit (Qiagen) with minor 
modifications to the original protocol. An overview of the major steps for the 
AllPrep DNA/RNA Mini Kit can be seen in Figure 2.2 and a more detailed 
description is provided in the following subsections. 
All reagents were provided with the kit unless otherwise stated, with all reagents 
and consumables used being sterile and DNase and RNase free. 
Before starting, every surface and all equipment were thoroughly cleaned using 
70% ethanol followed by RNaseZap (Thermo Fisher Scientific), and 100% 
ethanol (molecular biology grade, Sigma-Aldrich) was added to the RPE and 





Figure 2.2 – Overview of the experimental procedures for isolation of total RNA 
and genomic DNA using the AllPrep DNA/RNA Mini Kit. 




2.5.2.1. Tissue disruption and homogenization 
Briefly, I added 350 µL of lysis buffer (prepared fresh by adding β-
mercaptoethanol (Sigma-Aldrich) in a concentration of 1 µL of β-mercaptoethanol 
to 1 mL of buffer RLT Plus) to each tissue sample (up to 30 mg), disrupted the 
tissue using a DNAse free sterile plastic pestle and homogeniser, and further 
homogenised the lysate using a P1000 pipette. The lysate was centrifuged (3 
minutes at 16,000 x g) and the supernatant carefully removed and transferred to 
an AllPrep DNA spin column. 
 
2.5.2.2. Isolation of RNA 
The AllPrep DNA spin column (in a collection tube) was centrifuged (30 seconds 
at 10,000 x g), and the flow-through was used for RNA purification whilst the 
AllPrep DNA spin column was put aside for DNA isolation (Section 2.5.2.3). 
The flow-through was mixed with freshly prepared 70% ethanol (in a 1:1 ratio) 
and transferred it to the RNeasy spin column which was then centrifuged (15 
seconds at 10,000 x g) and the flow-through discarded. The RNA in the column 
was then washed with Buffer RW1 (350 µL) and centrifuged (15 seconds at 
10,000 x g), treated with DNase (80 µL for 15 minutes, Qiagen), washed with 
RW1 and centrifuged again (15 seconds at 10,000 x g), washed with Buffer RPE 
(500 µL) twice and centrifuged (15 seconds at 10,000 x g for the first wash, and 
2 minutes at 10,000 x g for the second wash). 
Finally, the RNeasy spin column was transferred into a new tube and centrifuged 
(1 minute at 16,000 x g), before being transferred to a collection tube and eluted 
in RNase-free water (50 µL) and centrifuged (1 minute at 10,000 x g). 
 
2.5.2.3. Isolation of genomic DNA 
The DNA spin column was kept at room temperature during RNA purification 
(Section 2.5.2.2). 
I added buffer AW1 (500 µL) to the AllPrep DNA spin column and centrifuged (30 
seconds at 10,000 x g), followed by the addition of buffer AW2 (500 µL) and 
centrifugation (2 minutes at 16,000 x g). 
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I then carefully placed the column into a new tube (making sure not to transfer 
any AW2 buffer) and eluted the DNA in buffer EB (50 µL) provided in the kit, 
incubated at room temperature for 1 minute, and centrifuged (1 minute at 10,000 
x g), repeating this process again (total volume of 100 µL). 
 
2.5.2.4. Storage of isolated samples 
Aliquots of eluted RNA were stored at -20ºC for short-term use (e.g. RIN score 
assessment described in Section 2.5.3.3., and RNA-seq experiments described 
in Chapter 4), with the remainder being transferred to -80ºC for long-term 
storage. Genomic DNA was stored at -20ºC. 
 
2.5.3. Assessment of quality and quantity of isolated nucleic 
acids 
2.5.3.1. Nanodrop 
Following extraction from brain tissue, DNA and RNA samples were quantified 
and checked for purity using a NanoDrop 8000 spectrophotometer (Thermo 
Scientific). 2µL of a ‘blank’ solution (elution buffer for DNA and RNase-free water 
for RNA) and 2µL from each DNA/RNA sample were used. 
Nucleic acids absorb UV light at a wavelength of 260nm, whereas proteins absorb 
UV light at a wavelength of 280nm and other compounds, such as 
ethylenediamine tetraacetic acid (EDTA), carbohydrates and phenol, absorb UV 
light at a wavelength of ~230nm. Therefore, the absorbency ratios of 260/280 and 
260/280 indicate the presence of protein and other contaminants in the DNA and 
RNA samples. A 260/280 ratio of ~1.8 (for DNA) and ~2.0 (for RNA), and a 
260/230 ratio between 1.8 and 2.2 is generally accepted as indicative of pure 
samples (Matlock, 2015). A typical pure nucleic acid nanodrop profile is shown in 
Figure 2.3. I initially obtained a suboptimal 260/230 ratio for the DNA testing 
samples (Table 2.2), suggestive of presence of contaminants that absorb at 230 
nm; however when I processed the samples used for this thesis I was careful in 
the final steps of the experimental procedure not to contaminate the samples with 
reagents containing phenol (from previous steps) which resulted in greatly 
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improved 260/230 ratios (~1.8) (example shown in Figure 2.4a). Representative 
DNA and RNA spectrographs from one of the mouse brain samples used in this 




Figure 2.3 – Typical nucleic acid spectrum. 






Table 2.2 – Description and Nanodrop results obtained for all methods tested for the isolation of DNA and RNA from test mouse brain 
samples. 
 









260/280 260/230 260/280 260/230 
AllPrep DNA/RNA Mini Kit 
(Qiagen) 
LH3 (Lilly) 19.1 mg 4.3 µg 1.96 0.69 5.8 µg 2.10 1.82 
LH4 (Lilly) 19.6 mg 4.8 µg 1.92 0.55 1.3 µg 1.99 0.32 
RNA/DNA/Protein Purification Plus kit 
(Norgen) 
LH1 (Lilly) 19.7 mg 1.4 µg 1.99 0.56 17.0 µg 2.12 1.96 
RH1 (Lilly) 16.7 mg 1.2 µg 1.84 0.58 16.1 µg 2.11 1.96 
Quick RNA MiniPrep 
(Zymo Research) 
RH5 (Lilly) 13.3 mg 1.6 µg 1.83 0.14 0.5 µg 1.45 0.65 
Manual extraction with TRIzol 
(Ambion) 
LH2 (Lilly) 14.4 mg 0.8 µg 0.91 0.29 8.1 µg 1.87 0.44 
LH5 (Lilly) ~7.8 mg 0.7 µg 0.81 0.18 6.0 µg 1.86 0.31 
Direct-zol RNA MiniPrep 
(Zymo Research) 
RH2 (Lilly) 18.6 mg - - - 6.7 µg 2.02 2.16 
RH3 (Lilly) 23.6 mg - - - 6.2 µg 2.00 2.17 






Figure 2.4 – UV spectrographs from one representative sample used in this study. 
(a) DNA spectrum (concentration: 57.71ng/µL; 260/280 ratio: 1.86; 260/230 ratio: 1.81). 




2.5.3.2 Agarose gel electrophoresis 
The integrity of high molecular weight DNA was further evaluated by running the 
testing samples through a 1% agarose gel by electrophoresis (Figure 2.5). To 
test smaller fragments (e.g. restriction digests, such as described in Section 
5.2.3.2 in Chapter 5) a lower concentration (0.8%) gel was used. This method 
relies on the separation of DNA fragments based on their charge and size by 
running the DNA through a three-dimensional agarose matrix. The DNA moves 
due to an electrical charge that forces the negatively charged DNA to migrate 
towards the positive end of the system. Because different sized molecules move at 
different speeds within the agarose matrix pores, with smaller molecules moving 
faster, fragmented DNA can be easily identified. Good quality genomic DNA is 
expected to produce a single band that should not move quickly due to its high 
molecular weight. The DNA is then viewed using compounds that intercalate into the 
DNA structure, allowing it to be visualised under UV light (e.g. ethidium bromide and 
Syto 60). 
Briefly, 2g of agarose powder (Sigma) was added to 200mL 1x tris-borate EDTA 
(TBE) buffer (prepared from 10x TBE buffer (Fisher Scientific)) in an Erlenmeyer 
flask. The mixture was heated in a microwave with frequent agitation until 
complete dissolution of the agarose and cooled under raining tap water. 1µL of 
ethidium bromide (Sigma-Aldrich) was added to the cooled agarose solution 
which was then mixed well by agitation, poured into a gel electrophoresis tray 
and left to solidify for about 30 minutes. During this time, 10µL of each extracted 
DNA sample was mixed with 2µL of loading buffer (Orange G, Sigma-Aldrich) in 
a 0.2 mL tube (PCR strips). The set gel was submerged in 1X TBE solution in an 
electrophoresis tank and 6µL of each sample-loading buffer solution was loaded 
into an individual well in the agarose gel. A molecular-weight size marker (1kb 
DNA ladder, New England BioLabs) was added to the first well for approximating 
the mass of DNA in comparably intense samples of similar size. The gel was left 




Figure 2.5 – Agarose gel to asses quality of DNA isolated from the test samples 
described in Table 2.2. 
Colours match Table 2.2. High molecular weight genomic DNA was obtained for each 
method that was tested. 
 
 
2.5.3.3. Calculating RNA integrity number (RIN) 
The purity and integrity of RNA isolated from the test samples (Table 2.2) was 
further assessed using an Agilent 2100 Bioanalyzer Instrument (Agilent 
Technologies) in conjunction with the Agilent RNA 6000 Nano Kit (Agilent 
Technologies). This system uses a fluorescent dye that binds to RNA on a gel 
electrophoresis chip. The Agilent Bioanalyzer Software analyses the resulting 
electrophoretic separation (Figure 2.6 and Figure 2.7) and calculates an RNA 
integrity number (RIN), that can range between 1 (suggesting that the RNA is 





Figure 2.6 – A total RNA sample was degraded for varying times and the resulting 
samples were analysed on the Agilent 2100 Bioanalyzer System using the 
Eukaryote Total RNA Nano assay. 
A shift towards shorter fragment sizes can be observed with progressing degradation. 




Figure 2.7 – Electropherogram (Bioanalyzer) detailing the regions that are 
indicative of RNA quality. 






Figure 2.8 – Examples of Bioanalyzer electropherograms from samples ranging 
from intact (RIN = 10) to very degraded (RIN = 2) RNA. 
Figure and legend adapted from Mueller et al. (2016). 
 
Following the Agilent RNA 6000 Nano Assay Protocol from the Agilent RNA 6000 
Nano Kit Guide (Agilent Technologies), I set up the chip priming station and the 
bioanalyzer to make sure they were ready to use, decontaminated the electrodes 
with RNaseZAP (Invitrogen), prepared the gel, and prepared and loaded the gel-
dye mix. I then pipetted 5 μL of the RNA 6000 Nano marker into each well, 
followed by 1 μL of RNA ladder into its corresponding well and 1 μL of each 
sample into each of the remaining wells. The chip was then vortexed for 60 
seconds at 2400 rpm in an IKA vortex mixer, inserted in the Agilent 2100 
Bioanalyzer and left to run. 
The gel and the resulting electropherograms are shown in Figure 2.9 and Figure 
2.10, respectively, where it can be seen that the RNA isolated with the AllPrep 
DNA/RNA Mini Kit (Qiagen, in green in Figure 2.9 and Figure 2.10) and with the 
RNA/DNA/Protein Purification Plus kit (Norgen, in blue in Figure 2.9 and Figure 






Figure 2.9 – Bioanalyzer electrophoresis to assess integrity for RNA isolated from 
testing samples described in Table 2. 
Colours match Table 2.2. Results obtained using the Agilent RNA 6000 Nano Kit and 







Figure 2.10 – Bioanalyzer electropherograms to assess integrity for RNA isolated 
from test samples described in Table 2. 
Colours match Table 2.2 and sample numbers match Figure 2.9. Results obtained 




The purity and integrity of RNA for the samples used in this thesis (obtained from 
mouse entorhinal cortex and hippocampus) was further assessed using a 2200 
TapeStation System (Agilent Technologies), in conjunction with the RNA 
ScreenTape Assay (Agilent Technologies). Similarly to the Bioanalyzer, the 
TapeStation System uses a fluorescent dye that binds to RNA on a gel 
electrophoresis chip, carrying out electrophoretic separation of the RNA. Agilent 
2200 TapeStation Software also evaluates the resulting electrophoretic 
separation and calculates the RIN for each sample. 
 
An overview of the experimental procedures for this part is given in Figure 2.11. 
 
 
Figure 2.11 – Overview of the experimental procedures for checking RNA 
concentration and integrity using the RNA ScreenTape Assay and 2200 
TapeStation System. 
Figure taken from the Agilent 2200 TapeStation User Manual (Agilent, 2013). 
 
Briefly, following the manufacturer’s instructions, in a 95-well plate, I added 5µL 
of RNA Sample Buffer (provided with the kit) to 1µL of each sample or 1µL of 
RNA Ladder (provided with the kit), vortexed using IKA vortexer and adaptor at 
2000 rpm for 1 min and performed a spin down to bring the samples to the bottom 
of the wells. I then heated the samples at 72ºC for 3 min in a thermocycler, placed 
the samples on ice for 2 min, and centrifuged to bring the samples to the bottom 
of the wells again. 
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After preparing the 2200 TapeStation instrument, including placing the sample 
block and loading tips, I inserted the ScreenTape into the TapeStation, placed 
the samples into the sample block, and started the run. When the run was 
finished, I checked the RNA quantity and quality (integrity) for each sample in the 
TapeStation Software. 
Figure 2.12 shows two representative examples from the RNA samples isolated 
from mouse entorhinal cortex for the purpose of the work for this thesis. The RNA 
profiles for the vast majority of the samples isolated had a similar profile to the 
example shown in Figure 2.12a, which corresponds to a sample that was used 
for downstream analysis (Chapter 4), and represented very high-quality RNA. 
One sample, shown in Figure 2.12b, had low RNA quality (RIN = 3.9) and was 
therefore not used for further analysis. All RNA samples used in my thesis were 




Figure 2.12 – TapeStation gel electrophoresis and corresponding 
electropherograms from RNA isolated from two mouse entorhinal cortex samples. 
(a) Example of a good quality sample (RIN = 9.0). (b) Example of a bad quality sample 
(RIN =3.9). Results obtained with the RNA ScreenTape Assay and 2200 TapeStation 





Chapter 3.  Characterising the progression of 
neuropathology in transgenic mouse models 
of Alzheimer’s disease 
3.1. Introduction 
Transgenic mice expressing mutant human MAPT and APP (see Chapter 1, 
Section 1.5) are characterised by progressive neuropathology in the brain. 
Previous studies have shown that rTg4510 mice (see Section 1.5.1.1) develop 
pretangles around 2.5 months of age, with neurofibrillary tangle (NFT) pathology 
starting in the neocortex and progressing rapidly into the hippocampus and limbic 
structures with increasing age (Ramsden et al., 2005, Sahara et al., 2014, 
Santacruz et al., 2005). In J20 mice (see Section 1.5.1.2), progressive deposition 
of amyloid plaques in the hippocampus and neocortex at 5-7 months, and 
ubiquitous plaque pathology by 8-10 months of age, has been described (Harris 
et al., 2010, Mucke et al., 2000). 
 
Immunohistochemistry, the most common application of immunostaining, relies 
on the selective identification of antigens within tissue sections by means of 
specific antibodies. Antigen-antibody binding is then visualised using a coloured 
histochemical reaction, visible by light microscopy (Ramos-Vara and Miller, 
2014). 
 
This chapter describes my use of immunohistochemistry to quantify the 
progression of neuropathology across multiple regions of the mouse brain 
(Figure 3.3 and Figure 3.4) using right hemisphere tissue sections from 
transgenic (TG) and wild-type (WT) littermate control mice (see Chapter 2). 
These experiments complement the genomic (gene expression and DNA 
methylation) analyses undertaken on the left hemisphere of the same brain 
samples (see Chapter 4, Chapter 5 and Chapter 6). All experiments for this 
chapter were performed in the Molecular Pathology laboratories at Eli Lilly & Co. 
Ltd. (Windlesham, United Kingdom), where I spent ~3.5 months during my PhD 
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(from May 2017 to August 2017). I prepared the sections with the help of Mark 
Ward (Eli Lilly). Mark Ward and Katherine Sung (Eli Lilly) assisted me with the 
immunostaining for tau and amyloid pathology, respectively. Katherine Sung, 
Josh Harvey, and Alice Fisher (Eli Lilly) provided me with training and assistance 
for the visualisation and quantification of immunostaining. Experiments were 
performed in a blinded and randomised fashion to avoid any biases in 
quantification and analysis. 
 
3.2. Methods 
In this section the specific experimental procedures used for the evaluation of tau 
and amyloid neuropathology in brain sections (described in Chapter 2, section 
2.4.) from rTg4510 and J20 mice (Chapter 2, section 2.1.) using 
immunohistochemistry are described in detail. A general overview of the 
immunohistochemistry procedures is given in Figure 3.1.  
 
3.2.1. Tissue preparation 
As described in Section 2.2 (Chapter 2), following the sacrifice of rTg4510 and 
J20 mice, the right brain hemispheres were immediately immersed in 10% 
buffered formalin for fixation (for 7-8 days) (Table 2.1b right, and Figure 3.1 in 
light green). Samples were subsequently processed using the Tissue TEK® VIP 
processor (GMI Inc), embedded in paraffin wax and stored for sectioning. 
Next, 6 μm serial sagittal mouse brain sections were prepared (from lateral 0.84 
to 1.08 mm from bregma – Figure 3.2) using rotary microtomes (HM 200 from 
Ergostar and HM 355S from Thermo Scientific). Sections were subsequently 
mounted on glass slides (two sections per slide) for immunohistochemistry 
assessments. These procedures were performed during my placement at Eli Lilly 






Figure 3.1 – An overview of the experimental steps used for the assessment of tau and amyloid pathology in brain sections from rTg4510 





Figure 3.2 – Sagittal sections from paraffin embedded mouse brain right 
hemispheres were prepared from 0.84 to 1.08 mm from bregma. 
Figures taken from Paxinos and Franklin (2001). 
 
3.2.2. Deparaffinisation 
Deparaffinisation of the brain sections was achieved using xylene (Fisher 
Scientific), followed by 70% ethanol (industrial methylated spirit, Fisher Scientific) 





3.2.3.1. Antigen retrieval and blocking 
Heat induced antigen retrieval was performed in an antigen retrieval device (PT 
Module, Thermo Scientific) containing citrate buffer (dilution 1:100). Samples 
were blocked using normal goat serum (Vector labs, catalogue number S-1000). 
3.2.3.2. Antigen-antibody labelling 
To assess tau pathology, we used mouse monoclonal PG-5 (provided by Peter 
Davies from Albert Einstein College of Medicine, Bronx, NY, USA) (Jicha et al., 
1999) as the primary antibody (diluted 1:8000), which recognises tau 
phosphorylated at Ser409 (p-tau). We used biotinylated goat anti-mouse IgG 
(Vector labs, catalog number BA-9200, lot number 2B0324) as the secondary 
antibody (diluted 1:200), as previously described (Ahmed et al., 2014). A sample 
with known tau pathology was used as a positive control, and one slide containing 
no primary antibody and one slide containing no secondary antibody were 
included as negative controls.  
To assess amyloid pathology, we used mouse monoclonal biotinylated 3D6 
(b3D6, provided by Eli Lilly (Demattos et al., 2012), diluted 1:1000), which binds 
both soluble and insoluble Aβ1-42, specifically targeting the amino acids 1-5 in Aβ. 
A sample with known amyloid pathology was used as a positive control, and a 
slide containing no biotinylated antibody was included as a negative control. 
All samples for each mouse model (rTg4510: n = 80 samples; J20: n = 79 
samples) were immunostained (two sections in each glass slide) in a single batch 
in an autostainer (Autostainer 720 for PG-5 and 720N for b3D6, Thermo 
Scientific). 
3.2.3.3. Detection 
For the detection of antibody staining we undertook enzymatic labelling using 
peroxidase (Vectastain Elite ABC HRP Reagent, Vector Laboratories) and DAB 





Tissues were counterstained with haematoxylin to provide contrast and 
dehydrated with ethanol and xylene to prepare for mounting. 
 
3.2.4. Mounting and image capture 
Samples were mounted in an automated coverslipper (ClearVue Coverslipper 
from Thermo Scientific) using ClearVue mountant. Images were digitised with 
Scanscope AT slide scanner (Aperio) at 20x magnification, and saved in svs 
(ScanScope Virtual Slide) format on an Eli Lilly network server. Images were 
subsequently accessed using the eSlide Manager system (Aperio). 
 
3.2.5. Visualisation and quantification 
Visualisation of the digitised tissue sections stored in the network server and 
delineation of the anatomical regions of the brain of interest (or regions of interest 
(ROI)) was achieved using the software ImageScope (version 12.2.1.5005; 
Aperio). ROI were selected to reflect the known progression of amyloid and tau 
pathology in the two models and to overlap with previous and ongoing studies at 
Eli Lilly in the same mouse models. 
For rTg4510, the ROI delineated and quantified were whole hippocampus 
(subdivided into CA1, CA3 and dentate gyrus (DG)), whole cortex (subdivided 
into secondary motor cortex (M2), primary motor cortex (M1), visual cortex, and 
retrosplenial cortex), and thalamus, which is expected to exhibit much lower tau 
pathology that is confined to late stages (Figure 3.3). 
In the J20 mice, the ROI delineated and quantified were whole hippocampus, 
whole cortex (further subdivided into rostral cortex and caudal cortex), and 






Figure 3.3 – Anatomical regions of the brain examined in rTg4510 mice. 
Brain regions tested for tau pathology: whole hippocampus (purple line), CA1 sub-
region of the hippocampus (light green area within the purple line), CA3 sub-region of 
the hippocampus (brown area within the purple line), dentate gyrus (DG) sub-region of 
the hippocampus (light red area within the purple line), whole cortex (orange line), 
secondary motor cortex (M2, dark yellow area within the orange line), primary motor 
cortex (M1, magenta area within the orange line), visual cortex (dark green area within 
the orange line), retrosplenial cortex (dark blue are within the orange line), thalamus 





Figure 3.4 – Anatomical regions of the brain examined in J20 mice. 
Brain regions tested for amyloid pathology: whole hippocampus (purple area), whole 
cortex (orange line), rostral cortex (magenta area within the orange line), caudal cortex 
(green area within the orange line), thalamus (dark grey square). 
 
Positivity was quantified automatically using the Aperio Positive Pixel Count 
Algorithm (Aperio), applied to the images using ImageScope (Aperio). The 
algorithm quantifies the amount of a specific stain present in a scanned slide 
image, based on user specification of colour (across a range of hues and 
saturation). Specifically, the number and intensity of pixels that fall within the 
parameters are quantified, which can be classified into intensity ranges (weak, 
positive, and strong) as defined by the user. For pixels which satisfy the colour 
specification, the algorithm counts the number and intensity‐sum in each intensity 
range, along with three additional quantities: average intensity, ratio of 
strong/total number, and average intensity of weak and positive pixels. Pixels 
which are stained, but do not fall into the positive‐colour specification, are 
considered negative stained pixels and contribute to determine the fraction of 
positive to total stained pixels. The values for the algorithm input parameters 
(Table 3.1 and  
Table 3.2), calibrated to ignore non-specific staining, were based on optimisation 




Table 3.1 – Algorithm inputs for PG-5 (tau pathology). 
Version 9.1 
View Width (Pixels) 1000 
View Height (Pixels) 1000 
Overlap Size 0 
Image Zoom 1 
Classifier None 
Classifier Neighbourhood 0 
Pixel Area (mm2) 2.46E-07 
Hue Value (Centre) 0.1 
Hue Width 0.1 
Colour Saturation Threshold 0.3 
Intensity Threshold WEAK (Upper Limit) 255 
Intensity Threshold WEAK (Lower Limit) 175 
Intensity Threshold MEDIUM (Upper Limit) 175 
Intensity Threshold MEDIUM (Lower Limit) 100 
Intensity Threshold STRONG (Upper Limit) 100 
Intensity Threshold STRONG (Lower Limit) 0 
Intensity Threshold Negative Pixels -1 
 
Table 3.2 – Algorithm inputs for b3D6 (amyloid pathology). 
Version 9.1 
View Width (Pixels) 1000 
View Height (Pixels) 1000 
Overlap Size 0 
Image Zoom 1 
Classifier None 
Classifier Neighbourhood 0 
Pixel Area (mm2) 2.46E-07 
Hue Value (Centre) 0.1 
Hue Width 0.1 
Colour Saturation Threshold 0.3 
Intensity Threshold WEAK (Upper Limit) 240 
Intensity Threshold WEAK (Lower Limit) 175 
Intensity Threshold MEDIUM (Upper Limit) 175 
Intensity Threshold MEDIUM (Lower Limit) 100 
Intensity Threshold STRONG (Upper Limit) 100 
Intensity Threshold STRONG (Lower Limit) 0 




Hue Value is a metric of colour defined from 0-1 (e.g Blue=0.66). Hue Width is 
the range around the Hue Value which will also satisfy positive quantification. 
Colour Saturation Threshold is a metric of how much of the positive colour is 
present within the tested pixel; defined between 0-1, with 1 corresponding to 
100% saturation of the pixel with the positive colour. Pixels with saturation under 
the threshold are not counted as positive. All of the Intensity Threshold values 
are defined using the same units, which is a measurement of the brightness of 
the pixels using the formula R+G+B/3. It has a possible range of 0-255 where 
0=completely black and 255=bright white. All the other parameters relate to how 
the algorithm runs on the analysis server and less to what is quantified; these 
were kept as default. 
A representative image showing how the algorithm distinguished tau and amyloid 
pathology in my samples is shown in Figure 3.5 and Figure 3.6, respectively. 




Figure 3.5 – Representative immunohistochemistry images from the hippocampus 
(CA1 sub-region) of a rTg4510 transgenic mouse, showing how the positive pixel 





Figure 3.6 – Representative immunohistochemistry image from the hippocampus 
of a J20 transgenic mouse, showing how the positive pixel count algorithm 
recognised the positive stain for quantification of tau pathology. 
 
 
3.2.6. Statistical analysis 
Statistical analysis (two-way factorial ANOVA) was performed using Microsoft 
Excel 2013. The following statistical model was used: 
 
𝑃𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 =  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 +  𝐴𝑔𝑒 +  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝐴𝑔𝑒 
 





3.3.1. Tau pathology in rTg4510 mice 
In rTg4510 mice we measured levels of phosphorylated tau (p-tau, using the 
antibody PG-5) at ages 2, 4, 6 and 8 months comparing them to WT controls at 
the same ages (n = 7-10 animals per group, total n = 74). This paralleled the 
collection of genomic data (gene expression and DNA methylation) on the same 
animals. In Figure 3.7 representative pictures for one sample from each rTg4510 
group are shown, demonstrating the clear accumulation of tau pathology in the 
hippocampus and cortex of rTg4510 TG mice, with tau pathology absent in WT 
mice at the same ages. Images depicting the negative and positive controls 
included in the experiment (see Section 3.2.3.4) are also shown. Tau 
accumulation in the hippocampus of rTg4510 TG mice, specifically the CA1 
hippocampal sub-region, is shown in detail in Figure 3.8. Overall, I observed 
intracellular accumulation of phosphorylated tau in neurons at the initial stages 
(upper panel in Figure 3.8), and an overall distribution of increased levels of 
phosphorylated tau in affected brain tissues in later stages (bottom panel in 
Figure 3.8). Following the quantification of the images, we detected a dramatic 
accumulation of tau pathology in the hippocampus and each of the cortex regions 
tested from rTg4510 TG mice (Table 3.3 and Figure 3.9), reflecting findings from 
previous studies (Ramsden et al., 2005, Sahara et al., 2014, Santacruz et al., 
2005). We also quantified neuropathology in the thalamus (Figure 3.9k), which 
is relatively protected from aggressive tau pathology. As expected, this region 
showed negligible levels of tau pathology relative to the other brain regions 
tested; despite these low levels, we observed statistically significant increases in 
TG mice indicating that there is some accumulation of phosphorylated tau in this 




Table 3.3 – Statistical results (two-way ANOVA) for PG-5 quantification in tested 
brain regions from rTg4510 mice to assess progression of tau pathology. 





73 F(3,66) = 69.76 1.96E-20 
CA1 74 F(3,67) = 68.86 1.96E-20 
CA3 73 F(3,66) = 64.22 1.51E-19 
DG 73 F(3,66) = 67.42 4.58E-20 
Whole cortex 72 F(3,65) = 53.33 1.65E-17 
M2 74 F(3,67) = 44.90 5.01E-16 
M1 73 F(3,66) = 29.28 3.74E-12 
Visual cortex 73 F(3,66) = 55.22 5.64E-18 
Retrosplenial 
cortex 
73 F(3,66) = 38.38 1.79E-14 







Figure 3.7 – Representative immunohistochemistry images showing the dramatic accumulation of tau pathology in the hippocampus and cortex of 
rTg4510 mice. 
Sagittal sections showing the dramatic accumulation of tau pathology (PG-5) in the brains of rTg4510 transgenic (TG) mice (second row) compared to wild-
type control (WT) mice (top) at 2, 4, 6 and 8 months of age. Primary antibody: PG-5 (1:8000); secondary antibody: biotinylated goat anti-mouse (1:200). Black 






Figure 3.8 – Representative immunohistochemistry images showing the dramatic accumulation of tau pathology in the hippocampus (CA1) of 
rTg4510 transgenic mice. 




Figure 3.9 – Transgenic mice expressing mutant human MAPT exhibit progressive neuropathology across the hippocampus and cortex. 
Quantification of PG-5 immunoreactivity for each of the tested brain regions: (a) whole hippocampus, (b) CA1 (c) CA3, (d) DG, (e) whole cortex, (f) M2, (g) 
M1, (h) visual cortex, (i) retrosplenial cortex, (j) thalamus. Dashed lines represent mean paths of pathological burden across the four age groups. n = 7-10 
animals per group. 
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3.3.2. Amyloid pathology in J20 mice 
We quantified levels of amyloid (using the antibody b3D6) in J20 TG mice at ages 
6, 8, 10 and 12 months comparing them to WT controls at the same ages (n = 9-
10 animals per group, total n = 73). Figure 3.10 shows representative images for 
one sample from each J20 group, demonstrating the accumulation of amyloid 
pathology in the hippocampus and cortex of J20 TG mice, with no pathology in 
WT mice. Pictures of the negative and positive controls included in the 
experiment (see Section 3.2.3.4) are also shown. Amyloid accumulation in the 
hippocampus of J20 TG mice is shown in detail in Figure 3.11. 
Following quantification of the images, we identified dramatic increases in 
amyloid pathology in the hippocampus, with a highly significant accumulation of 
amyloid also observed in each of the cortical regions tested (Table 3.4 and 
Figure 3.12), reflecting the results from other studies of this model (Harris et al., 
2010). No amyloid pathology was detected in thalamus in either TG or WT mice. 
 
Table 3.4 – Statistical results (two-way ANOVA) for b3D6 quantification in tested 
brain regions from J20 mice to assess progression of amyloid pathology. 
 
Brain region N 
Genotype*Age 
F-value P-value 
Hippocampus 77 F(3,68) = 66.85 3.00E-20 
Whole cortex 73 F(3,66) = 24.75 7.63E-11 
Rostral cortex 73 F(3,66) = 10.63 8.65E-06 
Caudal cortex 74 F(3,67) = 28.62 5.02E-12 







Figure 3.10 – Representative immunohistochemistry images showing accumulation of amyloid pathology in the hippocampus and cortex of J20 TG 
mice. 
Sagittal sections showing the dramatic accumulation of amyloid pathology (b3D6) in the brains of a J20 transgenic (TG) mouse (bottom) compared to a wild-
type control (WT) mouse (top) at 6, 8, 10 and 12 months of age. Primary antibody: mouse monoclonal biotinylated 3D6 (1:1000); no secondary antibody. 






Figure 3.11 – Representative immunohistochemistry images showing accumulation of amyloid pathology in the hippocampus of J20 transgenic 
mice. 








Figure 3.12 – Transgenic mice expressing mutant human APP exhibit progressive neuropathology across the hippocampus and cortex. 
Quantification of b3D6 immunoreactivity for each of the tested brain regions: (a) hippocampus, (b) whole cortex, (c) rostral cortex, (d) caudal cortex, (e) 





In this Chapter, I identified progressive accumulation of tau and amyloid 
neuropathology in brain regions from transgenic mice overexpressing mutated 
human MAPT (rTg4510 mouse model) and human APP (J20 mouse model). 
I measured levels of phosphorylated tau (using the antibody PG-5) in rTg4510 
mice at 2, 4, 6 and 8 months, comparing them to WT controls at the same ages. 
I observed highly significant increases in phosphorylated tau in the hippocampus 
and cortex of rTg4510 TG mice (including in specific hippocampal sub-regions 
and each of the cortical regions that I quantified), reflecting data from several 
parallel cohorts of mice from our rTg4510 colony profiled in previous and ongoing 
studies at Eli Lilly using antibodies beyond PG-5 (Blackmore et al., 2017, Wang 
et al., 2018). My findings were also in accordance with those from previous 
studies by others, including the first studies using this mouse model, which 
reported progressing NFT pathology with age in rTg4510 TG mice, starting in the 
neocortex and progressively affecting the hippocampus and limbic structures 
(Ramsden et al., 2005, Sahara et al., 2014, Santacruz et al., 2005). The spread 
of tau pathology in rTg4510 mice therefore reflects the spread of NFTs with 
increasing Braak stage in AD (Braak et al., 2006, Braak and Braak, 1991) (see 
Section 1.1 and Figure 1.2). Of note, in rTg4510 TG mice we also detected 
significant differences in the thalamus, particularly in late stages. The magnitude 
of these differences was much smaller, reflecting the later and less aggressive 
accumulation of tau in this region of the brain. 
I also quantified levels of amyloid pathology (using the antibody b3D6) in J20 
mice at ages 6, 8, 10 and 12 months, comparing them to WT controls at the same 
ages. Again, I identified dramatic increases in pathology in the hippocampus, with 
a highly significant accumulation of amyloid also observed in each of the cortical 
regions examined. These results concur with previous data highlighting 
progressive deposition of amyloid plaques in the hippocampus and neocortex of 
J20 mice at 5-7 months, and ubiquitous plaque pathology by 8-10 months of age 
(Harris et al., 2010, Mucke et al., 2000). The diffusion of amyloid pathology in J20 
mice is therefore similar to the progressive deposition of amyloid seen in humans 
with AD (Thal et al., 2002) (see Section 1.1 and Figure 1.2). 
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In addition to confirming dramatic and progressive accumulation of pathology in 
the rTg4510 and J20 mouse models, the results from these experiments provide 
accurate pathology burden data for each individual animal used for genomic 
profiling. This means that pathological burden can be related directly to the 
transcriptomic (Chapter 4) and methylomic data (Chapter 5 and Chapter 6) 
generated on each individual animal. 
 
Despite the potential challenges inherent when performing experiments using 
antibodies, for which immunohistochemistry-based assays are no exception (e.g. 
non-specific binding), the antibodies used in this chapter (PG-5 and 3D6) have 
been extensively validated (Blackmore et al., 2017, Demattos et al., 2012, 
Holmes et al., 2016). I carried out the immunocytochemistry experiments 
described in this chapter at Eli Lilly, where these stains are routinely undertaken. 
At Eli Lilly, my collaborators have assessed a variety of antibodies to stain tau 
and Aβ and optimised the conditions for them. Using paraffin embedded tissue, 
PG-5 and 3D6 showed the best results at staining tau inclusions and amyloid 
plaques, respectively. 
PG-5 labels p-tau species that are mainly present in NFTs, therefore being a good 
measure of aggregated tau burden (Blackmore et al., 2017, Holmes et al., 2016). 
There are many other antibodies available that can also be used to stain for p-
tau in tissue sections, but most are not as good at detecting aggregates or NFTs 
as PG-5 or result in high residual background staining. In general, other 
antibodies available, such as AT-8 (stains p-tau, phosphorylate at Ser202 and 
Thr205) and MC-1 (stains aggregated tau), show similar patterns of pathology as 
PG-5, but often the staining is fainter, and the NFT-like inclusions are not as 
clearly observed, with increasing antibody concentrations often resulting in high 
levels of background staining across the whole section. Of note, this is obviously 
dependent from other experimental conditions, such as the use of free floating or 
frozen cryostat sections, instead of paraffin-embedded tissue sections. 
Furthermore, my collaborators at Eli Lilly compared the results of PG-5 with MC-
1 and AT-8, as well as with the Gallyas method (a silver impregnation technique 
highly sensitivity for NFTs (Kuninaka et al., 2015)), observing that PG-5 
correlated well with all the other stains. Interestingly, PG-5 staining has been 
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shown to be reduced when rTg4510 TG mice were treated with doxycycline to 
switch off the transgene expression (Blackmore et al., 2017, Holmes et al., 2016). 
The antibody 3D6 binds to both soluble and insoluble Aβ at the extreme amino 
terminus (Aβ1-5). Interestingly, if the first amino acid is missing, the antibody 
affinity to Aβ drops dramatically, i.e., it is amino-terminal specific for full-length Aβ 
peptide. Other studies from our collaborators at Eli Lilly have compared 3D6 to 
other antibodies for amyloid staining, such as mE8, observing similar staining 
between 3D6 and mE8, with the labelling being more intense and widespread for 
the 3D6 antibody (Demattos et al., 2012). 
Finally, it is worth mentioning that soluble tau/ Aβ species were not assessed in 
this study, which have been hypothesised to have a major impact in AD-
associated toxicity (Koss et al., 2016). Other approaches, such as western blot 
and mass spectrometry to evaluate soluble toxic species would be useful 





Chapter 4.  Transcriptional signatures of 
progressive neuropathology in transgenic 
tau and amyloid mouse models 
 
This chapter represents a modified version of the primary manuscript arising from 
my thesis, currently available as a preprint and under review for publication 
(Castanho et al., 2019). 
 
For information about data availability and accessibility to supplementary tables 
see Supplementary Information (page 399). 
 
4.1. Introduction 
In this chapter I describe my analysis of transcriptional changes in the entorhinal 
cortex associated with the development of both tau and amyloid pathology. Using 
highly-parallel RNA sequencing (RNA-seq), I profiled transcriptional variation in 
rTg4510 and J20 mice, identifying changes in gene expression paralleling the 
development of tau or amyloid pathology measured using the 
immunohistochemistry data generated on the same individual mice (Chapter 3). 
Finally, I used systems-level analyses to identify gene co-expression networks 
associated with the progressive accumulation of tau or amyloid pathology and 
explored overlaps between these networks and AD-associated co-expression 
modules identified in the human cortex. 
Recent studies have identified widespread gene expression differences in 
transgenic mice harbouring a diverse range of mutations associated with aspects 
of AD pathology (Castillo et al., 2017, Landel et al., 2014, Matarin et al., 2015, 
Rothman et al., 2018, Swarup et al., 2019, Wes et al., 2014) (discussed in more 
detail in Section 1.5.2.1 in Chapter 1). However, most analyses to date have 
been undertaken on relatively small numbers of animals and have not attempted 
to directly relate transcriptional alterations to the progressive burden of pathology 
in the same mice. 
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In recent years, highly-parallel RNA sequencing (RNA-seq) has replaced gene 
expression arrays as the method of choice for transcriptional profiling. RNA-seq 
for strand-specific transcript sequencing was first described by Lister et al. (2008), 
and first reported in mammals, specifically mouse tissues, by Mortazavi et al. 
(2008). In addition to enabling the quantification of gene expression levels, RNA-
seq allows profiling and discovery of new transcripts – an obvious advantage 
compared to microarrays which are limited to pre-existing probes. Furthermore, 
if sufficient sequencing depth is achieved, the assessment of alternative splicing 
is also possible from RNA-seq data (Mortazavi et al., 2008). RNA-seq library 
preparation involves the initial conversion of RNA into complementary DNA 
(cDNA), followed by addition of adapters that prepare the libraries for high-
throughput sequencing (Figure 4.1). Illumina sequencers, such as the HiSeq 
2500 System used in my research, are powerful high-throughput sequencing 
systems that use Sequencing by Synthesis technology, with fluorescently-
labelled nucleotides to detect single bases as they are incorporated into growing 
DNA strands (Figure 4.2). The fragments are attached to the surface of a flow 
cell and amplified. The DNA molecule is sequenced by adding polymerase and 
fluorescently-labelled reversible terminator nucleotides (with each base having a 
different colour associated to it). A nucleotide is incorporated in each cycle, which 
is detected by fluorescence. After each cycle, the fluorescent label is removed 
from the terminator and the 3’-OH is then free for a new base to be incorporated. 
The resulting RNA-seq reads can then be individually mapped to a reference 
genome and quantified in order to obtain the number of reads corresponding to 
mRNA from each known exon, splice event or new candidate gene, which can be 







Figure 4.1 – Schematic representation of a typical RNA-seq library preparation 
protocol. 
Messenger RNA (mRNA)-specific library preparation is shown. (1) Poly(A) selection. 
(2) Conversion of mRNA into complementary DNA (cDNA) by reverse transcription. (3) 





Figure 4.2 – Outline of Illumina sequencing by synthesis. 
(1) Adaptors are annealed to the ends of sequence fragments. (2) Fragments bind to 
primer-loaded flow cell and bridge PCR reactions amplify each bound fragment to 
produce clusters of fragments. (3) During each sequencing cycle, one fluorophore 
attached nucleotide is added to the growing strands. A laser excites the fluorophores in 
each fragment being sequenced and an optic scanner collects the signals from each 
fragment cluster. Finally, the sequencing terminator is removed, and the next 





In this section, the experimental procedures used for the evaluation of genome-
wide transcriptional profiles using RNA-seq in entorhinal cortex (ECX, described 
in Chapter 2, Section 2.4 and Section 2.5) RNA samples from rTg4510 and J20 
mice (Chapter 2, Section 2.1) are described in detail. An overview of the 
laboratory and analytical procedures performed is given in Figure 4.3. 
 
 
Figure 4.3 – Overview of RNA-seq laboratory and analytical procedures used for 





Samples were separated into two batches, with the two mouse models processed 
and sequenced independently – 64 samples were profiled in each batch (64 
samples for the rTg4510 model, and 63 samples plus a negative control for the 
J20 model). Experiments were performed in a blinded and randomised fashion to 
avoid any biases in quantification and analysis. 
 
When I first started the analysis of my data, there was no standard protocol 
described for identifying progressive changes in gene expression whilst 
controlling for changes due to the presence of the transgenes (i.e., genotype-
associated differences). Therefore, before obtaining the final results, I optimised 
the analysis of my RNA-seq data by testing several approaches, including more 
than one analytical protocol (or “pipeline”), before selecting the most appropriate 
statistical strategy to address our biological questions. Section 4.2.4 and 
Section 4.2.5 cover both analytical pipelines and the respective bioinformatics 
software (or “packages) that I tested; the final packages used are shown in the 
bottom section of Figure 4.3. 
 
4.2.1. Assessment of RNA quality and concentration 
All RNA samples used for my RNA-seq experiments were quantified and checked 
for purity using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific), 
as described in Section 2.5.3.1 (Chapter 2). Before RNA-seq library preparation, 
RNA quality and quantity for all samples was checked using RNA ScreenTape 
(Agilent), as described in Section 2.5.3.3 (Chapter 2). 
 
4.2.2. Library preparation 
Stranded-specific mRNA sequencing libraries were prepared using the TruSeq 
Stranded mRNA Sample Prep Kit (Illumina) using the Bravo Automated Liquid 
Handling Platform (Agilent). An overview of the library prep workflow using this 
kit is given in Figure 4.4. I performed the experiments, with technical assistance 
from Audrey Farbos and supervision by Dr Karen Moore of the Sequencing 
Service at the University of Exeter. There was no need for optimisations as the 
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TruSeq Stranded mRNA Sample Prep Kit (Illumina) has been extensively 
validated and routinely used at the Exeter Sequencing Service. 
 
 
Figure 4.4 – TruSeq Stranded mRNA Library Prep Workflow. 
BBB: Bead Binding Buffer; BWB: Bead Washing Buffer; ELB: Elution Buffer; FPF: 
Fragment, Prime, Finish Mix; RPB: RNA Purification Beads; RSB: Resuspension 
Buffer; FSA: First Strand Synthesis Act D Mix; SMM: Second Strand Marking Master 
Mix; CTE: End Repair Control; EtOH: ethanol; ATL: A-Tailing Mix; CTA: A-Tailing 
Control; LIG: Ligation Mix; STL: Stop Ligation Buffer; CTL: Ligation Control; PMM: PCR 
Master Mix; PPC: PCR Primer Cocktail. Figure and taken legend adapted from the 




All reagents were provided with the kit unless otherwise stated, with all reagents 
and consumables being sterile and DNase/RNase free. External RNA Controls 
Consortium (ERCC) spike-in synthetic RNA controls – a control mixture of known 
transcripts which allows the evaluation of successful library preparation (Risso et 
al., 2014) – were added to all samples. 
 
The complete protocol for library preparation for the 64 samples from each batch 
(each mouse model processed separately, as described above) took four days, 
with the protocol repeated twice (total number of samples = 128 samples, 64 
samples for each mouse model / batch). All volume calculations (e.g. digestion 
master mix) were performed in advance. All reagents were prepared in advance, 
as indicated in the manufacturer’s instructions. On each day, before starting, 
every surface and all equipment were thoroughly cleaned using RNaseZap 
(Thermo Fisher Scientific). 
 
4.2.2.1. Sample dilutions (day 1) 
The eight most-optimal high-quality RNA samples for each group (RIN ≥ 8; mean 
RIN rTg4510 = 8.9 (SD = 0.2), mean RIN J20 = 8.6 (SD = 0.3); Supplementary 
Table 1 and Supplementary Table 2) were selected for transcriptional profiling 
(total n = 128 samples; two models (rTg4510/J20) x two groups (TG/WT) x four 
time-points x eight individual animals per group).  
Libraries were prepared from 450ng of total RNA plus ERCC spike-in synthetic 
RNA controls (Ambion, dilution 1:100). 450 ng of DNA from each sample, and 0.9 
μL of ERCC spike-in controls was transferred to a total volume of 100 μL of 
RNase-free water (Qiagen, see Section 2.5.2.3 of Chapter 2) in a 96-well plate, 
starting in well A01 and proceeding in columns. The plate was stored at -20°C 




4.2.2.2. Purify and fragment mRNA (day 2) 
In this step, the polyA mRNA molecules are purified using magnetic beads 
containing oligo-dT. Two rounds of purification are performed, with the RNA being 
fragmented and primed for cDNA synthesis during the second elution (Illumina, 
2017). A schematic illustration of this step is shown in Figure 4.5. 
 
Figure 4.5 – Purifying and fragmenting mRNA. 
The Poly-A containing mRNA molecules are purified using poly-T oligo attached 
magnetic beads. Following purification, the mRNA is fragmented into small pieces 
using divalent cations under elevated temperature. Figure and legend taken from the 
TruSeq stranded mRNA reference guide (Illumina, 2017). 
 
The total RNA was diluted in nuclease-free ultrapure water to a final volume of 
50 μl and added to each well of a RNA Purification Bead (RBP) plate. The RBP 
tube was brought to room temperature and vortexed vigorously to resuspend the 
oligo-dT beads. Using the Bravo Automated Liquid Handling Platform (Agilent), 
50 μl of RBP was added to each well of the RBP plate to bind the polyA RNA to 
the beads, and the entire volume was gently pipetted to mix thoroughly. The plate 
was placed on a pre-programmed thermocycler, and left to incubate as follows: 
65°C 5 minutes 
4°C ∞ 
 
When it reached 4°C, the plate was removed from the thermocycler, and left to 
incubate at room temperature for 5 minutes to allow the RNA to bind to the beads. 
The plate was then placed on a magnet stand at room temperature for at least 5 
minutes (until the liquid was clear) to separate the polyA RNA bound beads from 
the solution. The supernatant from each well was removed and discarded, and 
the tubes were removed from the magnetic stand. In order to remove unbound 
RNA, the beads were washed by adding 200 μl of Bead Washing Buffer to each 
well of the RBP plate, gently pipetting the entire volume to mix thoroughly, and 
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placing the plate on the magnetic stand at room temperature for 5 minutes. During 
incubation, the thawed Elution Buffer was centrifuged at 600 × g for 5 seconds. 
The supernatant from each well, containing most of the ribosomal and other non-
messenger RNA, was removed and discarded, and the plate was removed from 
the magnetic stand. 50 μl of Elution Buffer was added to each well, and the entire 
volume was gently pipetted to mix thoroughly. The plate was placed on a pre-
programmed thermocycler, and the following program was used: 
80°C 2 minutes 
25°C ∞ 
 
When it reached 25°C, the plate was removed from the thermocycler and placed 
on the bench at room temperature. 50 μl of Bead Binding Buffer was added to 
each well, and the plate was incubated at room temperature for 5 minutes. After 
incubation, the tubes were placed on a magnetic stand at room temperature for 
at least 5 minutes, and the supernatant from each well was removed and 
discarded. The plate was removed from the magnetic stand, and the beads were 
washed by adding 200 μl of Bead Washing Buffer to each well, and gently 
pipetting the entire volume to mix thoroughly. The plate was placed on the 
magnetic stand at room temperature for 5 minutes, and the supernatant from 
each well of the RBP plate was removed and discarded. After removing the plate 
from the magnetic stand, 19.5 μl of Fragment Prime Finish Mix was added to 
each well, and the entire volume was gently pipetted to mix well. The plate was 
placed on a pre-programmed thermocycler, and the following program was used: 
94°C 8 minutes 
4°C ∞ 
 
When it reached 4°C, the plate was removed from the thermocycler and placed 
on the magnetic stand at room temperature for 5 minutes. 17 μl of the supernatant 




4.2.2.3. Synthesise first strand cDNA (day 2) 
In this step the cleaved RNA fragments primed with random hexamers are 
reverse transcribed into first strand cDNA. First Strand Synthesis Act D Mix (FSA) 
contains Actinomycin D (a toxin) that prevents spurious DNA-dependent 
synthesis, while allowing RNA-dependent synthesis, and improving strand 
specificity (Illumina, 2017). A schematic illustration of this step is shown in Figure 
4.6. 
 
Figure 4.6 – Synthesising first strand cDNA. 
Cleaved RNA fragments are copied into first strand cDNA using reverse transcriptase 
and random primers. Adding Actinomycin D to FSA (First Stand Synthesis Act D mix) 
prevents spurious DNA-dependent synthesis, while allowing RNA-dependent 
synthesis, improving strand specificity. Figure and legend taken from the TruSeq 
stranded mRNA reference guide (Illumina, 2017). 
 
This step was performed manually. Before starting, the thawed First Strand 
Synthesis Act D Mix (FSA) tube was centrifuged at 600 × g for 5 seconds. The 
First Strand Synthetic + SuperScript II mix was prepared at a ratio of 1 μl 
SuperScript II to 9 μl FSA. 8 μl of the FSA plus SuperScript II mix was added to 
each well of the plate containing the libraries, which was placed in a thermocycler 
and left to run using the following program: 
25°C 10 minutes 
42°C 15 minutes 
70°C 15 minutes 
4°C ∞ 
 
4.2.2.4. Synthesise second strand cDNA (day2) 
In this stage of the experiment the RNA template is removed, a replacement 
strand is synthesised, and dUTPs are incorporated in place of dTTPs to generate 
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double-stranded cDNA. The incorporation of dUTP quenches the second strand 
during amplification., and the magnetic beads separate the double-stranded 
cDNA from the second strand reaction mix. The result is blunt-ended cDNA. A 
schematic illustration of this step is shown in Figure 4.7. 
 
Figure 4.7 – Synthesising second strand cDNA. 
Strand specificity is achieved by replacing dTTP with dUTP in the SMM (Second 
Strand Marking Mix), followed by second strand cDNA synthesis using DNA 
Polymerase I and RNase H. The incorporation of dUTP in second strand synthesis 
quenches the second strand during amplification. Figure and legend taken from the 
TruSeq stranded mRNA reference guide (Illumina, 2017). 
 
5 μl of diluted (1:50 dilution) End Repair Control was added to each well, followed 
by 20 μl of thawed Second Strand Marking Master Mix. All wells in the plate were 
mixed well by pipetting and the plate was incubated for one hour at 16°C. 
Using the Bravo Automated Liquid Handling Platform (Agilent), 90 µl of MgNa 
magnetic beads brought to room temperature was added to each well, mixed by 
pipetting, and incubated at room temperature for 5 minutes. The plate was placed 
on the magnetic stand for at least 5 minutes (until the beads were captured and 
the liquid was clear), and the liquid was carefully removed without disturbing the 
beads. With the plate on the magnetic stand, the beads were gently washed twice 
by adding 200 µl 80% ethanol, incubating at room temperature for 30 seconds, 
and carefully removing and discarding the ethanol. The plate was then removed 
from the magnetic stand and the beads were allowed to dry at room temperature 
for 3 minutes. The dried beads were resuspended in 17.5 µl of Resuspension 
Buffer, incubated at room temperature for 2 minutes, and the plate was placed 
on the magnetic stand for at least 5 minutes (until the beads were captured and 
the liquid was clear) once again. 15 μl of the supernatant from each well was 




4.2.2.5. Adenylate 3' ends (day 3) 
This step is characterised by the addition of one adenine (A) nucleotide to the 3ʹ 
ends of the blunt fragments to prevent them from ligating to each other during the 
adapter ligation reaction. One corresponding thymine (T) nucleotide on the 3ʹ end 
of the adapters provides a complementary overhang for ligating the adapter to 




Figure 4.8 – Adenylating 3' ends. 
A single 'A' nucleotide is added to the 3' ends of the blunt fragments to prevent them 
from ligating to each other during the adapter ligation reaction. A corresponding single 
'T' nucleotide on the 3' end of the adapter provides a complementary overhang for 
ligating the adapter to the fragment. This strategy ensures a low rate of chimera 
(concatenated template) formation. Figure and legend taken from the TruSeq stranded 
mRNA reference guide (Illumina, 2017). 
 
2.5 μl of diluted A-Tailing Control (1:100 dilution) was added to each well, followed 
by 12.5 μl of thawed A-Tailing Mix. Everything was mixed well by pipetting and 
the plate was placed in a thermocycler and incubated as indicated below: 
37°C 30 minutes 
70°C 5 minutes 
4°C ∞ 
 
4.2.2.6. Ligate adapters (day 3) 
In this stage of the protocol multiple indexing adapters are ligated to the ends of 
the double-stranded cDNA fragments, preparing them for hybridization onto a 





Figure 4.9 – Ligating adapters. 
Adapter ligation prepares the ds cDNA for hybridization onto a flow cell. Figure and 
legend taken from the TruSeq stranded mRNA reference guide (Illumina, 2017). 
 
A Barcode Plate, containing the 24 Adaptor Indexes (Illumina) described in Table 
4.1, was used. Adaptors are short chemically synthesised nucleotide sequences 
that can be added to the ends of DNA molecules, allowing DNA fragments to bind 
to a next generation sequencing flow cell, and for PCR enrichment of adapter‐
ligated DNA fragments. The adaptors include indexes (or "barcodes", such as the 
ones described in Table 4.1) that permit multiple samples (or libraries) to be 





Table 4.1 – Index adapters used for the RNA-seq library preparation. 
Truseq LT single indexing. 
 
Index Sequence 
TruSeq index 1 ATCACG 
TruSeq index 2 CGATGT 
TruSeq index 3 TTAGGC 
TruSeq index 4 TGACCA 
TruSeq index 5 ACAGTG 
TruSeq index 6 GCCAAT 
TruSeq index 7 CAGATC 
TruSeq index 8 ACTTGA 
TruSeq index 9 GATCAG 
TruSeq index 10 TAGCTT 
TruSeq index 11 GGCTAC 
TruSeq index 12 CTTGTA 
TruSeq index 13 AGTCAA 
TruSeq index 14 AGTTCC 
TruSeq index 15 ATGTCA 
TruSeq index 16 CCGTCC 
TruSeq index 18 GTCCGC 
TruSeq index 19 GTGAAA 
TruSeq index 20 GTGGCC 
TruSeq index 21 GTTTCG 
TruSeq index 22 CGTACG 
TruSeq index 23 GAGTGG 
TruSeq index 25 ACTGAT 





Using the Bravo Automated Liquid Handling Platform (Agilent), 2.5 µl of diluted 
Ligation Control (1:100 dilution) was added to each well of the plate containing 
the libraries, followed by 2.5 µl of Ligation Mix, and 2.5 µl of RNA Adapter Index 
(alternating between the different sets of adaptors – important for sample pooling 
described in Section 4.2.2.8). Everything was mixed well by pipetting and the 
plate was incubated at 30°C for 10 minutes. Following incubation, 5 µl of Stop 
Ligation Buffer was added to each well and mixed by pipetting. 42 µl of MgNa 
magnetic beads was added to each well, mixed by pipetting, and incubated at 
room temperature for 5 minutes. The plate was placed on the magnetic stand for 
5 minutes (until the beads were captured and the liquid was clear), and the liquid 
was carefully removed without disturbing the beads. With the plate on the 
magnetic stand, the beads were gently washed twice by adding 200 µl of 80% 
ethanol, incubating at room temperature for 30 seconds, and removing the 
ethanol carefully with a pipette. The plate was removed from the magnetic stand 
and the beads allowed to dry at room temperature for 3 minutes. The dried beads 
were then resuspended in 52.5 µl of Resuspension Buffer, and after incubating 
the plate at room temperature for 2 minutes, the place containing the libraries 
was place on the magnetic stand for 5 minutes (until the beads were captured 
and the liquid was clear). 50 µl of the supernatant from each well was transferred 
to a new plate, and 50 µl of MgNa beads were added and mixed by pipetting for 
a second wash. The new plate was incubated at room temperature for 5 minutes, 
place on the magnetic stand for 5 minutes (until the beads were captured and the 
liquid was clear), and the supernatant was carefully removed without disturbing 
the beads. Once again, with the plate on the magnetic stand, the beads were 
gently washed twice by adding 200 µl of 80% ethanol, incubating the plate at 
room temperature for 30 seconds, and removing the ethanol carefully with a 
pipette. The plate was then removed from the magnetic stand, and the beads 
were left to dry at room temperature for 3 minutes. The dried beads were 
resuspended in 22.5 µl of Resuspension Buffer, and after incubation at room 
temperature for 2 minutes, the plate was placed on the magnetic stand for 5 
minutes (until the liquid was clear) and 20 µl of the supernatant from each well 




4.2.2.7. Enrich DNA fragments (day 4) 
In this stage of the protocol, the DNA fragments that have adapter molecules on 
both ends are selectively enriched / amplified by PCR. A schematic illustration of 
this step is shown in Figure 4.10. 
 
Figure 4.10 – Enriching DNA Fragments. 
Polymerase used in the assay does not incorporate past dUTP. Therefore, the second 
strand is effectively quenched during amplification. The products are enriched with 
PCR and purified to create the final cDNA library. Figure and legend taken from the 
TruSeq stranded mRNA reference guide (Illumina, 2017). 
 
5 µl of the PCR Primer Cocktail and 25 µl of the PCR Master Mix was added to 
each well, mixed by pipetting, and the plate was placed in a thermocycler and left 
to run using the following program: 
Temperature Time Cycles 
98°C 30 seconds 1 
98°C 10 seconds 
15 60°C 30 seconds 
72°C 5 minutes 
4°C ∞  
 
50 µl of MgNa beads at room temperature were added to each well, mixed by 
pipetting, and left to incubate for 5 minutes. The plate was placed on the magnetic 
stand for 5 minutes (until the beads were captured and the liquid was clear), and 
the liquid was carefully removed (without disturbing the beads). With the plate on 
the magnetic stand, the beads were gently washed twice by adding 200 µl of 80% 
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ethanol, incubating the plate at room temperature for 30 seconds, and carefully 
removing the ethanol with a pipette. The plate was removed from the magnetic 
stand and the beads were left to dry at room temperature for 3 minutes. The dried 
beads were then resuspended in 32.5 µl of Resuspension Buffer and the plate 
was incubated at room temperature for 2 minutes. Finally, the plate was placed 
on the magnetic stand for 5 minutes (until the beads were captured and the liquid 
was clear), and 30 µl of the supernatant was transferred to a new plate. 
 
4.2.2.8. Sample pooling and quality control (day 4) 
Library concentrations were determined using the D1000 ScreenTape System 
(Agilent) (as described in Section 2.5.3.4 of Chapter 2). An overview of the 
experimental procedures for the High Sensitivity D1000 Screentape, designed for 
analysing DNA molecules from 35-1000 bp, is given in Figure 4.11. 
 
Figure 4.11 – Overview of the experimental procedures for DNA analysis using the 
High Sensitivity D1000 Screentape Assay and 2200 TapeStation System. 
Figure taken from the Agilent High Sensitivity D1000 ScreenTape System Quick Guide 
(Agilent, 2015). 
 
Following the manufacturer’s instructions, I added 2µL of D1000 Sample Buffer 
(provided with the kit) to 2µL of each pool or 2µL of Ladder (provided with the kit) 
into strip-tube wells. The mix was vortexed using an IKA vortexer and adaptor at 
2000 rpm for 1 min, and the tubes spun-down to bring the samples to the bottom. 
After preparing the 2200 TapeStation instrument, including placing the sample 
block and loading tips, I inserted the ScreenTape into the TapeStation, placed 




Samples were pooled together to a 2nM concentration, for subsequent 
sequencing (three pools of 22 samples for J20 samples and one pool of 64 
samples for rTg4510 samples). 
Before sequencing, pooled libraries were quantified using a Qubit Fluorometer 
(Thermo Fisher Scientific), Tapestation HS ScreenTape System (Agilent 




Final library pools (containing fragments with ~300 bp in size) were distributed 
across twelve HiSeq2500 (Illumina) lanes (six lanes for each mouse model) and 
subjected to 125bp paired-end sequencing yielding a mean untrimmed read 
depth of ~18-20 million reads/sample (Supplementary Table 1 and 
Supplementary Table 2). Paired-end sequencing was used as it enables both 
ends of the DNA fragment to be sequenced, which improves the alignment of the 
resulting RNA-seq reads significantly. 
 
4.2.4. Sequencing data processing 
4.2.4.1. Data pre-processing 
All sequencing data processing was performed on a Unix-based operating 
system server. Initial demultiplexing of the raw sequencing files into FASTQ files, 
contamination checks and ERCC spike-in control quality checks were performed 
in collaboration with Paul O’Neill at the University of Exeter Sequencing Service. 
Raw RNA-seq data (FASTQ) has been deposited in GEO under accession 
number GSE125957. 
 
4.2.4.2. Quality control of raw data using FastQC 
The randomised FASTQ files (Phred score (Q) ≥ 35, Supplementary Table 1 
and Supplementary Table 2) underwent quality control (QC) assessments using 
FastQC (Andrews, 2010) (version 0.11.4). We obtained a mean of 18.81 (SD = 
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3.37) million sequencing reads per sample for the rTg4510 dataset 
(Supplementary Table 1), and a mean of 22.05 (SD = 2.88) million sequencing 
reads per sample for the J20 dataset (Supplementary Table 2). 
 
FastQC provides quality metrics for each read and for each sample, and 
summarises them in an HTML report. A representative example of the quality 
measures reported graphically by FastQC for one sample is shown in Figure 4.14 
to Figure 4.19. 
“Per base sequence quality” (Figure 4.14), expressed as a Phred score (Q), 
represents the distribution of read quality scores at each position, i.e., the 
confidence in the base call (Korpelainen et al., 2014). To calculate Q, the 
logarithm to base 10 (log10) of the probability that the base is wrong is taken and 
multiplied by -10 (e.g. if there is a chance that 1 base in 100 is wrong, Q = -10 x 
log10(0.01) = 20). Q typically ranges from 0 to 40, with Q = 10 meaning that there 
is a 1 in 10 chance of the base being called incorrectly, Q= 20 meaning there is 
a 1 in 100 chance, Q = 30 meaning 1 in 1000 (Datta and Nettleton, 2014). 
Typically, base quality values start to decrease towards the end of a read, which 
is easily detected in the box plots for the base sequence quality along the reads. 
Moreover, the forward reads have usually higher quality towards the ends of the 
reads compared to the reverse reads. These are characteristics of all second-
generation sequencing data (Korpelainen et al., 2014). Reads containing low 
quality bases can be filtered and/or trimmed (see Section 4.2.4.3). 
“Per sequencing quality scores” (Figure 4.15) give the average quality per read. 
They inform about the distribution of the read’s mean quality, detecting if a subset 
of the sequences has universally poor quality (Andrews, 2010). 
“Per base sequence content” (Figure 4.16) plots base composition along the 
reads, expressing the proportion of DNA bases (A, C, T, G or N base calls) at 
each position over all reads. In a random library it is expected that there would 
be little to no difference in the base composition for the different bases, therefore 
the lines in this plot should run parallel with each other. Some types of libraries 
(including most RNA-seq libraries) produce base composition bias (caused by 
random hexamer priming during conversion of RNA into cDNA), normally at the 
start of the read (Hansen et al., 2010, Korpelainen et al., 2014, van Gurp et al., 
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2013). Despite generating a technical bias, this can be corrected by trimming off 
the first positions of every read (Section 4.2.4.3). 
“Per sequence GC content” (Figure 4.17) plots the GC content across the whole 
length of each sequence compared to a modelled normal distribution of GC 
content. In a normal diverse library an approximate normal distribution of GC 
content is expected, with the central peak corresponding to the overall GC 
content of the underlying genome (Andrews, 2010). 
“Sequence length distribution” (Figure 4.18) plots the distribution of fragment 
size, showing the relative amounts of each different size of sequence fragment 
(Andrews, 2010). In a properly diverse library most sequences should fall into the 
far left of the plot in both the red and blue lines. 
In the “Sequence duplication levels” (Figure 4.19) plot, the proportion of the 
library which is made up of sequences in each of the different duplication level 
bins is shown (Andrews, 2010). As reads are ends of random fragments, most 
reads should be unique, and in a random library it is expected that most 
sequences occur only once in the final set, i.e. most sequences fall into the far 
left of the plot in both the red and blue lines. For other next-generation sequencing 
approaches, high levels of identical reads (which tend to produce peaks towards 
the right of the plot) suggest PCR overamplification or the presence of low 
complexity contaminants; however, in RNA-seq data, duplicates are often 
associated with highly expressed transcripts. In order to detect lowly expressed 
transcripts, it is common to over-sequence highly expressed transcripts, which 
potentially creates large sets of duplicates. For these reasons, duplicates should 
not be removed for differential expression analysis, but their presence should be 
explored in cases where a tower of reads in one position is observed, which most 





Figure 4.12 – Number of raw RNA-seq reads for each sample in the rTg4510 dataset. 
 
 





Figure 4.14 – Per base sequence quality from the FastQC report for raw RNA-seq 
reads. 
Results for one representative sample, showing high quality per base sequencing 
across the entire read for the (a) forward (read 1) and (b) reverse (read 2) reads from 
the same sample. A box and whisker plot is drawn for each position, with the central 
line corresponding to the median value, the yellow box representing the inter-quartile 
range (25-75%), the upper and lower whiskers representing the 10% and 90% points, 
and the blue line representing the mean quality. The background of the graph divides 
the y axis into very good quality calls (green), calls of reasonable quality (orange), and 
calls of poor quality (red). The quality of calls on most platforms will degrade as the run 
progresses, so it is common to see base calls falling into the orange area towards the 





Figure 4.15 – Per sequencing quality scores from the FastQC report for raw RNA-
seq reads. 
Results for the (a) forward (read 1) and (b) reverse (read 2) from one representative 
sample, showing high quality score distribution over all sequences measured by Phred 




Figure 4.16 – Per base sequence content from the FastQC report for raw RNA-seq 
reads. 
Results for the (a) forward (read 1) and (b) reverse (read 2) from one representative 





Figure 4.17 – Per sequence GC content from the FastQC report for raw RNA-seq 
reads. 






Figure 4.18 – Sequence length distribution from the FastQC report for raw RNA-
seq reads. 






Figure 4.19 – Sequence duplication levels from the FastQC report for raw RNA-seq 
reads. 
Results for the (a) forward (read 1) and (b) reverse (read 2) from one representative 
sample. The blue line corresponds to the full sequence set and shows how its 
duplication levels are distributed. The red line corresponds to the sequences that are 
de-duplicated and shows the proportions of the deduplicated set which come from 
different duplication levels in the original data.  
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4.2.4.3. Trimming and quality filtering 
After inspection of the quality-control plots, additional filtering steps were 
necessary, including removal of reads containing ambiguous bases, removal or 
trimming Illumina’s adapter sequences, removal of ERCC RNA spike-in controls, 
and removal of PCR duplicates. Other labels, such as multiplexing identifiers and 
primers, also needed to be removed. All of these are best identified when using 
paired-end reads, which was the case. Of note, currently there is no consensus 
about the optimal quality thresholds for trimming (which allows the removal of 
low-quality ends of reads) and filtering (which removes the entire read) in the 
context of RNA-seq; despite trimming low quality bases may improve the 
alignment of reads to a reference, it also reduces size and number of reads – 
choosing a quality threshold is therefore a trade-off between the two (Aronesty, 
2011). Considering this, trimming and filtering (ribosomal sequences removal, 
quality threshold 20, minimum sequence length 35) was performed with fastqmcf 
(Aronesty, 2011) (version 1.0). This software scans the FASTQ file for adapters, 
and, based on a log-scaled threshold, determines a set of clipping parameters, 
performing the following steps: 1) detection and removal of sequencing adapters 
and primers; 2) detection of limited skewing at the ends of reads; 3) detection and 
removal of poor quality at the ends of reads; 4) detection and removal of Ns from 
the ends of reads; 5) discarding sequences that are too short after previous steps 
(Aronesty, 2011). In addition, before running fastqmcf, ribosomal sequences 
were removed using bowtie2 (Langmead et al., 2009) (version 2.3.0). 
The number of RNA-seq reads after filtering for all samples is shown in Figure 
4.20 and Figure 4.21. A mean output of 18.18 (SD = 3.33) million filtered 
sequencing reads per sample was obtained for the rTg4510 dataset, and a mean 
output of 21.27 (SD = 2.93) million filtered sequencing reads per sample was 
obtained for the J20 dataset. A representative example of the quality measures 
reported by FastQC for the same sample shown above is provided in Figure 4.22 
to Figure 4.27. Following confirmation of genotype and QC, 7 samples were 
excluded from subsequent analysis leaving a final number of 121 high-quality 




Figure 4.20 – Number of filtered RNA-seq reads for each sample in the rTg4510 dataset. 
 
 





Figure 4.22 – Per base sequence quality from the FastQC report for filtered RNA-
seq reads. 
Results for one representative sample, showing high quality per base sequencing 
across the entire read for the (a) forward (read 1) and (b) reverse (read 2) reads from 





Figure 4.23 – Per sequencing quality scores from the FastQC report for filtered 
RNA-seq reads. 
Results for the (a) forward (read 1) and (b) reverse (read 2) from one representative 
sample, showing high quality score distribution over all sequences measured by Phred 





Figure 4.24 – Per base sequence content from the FastQC report for filtered RNA-
seq reads. 
Results for the (a) forward (read 1) and (b) reverse (read 2) from one representative 





Figure 4.25 – Per sequence GC content from the FastQC report for filtered RNA-
seq reads. 






Figure 4.26 – Sequencelength distribution from the FastQC report for filtered RNA-
seq reads. 






Figure 4.27 – Sequence duplication levels from the FastQC report for filtered RNA-
seq reads. 





4.2.4.4. Alignment to the mouse reference genome and mapping quality 
control 
Aligning or mapping sequencing reads refers to the lining up of the sequences to 
a reference, allowing us to estimate where the read originated from. Mapping of 
RNA-seq reads is usually achieved by mapping them to a reference genome, or 
a reference transcriptome (Figure 4.28). Mapping reads to a reference genome 
provides genomic location information that can be used for the discovery of new 
genes and/or transcripts, in addition to quantifying gene expression. If a reference 
genome is not available, or if we wish to quantify known transcripts only, reads 
can be mapped to the transcriptome instead (Korpelainen et al., 2014). Mapping 
can be quite challenging for a myriad of reasons, namely: 1) sequencing reads 
are relatively short and there are millions of them; 2) genomes can be large (e.g. 
mammalian genomes) and contain non-unique sequences (e.g. repeated 
sequences and pseudogenes), which increases mapping complexity; 3) 
mismatches and indels (defined as an insertion or deletion of bases in the 
genome of an organism) can be present, caused by genomic variation and 
sequencing errors; and 4) RNA-seq reads align to the genome non-contiguously 
(given that introns are removed from RNA during splicing events), meaning that 
aligners have to place spliced reads across introns and determine exon-intron 
boundaries correctly (Korpelainen et al., 2014). 
The list of available software for each step of the RNA-seq analysis is constantly 
expanding (e.g.: more than ninety aligners are currently available (Fonseca et al., 
2012)). Examples of typical workflows and software available for each step are 




Figure 4.28 – Typical workflows used in RNA-seq data analysis, showing the 
variety of software available for each step. 
Figure adapted from Korpelainen et al. (2014). 
 
As briefly mentioned in the beginning of Section 4.2, I tested several approaches 
based on the analysis pipelines that have been suggested and widely described 
as the best practices for RNA-seq data analysis (Conesa et al., 2016, Korpelainen 
et al., 2014). The two main analytical protocols (or “pipelines”) that I have 
explored in higher depth are shown in Figure 4.29. First, I used the “Tuxedo” 
protocol, where trimmed samples were aligned to the mm10 (GRCm38.p4) 
reference mouse genome using Tophat (Trapnell et al., 2009) (version 2.1.1), a 
program that is built on the short read mapping program Bowtie (Langmead et 
al., 2009). This pipeline turned out to be suboptimal for our analysis for several 
reasons (explained in more detail in Section 4.2.5), and so I decided to explore 
extensively other options. Based on the workflow recommended by Bioconductor 
(www.bioconductor.org) (Love et al., 2016b), additional recommendations by 
others (Datta and Nettleton, 2014), and my own research about each method, I 
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elected the “alternative” protocol described on the right side of Figure 4.29 as the 
best approach for my RNA-seq data analysis, for which the results described in 
Section 4.3 are based on. Within this protocol, I used STAR (Dobin et al., 2013) 
(version 2.5.3a) to align the trimmed FASTQ samples to the mm10 (GRCm38.p4) 
reference mouse genome, which performed a much faster mapping of the reads 
compared to Tophat2, and resulted on an average mapping ≥ 85% (Figure 4.30, 
Figure 4.31, Supplementary Table 1 and Supplementary Table 2). Both 
TopHat2 and STAR are spliced aligners, meaning that both aligners can map 
RNA-seq reads to genomes that contain introns (Korpelainen et al., 2014). 
 
 






Figure 4.30 – Ratio of filtered sequences that mapped to the mouse reference genome for each sample in the rTg4510 RNA-seq dataset. 
 
 




4.2.5. Differential expression 
4.2.5.1. Gene expression analysis using the “Tuxedo” pipeline 
As explained in Section 4.2.4.4 and Figure 4.29, the “Tuxedo” protocol was the 
first workflow that I tested, where the “classic” workflow includes read mapping 
with TopHat, assembly with Cufflinks, and visualization and exploration of results 
with CummeRbund (Figure 4.32) (Trapnell et al., 2012). Tophat, used for 
alignment of the sequencing reads, was described in Section 4.2.4.4. Cufflinks 
(Trapnell et al., 2012, Trapnell et al., 2010), a tool for transcriptome assembly 
and isoform quantification from RNA-seq reads, combines the deconvolution of 
expression data into isoforms with differential expression testing (Korpelainen et 
al., 2014); it is both the name of a suite of tools and a program within that suite., 
where the program assembles transcriptomes from RNA-Seq data and quantifies 
their expression. CummeRbund, originally designed for microarray data, is an R 
visualisation package designed to simplify the analysis of RNA-seq data output 
from Cufflinks. 
Despite allowing me to perform a preliminary analysis of my RNA-seq data 
relatively easily, this workflow turned out to have very little flexibility, with very 
limited opportunity to perform more complex statistical analyses. For example, it 
only allowed me to compare samples by genotype (WT versus TG) at each time 
point, without offering me the possibility of implementing a statistical model 
containing an interaction term between genotype and age. P-values below 10-5 
were also not possible to obtain with the latest version of the workflow, which 
meant that I ended up with many genes with a p-value of 1 x 10-5. Furthermore, 
despite normalising the data for transcript length, this workflow does not include 
filtering of outliers, resulting in the presence of a few clear false positives within 
my results. For all these reasons I concluded that the Tuxedo protocol was 
inadequate for the implementation of my final analysis and I decided to explore 




Figure 4.32 – General overview of the Tuxedo protocol and its software 
components. 
Bowtie forms the algorithmic core of the TopHat, aligner. TopHat's read alignments are 
assembled by Cufflinks and its associated utility program to produce a transcriptome 
annotation of the genome. Cuffdiff quantifies this transcriptome across multiple 
conditions using the TopHat read alignments. CummeRbund facilitates exploration and 
visualisation of the data produced by Cuffdiff, including differentially expressed genes 




4.2.5.2. Gene expression analysis using featureCounts and DESeq2 
Gene expression quantification (i.e. the quantification of fragments or templates, 
hereby referred as read counts) was achieved using featureCounts (Liao et al., 
2014) (version 1.5.2), a read summarization program that counts mapped reads 
for genomic features such as genes, exons, promoters, gene bodies, genomic 
bins and chromosomal locations. 
Read counts were analysed for differential expression using the R package 
DESeq2 (Love et al., 2014) (version 1.16.1) downloaded from Bioconductor 
(www.bioconductor.org). DESeq2 uses the raw read counts, applies an internal 
normalisation method, and does estimation of library size, estimation of 
dispersion, and negative binomial generalised linear model fitting. The internal 
normalisation consists of calculating the geometric mean for each gene across 
all samples, with the counts for a gene in each sample being divided by this mean. 
The median of these ratios in a sample is the size factor for that sample. This 
procedure corrects for library size and RNA composition bias, which can arise for 
example when only a small number of genes are very highly expressed in one 
experiment condition but not in the other. Furthermore, DESeq2 uses shrinkage 
estimation for dispersions and fold changes, with a dispersion value estimated 
for each gene through a model fit procedure, only possible if an appropriate 
number of replicates is included in the experiment. For every gene and for every 
sample, DESeq calculates Cook’s distance, a diagnostic test for outliers, 
automatically flagging genes which contain a Cook’s distance above a cutoff for 
samples which have three or more replicates. The p-values for these genes are 
set to “NA”. When there are seven or more replicates, DESeq automatically 
replaces counts with large Cook’s distance with the trimmed mean over all 
samples, scaled up by the size factor or normalisation factor for that sample, i.e., 
it replaces the outlier value with the value predicted by the null hypothesis (Love 
et al., 2016a). 
Datasets were filtered for non-expressed and lowly expressed genes (minimum 
of 6 counts across all samples), and similarity in the genome-wide expression 
profile between samples was visualised in a heatmap clustered by Euclidean 
distance (Figure 4.34 and Figure 4.35) and a principal component analysis 
(PCA) plot of the first two principal components (Figure 4.36 and Figure 4.37). I 
was interested in detecting both genotype effects and progressive changes 
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across age between the transgenic and wild type samples (Figure 4.33). For that 
purpose, I used the following statistical model, including main effects for both 
Genotype and Age (both coded as categorical variables) and an interaction 
between these two terms: 
 
𝐺𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 +  𝐴𝑔𝑒 +  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝐴𝑔𝑒  
 
To identify significant Genotype effects a Wald test was used, and to identify 
significant effects of age and interaction effects (i.e. Genotype*Age) we used the 
likelihood-ratio test, both applied with the DESeq function from the DESeq2 
package (Love et al., 2014). P values were adjusted for multiple testing, using 
the false discovery rate (FDR) method (also known as Benjamini and Hochberg 
correction) (Benjamini and Hochberg, 1995) implemented with the R function 
p.adjust; FDR-adjusted P values < 0.05 were defined as significant. Potential 
differences in proportions of genes with increased versus decreased expression 
as well as overlapping fold changes in both models were interrogated using the 
binomial test. Functional annotation and gene ontology analyses were done with 
GOseq (Young et al., 2010) (1.30.0), based on genes with FDR < 0.05. Goseq is 
an approach for gene ontology analysis of RNA-seq data, which takes gene 
length bias into account (Oshlack and Wakefield, 2009). All analyses were 














Figure 4.34 – Euclidean distance between samples in rTg4510 mice. 







Figure 4.35 – Euclidean distance between samples in J20 mice. 





Figure 4.36 – Principal component analysis (PCA) plot of the first two principal 




Figure 4.37 – Principal component analysis (PCA) plot of the first two principal 




4.2.5.3 Quantifying human transgene expression 
Mouse and human App/APP and Mapt/MAPT sequences were compared using 
BLAT (Kent, 2002) for divergent transcript sequences representing specific 
mouse and human gene sequences. Two 200bp regions spanning 4 exons were 
chosen as representative of mouse-specific App. Similar regions consisting of 
two 200bp exonic regions were also chosen for human APP. Mouse-specific Mapt 
and human-specific MAPT sequences were chosen from a 2kb region present in 
the 3’UTR. Using Bowtie2 (Langmead et al., 2009) (version 2.3.4.3), indices 
based on these sequences were then built, and alignments were performed using 
the FASTQ read 1 sequences. Counts of read alignments for mouse and human 
specific indices were then plotted as a ratio of unique (mouse or human) reads 
relative to the total number of input reads. 
 
4.2.5.4. Comparison with RNA-seq data from the Mouseac database 
RNA-seq data (transcripts per million, TPM) from two mouse models (Matarin et 
al., 2015, Salih et al., 2018) (TAU (Camk2a-MAPTP301L) and TAS10 (SwAPP, 
K670N/M671L)) were downloaded from the Mouseac online database 
(www.mouseac.org), with corresponding detailed phenotypic data downloaded 
from GEO (Barrett et al., 2013, Edgar et al., 2002) (accession number 
GSE64398). Only genes identified as differentially expressed (FDR < 0.05) in our 
analysis (for rTg4510 and J20 mice) were kept for further statistical analysis. TPM 
was log transformed (log2(x+1)) and the same linear regression model described 
above (𝐺𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 +  𝐴𝑔𝑒 +  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝐴𝑔𝑒), using ANOVA 
to test for significant differences associated with either the Genotype, Age, or 
Genotype*Age terms, was used. P values were corrected for the number of genes 
compared across datasets using Bonferroni correction. Potential differences in 
proportions of genes with increased versus decreased expression as well as 





4.2.6. Co-expression network analysis 
Gene co-expression changes were detected using weighted gene correlation 
network analysis (WGCNA) (Langfelder and Horvath, 2008, Zhang and Horvath, 
2005), a systems biology method for evaluating correlation expression patterns 
among genes across samples. It can be used 1) to find clusters (modules) of 
highly correlated genes; 2) to summarise those clusters using the module 
eigengene or an intramodular hub gene; 3) to relate modules to other modules; 
4) to relate modules to external sample traits (using eigengene network 
methodology); and 5) to calculate module membership measures. 
Using the WGCNA R package (Langfelder and Horvath, 2008) (version 1.63), I 
constructed a signed co-expression network for each mouse model using log 
transformed counts from all samples. Logarithmic transformation of raw counts 
was achieved using the rlog function from DESeq2, which minimises variability in 
genes with low counts (Love et al., 2014). I checked the data for missing values 
and outliers, and removed one sample from the analysis for the rTg4510 dataset 
(flagged as an outlier) before building the networks. Signed WGCNA co-
expression networks were built using the lowest power for which the scale-free 
topology fit index curve flattened out after reaching 0.90 resulting in a soft-
threshold power of 10 and 9 for rTg4510 and J20 datasets, respectively, and a 
minimum module size of 30. For each module of highly interconnected genes, 
colour-labelled according to the WGCNA conventions, I calculated the module 
eigengenes (MEs) as the first principal component of the expression matrix, 
which provide a representative expression profile for each module (Langfelder 
and Horvath, 2008). In order to identify modules significantly associated with 
pathology burden, I calculated correlation coefficients between these MEs with 
the available pathology data and explored the most significant associations. In 
addition we used the same linear regression model as described for the gene-
level analysis (𝑀𝐸 =  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 +  𝐴𝑔𝑒 +  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝐴𝑔𝑒) using ANOVA to test 
for significant differences due to either the Genotype, Age, or Genotype*Age 
terms. P values were corrected for multiple comparisons using the Bonferroni 
correction, to correct for 18 modules in the rTg4510 (statistical threshold was 
adjusted to 0.05/18 = 0.0028) and 21 modules in the J20 (statistical threshold 
was adjusted to 0.05/21 = 0.0024) mice. I used the GOseq R package (version 
1.30.0) to perform functional annotation and gene ontology (GO) analyses for 
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each module, where significant pathways were selected using an FDR threshold 
of 0.05 as previously described (Young et al., 2010). Finally, I used Cytoscape 
(Shannon et al., 2003) (version 3.7.0) for network visualisation  using the 
topological overlap matrix for the log transformed expression data. 
4.2.6.1. Comparison with human co-expression networks 
Significant rTg4510 co-expression modules were compared to AD-associated co-
expression modules, reported in a recent human post-mortem RNA-seq meta-
analysis (Logsdon et al., 2019), which was done in collaboration with Emma Laing 
from Eli Lilly. The six rTg4510-associated co-expression modules identified in this 
study (“salmon”, “turquoise”, “purple”, “yellow”, “light-cyan”, and “red”, see 
Section 4.3.6), and AD-associated human co-expression modules in the 
dorsolateral prefrontal cortex (DLPFC) and temporal cortex (TCX) from Logsdon 
et al. were reduced to contain only mouse-human homologs as defined by 
Ensembl (Zerbino et al., 2018) (accessed on 14/11/2018). The level of overlap 
between gene members of each pair of modules was assessed via a 
hypergeometric test using the R (version 3.5.1) function phyper. P values were 
corrected for multiple comparisons using Bonferroni correction in a tissue-specific 
manner, where only the set of raw P values related to DLPFC (statistical threshold 
was adjusted to 0.05/24 = 0.0021) or TCX (statistical threshold was adjusted to 
0.05/30 = 0.0017) modules’ overlap were considered. Using GOseq (version 
1.30.0), we performed functional annotation and GO analyses for the common 
genes in each overlapping pair of modules. 
 
4.2.7. Iba1 immunohistochemistry 
Given the enrichments for immune-related biological pathways amongst the 
genes characterised progressive gene expression changes identified in the 
rTg4510 mice (see Section 4.3.4), I quantified Iba1, a microglia/macrophage-
specific calcium-binding protein (Ohsawa et al., 2004), in matched tissue sections 
from the right brain hemisphere (n = 7-10 animals per group, total n = 70). This 
was performed as described in Chapter 3 (Section 3.2) for PG-5, except that I 
used rabbit polyclonal anti-Iba1 (Wako, catalog number 019-19741, lot number 
LKG5732) as the primary antibody (diluted 1:6000), and biotinylated goat anti-
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rabbit IgG (Vector labs, catalog number BA-1000, lot number ZB1007) as the 
secondary antibody (diluted 1:200). 
 
4.3. Results 
4.3.1. Sequencing metrics 
Raw RNA-seq data are available for download from the Gene Expression 
Omnibus (GEO) database (Barrett et al., 2013, Edgar et al., 2002) (accession 
number GSE125957). No differences in read-depth were identified between TG 
and WT controls in both the rTg4510 (n = 59 animals, two-tailed unpaired t-test, 
t(57)= 1.35, P = 0.18) and J20 (n = 62 animals, two-tailed unpaired t-test, t(60) = 
0.41, P = 0.18) mouse models (Figure 4.38). In addition, no differences in the 
number of sequences mapped to the mouse genome were identified when 
comparing TG to WT samples in both rTg4510 (n = 59 animals, two-tailed 
unpaired t-test, t(57) = -1.36, P = 0.089) and J20 (n = 62 animals, two-tailed 







Figure 4.38 – Comparison of RNA-seq reads in transgenic and wild type animals for both models. 
The number of raw RNA-seq reads did not differ between WT and TG mice for comparisons of either the (a) rTg4510 or (b) J20 models. The proportion of 
RNA-seq reads uniquely mapped to the mouse genome did not differ between WT and TG mice for comparisons of either the (c) rTg4510 or (d) J20 models. 
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4.3.2. The rTg4510 model of tau pathology is characterised by 
widespread transcriptional differences in the entorhinal cortex 
Across all samples, striking differences in gene expression were identified in 
rTg4510 TG animals relative to WT control mice (n = 29 TG, n = 30 WT); gene 
expression results for all 18,822 detected transcripts are available to download 
from our online database (www.epigenomicslab.com/ADmice). In total, we 
identified 154 differentially-expressed transcripts at false discovery rate (FDR) < 
0.05 (Figure 4.39 and Supplementary Table 3). Among these, there was a 
significant (exact binomial test, n = 154 transcripts, P = 0.00014) enrichment of 
transcripts with decreased expression (n = 101 (66%) transcripts with reduced 
expression in TG compared to n = 53 (34%) transcripts with elevated expression 
in TG). Of note, differences for five of these transcripts are likely to reflect known 
deletions of the transgene integration sites for the Camk2a-tTA (encompassing 
Wdr60, Esyt2, Ncapg2, and Ptprn2) and MAPT (encompassing Fgf14) 
transgenes (Goodwin et al., 2017). Given the high homology between transcribed 
regions of the human and mouse tau gene, I also found highly elevated levels of 
Mapt (Wald test, Wald statistic = 11.11, log2 fold change = 0.50, FDR = 7.08E-
25) (Figure 4.40a) confirming stable activation of the MAPT transgene in TG 
mice; of note, human-specific MAPT sequence domains were only detected in 
TG RNA-seq datasets (Figure 4.40b-c). Furthermore, because the rTg4510 
transgene is inserted into the context of two untranslated exons of the mouse 
prion protein gene (Prnp), as expected we observed elevated expression of these 
Prnp domains in TG mice (Wald statistic = 25.40, log2 fold change = 1.54, FDR 
= 4.88E-138). 
Beyond these expected direct transgene-induced changes, we observed 
evidence for widespread transcriptional consequences of the rTg4510 genotype. 
The most significant rTg4510-associated differentially-expressed transcript is 
Car4, which encodes carbonic anhydrase 4 (Table 4.2 and Figure 4.41a; 
increased expression in TG mice). Other differentially expressed genes in mice 
carrying the rTg4510 transgene include Gpr17, which encodes the G protein-
coupled receptor 17 that is involved in regulating oligodendrocyte differentiation 
and maturation (Chen et al., 2009) (Table 4.2 and Figure 4.41b; decreased 
expression in TG mice;); Blnk, which encodes a cytoplasmic linker protein that 
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plays a critical role in B cell development and is involved in the TREM2 activation 
pathway (Zajkowicz et al., 2018) (Table 4.2 and Figure 4.41c; increased 
expression in TG mice); and Hspa5 (also known as Bip or Grp78), which encodes 
a member of the heat shock protein 70 (HSP70) family that is localised in the 
lumen of the endoplasmic reticulum (ER) and involved in the folding and 
assembly of proteins, and has been previously implicated in neuroprotection and 
AD (Casas, 2017, Hoozemans et al., 2005) (Table 4.2 and Figure 4.41d; 
decreased expression in TG mice). 
Hierarchical clustering of individual mice based on expression levels for 
genotype-associated transcripts robustly discriminates between rTg4510 and WT 
groups (Figure 4.39). Within the rTg4510 TG group, samples also cluster by time-
point, suggesting, importantly, that there are progressive changes in gene 








Figure 4.39 – Genotype-associated transcriptional variation robustly discriminates 
between rTg4510 transgenic and wild type mice. 
Hierarchical clustering of each individual mouse based on expression levels for 
differentially expressed genes (DEGs) associated with rTg4510 genotype (n = 59 mice 
(29 TG, 30 WT), 147 transcripts). Direction of normalised DESeq2 read counts, relative 
to mean levels of expression across all individual mice (“relative gene expression”), is 





Figure 4.40 – Apparent up-regulation of Mapt in rTg4510 mice results from human-
specific sequences only present in transgenic mice. 
Apparent up-regulation of Mapt in rTg4510 transgenic (TG, blue) female mice 
compared to wild type (WT, black) littermate control mice (n = 59 animals). (a) Mapt 
gene expression from DESeq2 highlights elevated expression of Mapt in TG mice. (b) 
Ratio of unique reads that mapped to mouse-specific sections of Mapt or (c) human-
specific sections of MAPT. Normalised counts were obtained using DESeq2. Dashed 

















8.36 1.11 2.41E-13 
59 
Gpr17 -6.73 -0.62 5.11E-08 
Blnk 6.48 0.80 2.12E-07 




Figure 4.41 – Top-ranked differentially expressed transcripts associated with 
rTg4510 genotype. 
Shown are individual plots for: (a) Car4, (b) Gpr17, (c) Blnk, and (d) Hspa5. Total n = 
59 animals (29 TG, 30 WT). Normalised counts were obtained using DESeq2. Dashed 
lines represent mean paths across age groups. rTg4510 transgenic (TG, blue) female 




4.3.3. The J20 model of amyloid pathology is characterised by 
differential expression of Ccdc80, Abca8a, Htr1a and Hspa5 
Relative to the widespread transcriptional signatures associated with the rTg4510 
model, fewer significant expression differences were identified in J20 TG mice 
compared to WT control mice (n = 30 TG, n = 32 WT); gene expression results 
for all 18,745 expressed transcripts are available to download from our online 
database (www.epigenomicslab.com/ADmice). As expected, there was an 
apparent increase in expression of App (Wald test, Wald statistic = 8.55, log2 fold 
change = 0.66, FDR = 2.37E-13) (Figure 4.42a), reflecting the high sequence 
homology with the human APP transgene, and confirming stable activation of the 
mutant transgene in TG mice; of note, we mapped our RNA-seq reads to human-
specific APP sequence domains and only observed signal in TG animals (Figure 
4.42b-c). In total we identified four additional differentially-expressed transcripts 
at a stringent false discovery rate (FDR) < 0.05 (Figure 4.43 and Supplementary 
Table 4): Ccdc80, encoding a protein involved in cell adhesion and matrix 
assembly (O'Leary et al., 2013) (increased expression in TG samples); Abca8a, 
encoding a member of the A-subclass of ATP-binding cassette (ABC) transporter 
family which regulates brain lipid homeostasis and has been implicated in AD 
(Piehler et al., 2012) (decreased expression in TG samples); Htr1a, encoding a 
major G-protein-coupled serotonin receptor, the 5-HT1A receptor, that is widely 
expressed in the central nervous system (decreased in TG samples); and Hspa5 
(decreased expression in TG samples) (Table 4.3 and Figure 4.44). Overall, 
expression of these genotype-associated transcripts discriminates between J20 
and WT groups (Figure 4.43), although, in contrast to the rTg5410 differentially 
expressed transcripts, there are no clear age effects in the J20 TG mice. Even 
though the transcriptional changes associated with the rTg4510 and J20 
genotypes are generally distinct – there is no robust correlation of effect sizes 
(TG vs WT) between models for differentially expressed transcripts identified in 
either the rTg4510 (Pearson correlation, r = 0.15, P = 0.063, Figure 4.45a) or J20 
(r = 0.66, P = 0.23, Figure 4.45b) models – it is noteworthy that the expression 
of Hspa5 is significantly decreased (FDR < 0.05) in the same direction in both 






Figure 4.42 – Apparent up-regulation of App in J20 mice results from human-
specific sequences only present in transgenic mice. 
Apparent up-regulation of App in J20 transgenic (TG, red) female mice compared to 
wild type (WT, black) littermate control mice (n = 62 animals). (a) App gene expression 
from DESeq2 highlights elevated expression of App in TG mice. (b) Ratio of unique 
reads that mapped to mouse-specific sections of App or (c) human-specific sections of 
APP. Normalised counts were obtained using DESeq2. Dashed lines represent mean 





Figure 4.43 – Genotype-associated transcriptional variation robustly discriminates 
between J20 transgenic and wild type mice. 
Hierarchical clustering of each individual mouse based on expression levels for 
differentially expressed genes (DEGs) associated with J20 genotype (n = 62 mice (30 
TG, 32 WT), 5 transcripts). Direction of normalised DESeq2 read counts, relative to 
mean levels of expression across all individual mice (“relative gene expression”), is 
represented in the heatmap (scaled) from high (red) to low (blue). 
 













6.37 0.81 1.74E-06 
62 
Abca8a -4.67 -0.81 0.020 
Htr1a -4.48 0.51 0.035 





Figure 4.44 – Top-ranked differentially expressed transcripts associated with J20 
genotype. 
Shown are individual plots for: (a) Ccdc80, (b) Abca8a, (c) Htr1a, and (d) Hspa5. Total 
n = 62 animals (30 TG, 32 WT). Normalised counts were obtained using DESeq2. 
Dashed lines represent mean paths across age groups. J20 transgenic (TG, red) 
female mice compared to wild type (WT, black) littermate control mice. 
 
 
Figure 4.45 – There is no overall consistency between mouse models in effect 
sizes for genotype-associated differentially-expressed transcripts identified in 
each individual mouse model. 
(a) Negligible correlation for effect size (Log2 fold change) across models for 
differentially expressed transcripts (FDR < 0.05) associated with rTg4510 genotype 
(Pearson correlation, r = 0.18, P = 0.029; exact binomial test, n = 147 transcripts, P = 
0.69). (b) No correlation for effect size (Log2 fold change) across models for 
differentially expressed transcripts (FDR < 0.05) associated with J20 genotype 
(Pearson correlation, r = 0.66, P = 0.23; exact binomial test, n = 4 transcripts, P = 
0.13). Despite the overall lack of consistency between models, the expression of one 





4.3.4. Progressive changes in gene expression in the entorhinal 
cortex mirror the development of tau neuropathology in 
rTg4510 mice 
Given the progressive accumulation of brain neuropathology in TG mice (see 
Section 3.3.1 in Chapter 3), I next explored temporal changes in gene 
expression associated with genotype to identify transcriptional signatures 
paralleling the increases in tau and amyloid pathology in TG mice over time 
(Figure 4.33). I initially focused on the rTg4510 mice given the clear temporal 
clustering of samples amongst genotype-associated differentially-expressed 
transcripts identified in this model (Figure 4.39). Using an approach designed to 
identify interactions between genotype (TG vs WT) and age group, we identified 
1,762 transcripts (FDR < 0.05) whose expression significantly changed with the 
progression of tau pathology in rTg4510 mice (Supplementary Table 5). 
Expression differences at these transcripts were found to progressively increase 
with age relative to baseline (age 2 months) (Figure 4.46 and Table 4.4), 
paralleling the accumulation of tau pathology in these same individual animals. 
The top tau-associated differentially-expressed gene in rTg4510 TG mice was 
Gfap, encoding glial fibrillary acidic protein (GFAP), a gene predominantly 
expressed in both mouse and human astrocytes (Raff et al., 1979, Zhang et al., 
2016), and known to be upregulated in reactive astrocytes associated with brain 
pathology (Ben Haim et al., 2015). Expression of Gfap was dramatically amplified 
with progressive tau pathology (Table 4.5 and Figure 4.47a), similar to results 
from another study reporting age-dependent (12-18 months) increase in 
expression of hippocampal Gfap in tau (Camk2a-MAPT P301L) and amyloid 
(APP/PSEN1) mouse models (Matarin et al., 2015), and paralleling the 
astrogliosis observed in human AD brain (Liddelow et al., 2017, Panter et al., 
1985). Other top-ranked genes progressively altered in rTg4510 mice were 
notably enriched for microglial markers previously shown to have their expression 
augmented in AD (Hopperton et al., 2018, Keren-Shaul et al., 2017), including 
Cd68 (Table 4.5 and Figure 4.47b), Itgax (or Cd11c) (Table 4.5 and Figure 
4.47c), and Clec7a (Table 4.5 and Figure 4.47d). Expression of all these genes 
has been previously reported to be increased in hippocampal tissue from 6-month 
old rTg4510 female mice (Wes et al., 2014), in isolated microglia from rTg4510 
mice (Wang et al., 2018), in the cortex of amyloid mice at late stages of pathology 
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(Rothman et al., 2018), and in the neocortex, hippocampus and microglia of mice 
with amyloid and tau pathology (Keren-Shaul et al., 2017, Landel et al., 2014). 
Furthermore, recent transcriptional studies in human brain have shown that 
microglial gene networks exhibit an increase in expression in response to AD 
neuropathology (Felsky et al., 2019). 
 
Figure 4.46 – Transcriptional trajectories associated with the accumulation of tau 
pathology in rTg4510 mice. 
Violin plot showing increasing absolute effect size (Log2 fold change) across age 
groups for transcripts characterised by significant (FDR < 0.05, n = 1,762 transcripts) 
temporal changes in gene expression associated with genotype. White dots represent 
the median absolute fold-change. 
 
Table 4.4 – Significant progressive increase with age of expression differences 
associated with the accumulation of tau pathology. 
 
Age group 



































Table 4.5 – Top-ranked differentially expressed transcripts associated with 













106.32 2.75 1.28E-18 
59 
Cd68 103.77 1.85 2.26E-18 
Itgax 86.85 4.42 6.54E-15 




Figure 4.47 – Top-ranked differentially expressed transcripts associated with 
progression of tau pathology in rTg4510. 
Shown are individual plots for: (a) Gfap, (b) Cd68, (c) Itgax, and (d) Clec7a. 
Normalised RNA-seq read counts were obtained using DESeq2. Dashed lines 
represent mean paths for each time point. rTg4510 transgenic (TG, blue) female mice 
compared to wild type (WT, black) littermate control mice. Total n = 59 animals (6-8 




I used GOseq (see Section 4.2.5.2) to identify ontological enrichments amongst 
genes characterised by progressively-altered gene expression in rTg4510 mice, 
finding highly-significant enrichments for immune-related biological pathways 
including "immune system process" (FDR = 1.03E-25), “defence response” (FDR 
= 2.98E-24) and “immune response” (FDR = 4.79E-24) (Supplementary Table 
6). Given these findings, I decided to next quantify Iba1 (see Section 4.2.7), a 
microglia/macrophage-specific calcium-binding protein (Ohsawa et al., 2004), in 
matched tissue sections from the right brain hemisphere (n = 7-10 animals per 
group, total n = 70). I observed a significant increase in Iba1 in all brain regions 
assessed (hippocampus: factorial ANOVA, F(3,62) = 12.60, P = 1.56E-06; cortex: 
factorial ANOVA, F(3,62) = 18.13, P = 1.47E-08; thalamus: factorial ANOVA, 
F(3,62) = 18.85, P = 8.37E-09) (Figure 4.48). 
 
 
Figure 4.48 – rTg4510 mice show a progressive increase in Iba1 immunoreactivity. 
(a-c) Quantification of Iba1 immunoreactivity in each tested region: (a) hippocampus 
(total n = 70 animals, 7-10 animals per group), (b) cortex (total n = 70 animals, 7-10 
animals per group), (c) thalamus (total n = 70 animals, 7-10 animals per group). 
rTg4510 transgenic (TG, blue) female mice compared to wild type (WT, black) 




4.3.4.1. Progressively changed transcripts include genes nominated from 
genetic studies of AD 
The list of transcripts progressively altered in rTg4510 mice includes genes 
robustly associated with familial AD from genetic studies of human patients, 
including App (Figure 4.49a; Likelihood-ratio test, LRT statistic = 13.88, log2 fold 
change (2-8 months) = -0.35, FDR = 0.037), a key driver of amyloid pathology. It 
also includes genes annotated to both common and rare variants identified in 
GWAS and exome-sequencing studies of late-onset sporadic AD (LOAD), 
including Trem2 (Likelihood-ratio test, LRT statistic = 43.82, log2 fold change (2-
8 months) = 1.46, FDR = 3.73E-07), Pld3 (Likelihood-ratio test, LRT statistic = 
36.80, log2 fold change (2-8 months) = -0.58, FDR = 5.80E-06), Frmd4a 
(Likelihood-ratio test, LRT statistic = 27.81, log2 fold change (2-8 months) = 0.36, 
FDR = 0.00022), Clu (Likelihood-ratio test, LRT statistic = 27.73, log2 fold change 
(2-8 months) = 0.80, FDR = 0.00023), Apoe (Likelihood-ratio test, LRT statistic = 
22.99, log2 fold change (2-8 months) = 0.86, FDR = 0.0014), Picalm (Likelihood-
ratio test, LRT statistic = 21.37, log2 fold change (2-8 months) = 0.26, FDR = 
0.0025), Cd33 (Likelihood-ratio test, LRT statistic = 27.32, log2 fold change (2-8 
months) = 1.14, FDR = 0.00026), and Abi3 (Likelihood-ratio test, LRT statistic = 






Figure 4.49 – Transcripts progressively altered in rTg4510 mice include many 
genes implicated in familial and sporadic AD from genetic association studies. 
Genes showing temporal shifts in expression in rTg4510 mice included: (a) App; (b) 
Trem2; (c) Pld3; (d) Frmd4a; (e) Clu; (f) Apoe; (g) Picalm; (h) Cd33; and (i) Abi3. Total 
n = 59 animals (29 TG, 30 WT). Normalised counts were obtained using DESeq2. 
Dashed lines represent mean paths across age groups. rTg4510 transgenic (TG, blue) 
mice compared to wild type (WT, black) littermate controls. 
 
 
4.3.5. Progressive changes in gene expression in the entorhinal 
cortex mirror the development of amyloid neuropathology in 
J20 mice 
In contrast to the dramatic and progressive changes in gene expression identified 
in rTg4510 mice, fewer significant temporal transcriptional differences associated 
with the progression of amyloid pathology were identified in the J20 mice; in total 
we identified five transcripts (Cst7, Wdfy1, Grxcr2, Itgax, and Ifitm1) whose 
expression profile significantly changed (FDR < 0.05) with the progression of 
amyloid pathology (Table 4.6 and Supplementary Table 7). The relatively low 
number of significantly-altered genes in J20 mice potentially reflects the slower 
and later accumulation of pathology in these mice compared to rTg4510 mice. 
Previous work has shown relatively limited amyloid pathology in J20 entorhinal 
cortex even at 14 months of age (Harris et al., 2010), with neuronal cell loss 
varying by brain region (Wright et al., 2013). Nevertheless, we found that effect 
sizes for the 1,762 transcripts identified as being progressively dysregulated in 
rTg4510 mice were significantly correlated across both models, suggesting some 
common molecular signals associated with both tau and amyloid pathology 
(Figure 4.50; Pearson correlation, r = 0.46, P = 1.50E-92; exact binomial test, n 
= 1762 transcripts, P = 1.97e-05). Interestingly, two genes, Cst7 and Itgax, 
identified as being associated with progressive tau pathology in rTg4510 mice 
(Figure 4.52a and Figure 4.47c) were also significantly associated with amyloid  
pathology in J20 mice (Figure 4.51, Figure 4.52b, and Figure 4.53). Cst7 
encodes the protein cystatin F, a member of the cystatin superfamily of naturally 
occurring cysteine protease inhibitors (Hamilton et al., 2008, Ni et al., 1998). 
Cysteine proteases are involved in protein disruption during programmed cell 
death, and the regulation of their activity is essential for cell homeostasis, with 
other cysteine protease inhibitors (e.g. cystatin C) having been shown to play a 
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protective role in AD and other neurodegenerative diseases (Hasanbasic et al., 
2016). According to Hamilton et al. (2008), the aminopeptidase cathepsin C is a 
major target of cystatin F in different immune cell types, which regulates the 
activation of effector serine proteases in T cells, natural killer cells, neutrophils 
and mast cells, suggesting an important role for cystatin F in the regulation of 
various immune cell effector functions. Cst7 is expressed selectively in immune 
cells, and like Itgax is a marker for activated microglia (Hansen et al., 2018). Of 
note, the expression of Cst7 has been reported to be increased in the presence 
of AD pathology in other studies (Keren-Shaul et al., 2017, Ofengeim et al., 2017), 
and was found as the top gene showing an increase in expression in cortex 
samples from 12 month-old APP NL-G-F knock-in mice (Castillo et al., 2017). 
Itgax codes for the integrin CD11c (or integrin alpha X) protein, which combines 
with integrin β2 (ITGB2/CD18) to form the leukocyte-specific integrin known as 
inactivated-C3b (iC3b) receptor 4 (CR4) (Bilsland et al., 1994). The resulting 
complex has a role in the phagocytosis of complement coated particles. CD11c 
is highly expressed in most dendritic cells, but also on monocytes, macrophages, 
neutrophils, and some B cells (Bilsland et al., 1994, Ugarova and Yakubenko, 
2001). Only a limited number of cells in the mouse brain express CD11c under 
physiological conditions; however, in pathological conditions, including AD, 
changes in the number, morphology, and distribution of CD11c-expressing 
microglia occur, and CD11c+ microglia have been observed to be spatially 
associated with amyloid plaques in an AD mouse model (Kamphuis et al., 2016). 
Additionally, CD11c has been reported to be increased in microglia surrounding 
Aβ plaques in human AD brains in immunohistochemistry analyses (Akiyama and 
McGeer, 1990). Together these results suggest common mechanisms of 
microglia activation in response to tau pathology in rTg4510 and amyloid 




Table 4.6 – Differentially expressed transcripts associated with progression of 













37.37 2.42 0.00072 
62 
Wdfy1 29.34 0.65 0.018 
Grxcr2 27.61 1.36 0.022 
Itgax 27.49 1.44 0.022 
Ifitm1 26.42 1.55 0.029 
 
 
Figure 4.50 – Effect sizes at differentially expressed transcripts associated with 
the progression of tau in rTg4510 mice are correlated with those associated with 
the progression of amyloid in J20 mice. 
Positive correlation for effect size (Log2 fold change from latest time point compared to 
baseline) for significant transcripts in rTg4510 mice (Pearson correlation, r = 0.46, P = 





Figure 4.51 – Effect sizes at differentially expressed transcripts associated with 
the progression of amyloid in J20 mice are correlated with those associated with 
the progression of tau in rTg4510 mice. 
Two transcripts (Cst7 and Itgax) were significantly associated with the progression of 
both tau (Tg4510) and amyloid (J20) pathology (Pearson correlation, r = 0.77, P = 0.13; 






Figure 4.52 – Cst7 was significantly associated with the progression of both tau 
and amyloid pathology. 
(a) Cst7 gene expression in rTg4510 mice (Total n = 59 animals, 6-8 animals per 
group, Likelihood-ratio test, LRT statistic = 36.10, log2 fold change (2-8 months) = 
6.59, FDR = 7.71E-06). rTg4510 transgenic (TG, blue) female mice compared to wild 
type (WT, black) littermate control mice. (b) Cst7 gene expression in the J20 mice 
(Total n = 62 animals, 6-8 animals per group, Likelihood-ratio test, LRT statistic = 
37.37, log2 fold change (6-12 months) = 2.42, FDR = 0.00072). J20 transgenic (TG, 
red) female mice compared to wild type (WT, black) littermate control mice. Normalised 







Figure 4.53 – Itgax gene expression increases with age and the progression of 
amyloid pathology in J20 mice. 
The expression of Itgax in J20 mice (Total n = 62 animals, 6-8 animals per group, 
Likelihood-ratio test, LRT statistic = 37.37, log2 fold change (6-12 months) = 2.42, FDR 
= 0.00072) reflects the changes seen in rTg4510 mice (see Figure 4.47c). Normalised 
counts were obtained using DESeq2. Dashed lines represent mean paths for each time 
point. J20 transgenic (TG, red) female mice compared to wild type (WT, black) 




4.3.6. Transcriptional changes identified in rTg4510 mice reflect 
those observed in other models of tau pathology 
A number of recent studies have described further evidence for differential gene 
expression in transgenic models of familial AD gene mutations (Castillo et al., 
2017, Keren-Shaul et al., 2017, Landel et al., 2014, Matarin et al., 2015, Rothman 
et al., 2018, Wang et al., 2018, Wes et al., 2014) (see Section 1.5.2.1 in Chapter 
1). We therefore explored hippocampal RNA-seq data from two other transgenic 
models (TAU (Camk2a-MAPTP301L) and TAS10 (SwAPP, K670N/M671L)) 
downloaded from the Mouseac database (Matarin et al., 2015, Salih et al., 2018) 
(www.mouseac.org) to identify consistencies in the transcriptional signatures 
between different models of tau and amyloid pathology. Effect sizes for 
transcripts identified as associated with rTg4510 genotype and also present in 
the Mouseac TAU RNA-seq dataset (n = 138) were significantly correlated 
between the two models (r = 0.33, P = 7.7E-05). Despite this consistency in effect 
sizes, many of the differentially expressed genes associated with rTg4510 
genotype were not statistically replicated in the TAU model (Table 4.7, Figure 
4.54 and Supplementary Table 8), although this likely reflects the distinct 
genetic background of the different transgenic lines and the modest power to 
detect effects given the small number of samples profiled in the Mouseac dataset 
(n = 49 RNA-seq samples, 1-4 animals per age group, after filtering for samples 
with complete phenotypic data). Differential expression of Gpr17 was associated 
with TAU genotype (Bonferroni-corrected P < 0.00035), although the exact profile 
for this gene differed to that observed in the rTg4510 mice (Figure 4.55b). This 
putative receptor for leukotrienes, uracil nucleotides and/or oxysterols may 
warrant further investigation as its expression is associated with damage to 
neural tissue including white matter (Fumagalli et al., 2016). As expected, given 
the limited evidence for consistency in genotype effects between rTg4510 and 
J20 mice, there was no correlation between effects observed in rTg4510 and 





Figure 4.54 – Comparison of rTg4510 genotype-associated transcriptional 
differences in another transgenic model of tau pathology. 
(a) Correlation of effect size (log2 fold change) between rTg4510 genotype-associated 
genes and the same genes in the TAU mouse model from Mouseac (Pearson 
correlation, r = 0.33, P = 7.73E-5, exact binomial test, n = 138 transcripts, P = 0.11). (b) 
Correlation of genotype-associated P values (applying the same linear regression 
model) between rTg4510 and the same genes in the TAU mouse model from Mouseac 




Table 4.7 – The majority of the top-ranked differentially expressed transcripts 
associated with rTg4510 genotype were not statistically replicated in the TAU 
mouse model from Mouseac. 









t(20) = -0.18 -1.31 0.87 
25 
Gpr17 t(20) = 4.49 3.13 0.00023 
Blnk t(20) = 1.35 1.11 0.19 




Figure 4.55 – Most of top-ranked differentially expressed transcripts associated 
with rTg4510 genotype were replicated in another mouse model of tau pathology. 
Shown are individual plots for: (a) Car4. (b) Gpr17. (c) Blnk. (d) Hspa5. Total n = 25 
animals (2-4 animals per group). TAU transgenic transcriptomic data obtained from 
Mouseac (dark blue) compared to wild type (black) controls. Dashed lines represent 




In contrast, association statistics for the 1640 transcripts identified as being 
progressively altered with age in rTg4510 mice and also present in the Mouseac 
datasets (Supplementary Table 9 and Supplementary Table 10) were 
significantly correlated with those for the same genes in both TAU (r = 0.46, P = 
1.2e-86) and TAS10 (r = 0.23, P = 3.9E-21) transgenic mice (Figure 4.56). Given 
the small number of progressive alterations observed in J20 mice, it was not 
possible to systematically explore overlaps between differentially regulated 
genes in this model and the two Mouseac models. Of note, however, the two 
genes identified as being temporally-altered in both rTg4510 and J20 mice – Cst7 
and Itgax – were both similarly altered in both the TAU and TAS10 models (Table 





Figure 4.56 – Analysis of genes showing progressive transcriptional differences 
in rTg4510 mice in other transgenic models. 
(a) Correlation of P values between the rTg4510 and TAU mouse models (using 
transcriptional data from Mouseac) for an analysis of interactions between and 
genotype and age for genes identified as significant in rTg4510 mice (Pearson 
correlation, r = 0.46, P = 1.22E-86, exact binomial test, n = 1640 transcripts, P < 2.2e-
16). (b) Correlation of P values between the rTg4510 and TAS10 mouse models (using 
transcriptional data from Mouseac) for an analysis of interactions between genotype 
and age for genes identified as significant in rTg4510 mice (Pearson correlation, r = 




Table 4.8 – Differential expression of Cst7 and Itgax were statistically replicated in 
TAU and TAS10 Mouseac mouse models. 












F(3,16) = 48.73 187.00 1.46E-8 25 
TAS10 F(3,15) = 43.42 11.58 6.50E-8 24 
TAU 
Itgax 
F(3,16) = 137.86 28.59 3.95E-12 25 




Figure 4.57 – Cst7 and Itgax were similarly altered in both the TAU and TAS10 
models. 
(a) Cst7 in TAU mice from Mouseac (Total n = 25 animals, 2-4 animals per group). 
TAU transgenic mice (dark blue) compared to wild type (black) controls. (b) Cst7 in 
TAS10 mice from Mouseac (Total n = 24 animals, 1-4 animals per group). TAS10 
transgenic mice (pink) compared to wild type (black) controls. (c) Itgax in TAU mice 
from Mouseac (Total n = 25 animals, 2-4 animals per group). TAU transgenic mice 
(dark blue) compared to wild type (black) controls. (d) Itgax in TAS10 mice from 
Mouseac (Total n = 24 animals, 1-4 animals per group). TAS10 transgenic mice (pink) 





4.3.7. Gene co-expression networks associated with the 
progression of tau pathology are enriched for functional 
pathways related to AD including synaptic transmission, the 
immune system, and glial cell activation 
Given the dramatic transcriptional changes identified in the rTg4510 mice, I next 
used WGCNA (see Section 4.2.6.) to identify discrete co-expression modules 
and describe systems-level transcriptional variation associated with rTg4510 
genotype and the progression of tau pathology. I constructed co-expression 
networks using entorhinal cortex RNA-seq data from rTg4510 TG and WT mice 
(n = 58 mice), identifying 18 discrete co-expression modules (Figure 4.58). Next, 
I used a linear regression model (see Section 4.2.6.) and identified six co-
expression modules (here named as “salmon”, “turquoise”, “purple”, “yellow”, 
“light-cyan”, and “red”) that were significantly (Bonferroni corrected, P < 0.0028) 
associated with rTg4510 genotype (Figure 4.58, Table 4.9, Figure 4.59 and 
Supplementary Table 11). Strikingly, these tau-associated co-expression 
modules are highly enriched for molecular functions and biological pathways 
directly related to AD. The red module, for example, which was down-regulated 
in TG mice compared to WT mice (β = -0.18, P = 1.43E-10), is highly enriched 
for functional pathways involved in synaptic transmission (Supplementary Table 
12). The turquoise module, which was up-regulated in TG mice compared to WT 
mice (β = 0.18, P = 3.04E-10), is enriched for pathways involved in activation of 
the immune system (Supplementary Table 13). The salmon module, which was 
consistently up-regulated in TG mice compared to WT mice (β = 0.14, P = 3.58E-
06), is enriched for genes involved in myelination and glial cell activation 
(Supplementary Table 14). The purple module, which was down-regulated in 
TG mice compared to WT mice (β = -0.13, P = 0.00012), is enriched for pathways 
related to cellular component disassembly (Supplementary Table 15). Finally, 
the yellow module, which was down-regulated in TG mice compared to WT mice 
(β = -0.10, P = 0.0015), is enriched for pathways related to mitochondria and 
synaptic processes (Supplementary Table 16). 
The module eigengenes for three of these co-expression modules (turquoise, 
yellow and red) were characterised by a significant interaction between genotype 
and age in rTg4510 mice (Figure 4.58 and Supplementary Table 11), 
suggesting that they are temporally linked to the development of tau pathology in 
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TG mice (Figure 4.60). The turquoise module becomes increasingly up-regulated 
with the development of tau pathology (β = 0.28, P = 4.23E-06), the red module 
becomes increasingly down-regulated with the development of tau pathology (β 
= -0.21, P = 0.0022), and the yellow module becomes down-regulated specifically 
during the later stages of tau pathology (β = -0.29, P = 0.0018). Using the 
matched immunohistochemistry data generated across multiple brain regions for 
each mouse we were able to explore the relationship between co-expression 
modules and actual tau pathology in rTg4510 mice, confirming that the turquoise, 
yellow, and red modules are robustly associated with the accumulation of tau 
across the brain (Figure 4.62). The association with pathology was particularly 
strong in highly affected brain regions such as the hippocampus (Figure 4.61, 
Figure 4.63, Figure 4.64, Figure 4.65 and Figure 4.66), in which the module 
eigengene for the turquoise module is positively correlated with levels of tau in 
TG mice (r = 0.85, P = 1.20E-16), and those for the yellow and red modules are 
negatively correlated with levels of tau in TG mice (yellow: r = -0.63, P = 2.00E-
07, red: r = -0.79, P = 4.61E-13). Although these co-expression modules were 
also correlated with measures of tau pathology in the thalamus, the magnitude of 
effects was much lower, reflecting the later and less aggressive accumulation of 




Figure 4.58 – Co-expression modules associated with tau pathology in rTg4510 
mice. 
In total 18 co-expression modules (each labelled with an arbitrary colour) were 
identified in the rTg4510 TG and WT mice (n = 58 RNA-seq datasets). Shown is the 
association of each module with genotype, age and progressive changes in TG mice 
(i.e. the interaction between genotype and age). Bonferroni corrected significant 
(α=0.05) P values are highlighted with an asterisk. The total number of genes in each 




Table 4.9 – Six co-expression modules were associated with rTg4510 genotype. 










t(53) = -7.93 -0.18 1.43E-10 
58 
Turquoise t(53) = 7.73 0.18 3.04E-10 
Salmon t(53) = 5.17 0.14 3.58E-06 
Light-cyan t(53) = -4.81 -0.13 1.29E-05 
Purple t(53) = -4.15 -0.13 0.00012 





Figure 4.59 – Entorhinal cortex co-expression modules associated with rTg4510 
genotype. 
Six modules were significantly different (Bonferroni corrected P < 0.0028) between TG 
and WT mice. (a) Red module. (b) Turquoise module. (c) Salmon module. (d) Light-
cyan module. (e) Purple module. (f) Yellow module. Shown for each module is the 
module eigengene value for each individual animal (total n = 58 mice). Coloured circles 
represent rTg4510 TG mice and white circles represent WT control mice. Each circle 








Figure 4.60 – Variation in three entorhinal cortex co-expression modules parallels the accumulation of tau pathology in rTg4510 mice. 
Shown are module eigengene values for each individual mouse at four time-points for (a) the turquoise module (n = 3091 transcripts, linear regression, 
F(3,50) = 12.18, β = 0.28, P = 4.23E-06), (b) the yellow module (n = 1102 transcripts, linear regression, F(3,50) =5.79, β = -0.29, P = 0.0018), and (c) the red 
module (n = 726 transcripts, linear regression, F(3,50) = 5.58, β = -0.21, P = 0.0022). Total n = 59 animals (6-8 animals per group). Coloured circles represent 
rTg4510 TG mice and white circles represent WT control mice. Each circle represents a single individual mouse. Dashed lines represent mean paths for each 







Figure 4.61 – The same three tau-associated co-expression modules are correlated with actual levels of tau pathology quantified using 
immunohistochemistry in the same mice. 
Shown are scatter-plots highlighting the (a) positive correlation between module eigengene in the turquoise module and tau pathology in the hippocampus 
(Pearson correlation, r = 0.85, P = 5.00E-17), (b) negative correlation between module eigengene in the yellow module and tau pathology in the hippocampus 
(Pearson correlation, r = -0.63, P = 1.00E-07), and (c) negative correlation between module eigengene in the red module and tau pathology in the 
hippocampus (Pearson correlation, r = -0.79, P = 2.00E-13). Coloured circles represent rTg4510 TG mice and white circles represent WT control mice. Each 






Figure 4.62 – Entorhinal cortex co-expression modules are strongly correlated 
with tau pathology across multiple brain regions. 
Heatmap representing module-trait relationships between module eigengenes and tau 
pathology measured using immunohistochemistry in each brain region assessed, 
where red indicates a positive correlation and blue indicates a negative correlation. 
Values indicate Pearson correlation (r) coefficients and their corresponding P values in 









Figure 4.63 – Module membership for each transcript from the three co-expression networks showing progressive changes in rTg4510 mice is 
strongly correlated with actual levels of pathology in the hippocampus measured using immunohistochemistry. 
Shown is the correlation of module membership for each transcript with tau pathology in the hippocampus in (a) the turquoise module (n = 3091 transcripts, 
Pearson correlation, r = 0.85, P < 1.00E-200), (b) the yellow module (n = 1102 transcripts, Pearson correlation, r = 0.49, P = 1.30E-67), and (c) the red 









Figure 4.64 – Intramodular connectivity for each transcript from the three co-expression networks showing progressive changes in rTg4510 mice is 
strongly correlated with actual levels of pathology in the hippocampus measured using immunohistochemistry. 
Shown is the correlation of intramodular connectivity for each transcript with tau pathology in the hippocampus in (a) the turquoise module (Pearson 
correlation, r = 0.75, P < 1.00E-200), (b) the yellow module (Pearson correlation, r = 0.48, P = 1.40E-64), and (c) the red module (Pearson correlation, r = 








Figure 4.65 – Intramodular connectivity for each transcript from the three co-expression networks showing progressive changes in rTg4510 mice is 
strongly correlated with its module membership. 
Shown is the correlation of module membership raised to power 6 (y-axis) against intramodular connectivity (x-axis) in (a) the turquoise module (Pearson 
correlation, r = 0.99, P < 1.00E-200), (b) the yellow module (Pearson correlation, r = 0.98, P < 1.00E-200), and (c) the  red module (Pearson correlation, r = 








Figure 4.66 – The three tau-associated co-expression modules are strongly correlated with pathological burden measured by immunohistochemistry 
in regions of the brain affected early in AD. 
(a) Correlation of module eigengenes for each sample with tau pathology in the CA1 sub-region of the hippocampus in the turquoise module (Pearson 
correlation, r = 0.87). (b) Correlation of module eigengenes for each sample with tau pathology in the CA3 sub-region of the hippocampus in the yellow 
module (Pearson correlation, r = -0.63). (c) Correlation of module eigengenes for each sample with tau pathology in the visual cortex in the red module 
(Pearson correlation, r = -0.79). Correlations and corresponding P values for all modules and traits can be seen in Figure 4.62. Each circle represents a single 









Figure 4.67 – The three tau-associated co-expression modules are less strongly correlated with pathological burden measured by 
immunohistochemistry in regions of the brain affected in later stages. 
(a) Correlation of module eigengenes for each sample with tau pathology in the thalamus in the turquoise module (Pearson correlation, r = 0.70). (b) 
Correlation of module eigengenes for each sample with tau pathology in the thalamus in the yellow module (Pearson correlation, r = -0.59). (c) Correlation of 
module eigengenes for each sample with tau pathology in the thalamus in the red module (Pearson correlation, r = -0.64). Correlations and corresponding P 
values for all modules and traits can be seen in Figure 4.62. Each circle represents a single individual mouse, with coloured circles representing rTg4510 TG 




Within each of these three modules we ranked transcripts based on their 
intramodular connectivity to identify “hub” genes within each network, finding 
many genes known to play a major role in the neuro-immunological and 
neurodegenerative processes involved in AD. In the turquoise module the four 
genes with the highest intramodular connectivity (i.e. those with most connections 
to other genes) were Cd63, Msn, Npc2 and Tnfrsf1a (Supplementary Table 17), 
with other highly interconnected transcripts including several genes identified as 
having a role in LOAD from GWAS (e.g. Abca1, Clu and Apoe) in addition to 
genes previously implicated in AD pathology (e.g. Itgax, Clec7a and Cd68). 
Furthermore, genes identified as having the strongest connections (edges) to 
other genes (nodes) in the turquoise module included C1qb, Mpeg1, Tyrobp, and 
Trem2 (Figure 4.68). In the yellow module the four genes with the highest 
intramodular connectivity were Atp9a, Ywhag, Rab3a and Svop (Supplementary 
Table 18), with App also being a highly-connected gene in this module. Genes 
identified as having the strongest connections to other genes in the yellow module 
included Atp9a, Faim2, Ppp2r1a (Figure 4.69). In the red module Atxn7l3, Sept5, 
Cbx6 and Fbxl16 were the top most connected genes (Supplementary Table 
19). Genes with the strongest connections to other genes in the red module 




Figure 4.68 – Network plot highlighting core members of the turquoise gene co-
expression module associated with the development of tau pathology. 
Shown are the top 50 nodes (i.e. genes) with the strongest edges (representing 
individual connections with other genes) for the turquoise module (all genes with 
increased expression – log2 fold change for latest time point against baseline). 
Stronger colours reflect higher absolute log2 fold change (8 months against 2 months). 





Figure 4.69 – Network plot highlighting core members of the yellow gene co-
expression module associated with the development of tau pathology. 
Shown are the top 50 nodes (i.e. genes) with the strongest edges (representing 
individual connections with other genes) for the yellow module (genes with decreased 
expression are shown in yellow, and genes with increased expression are shown in 
grey). Stronger colours reflect higher absolute log2 fold change (8 months against 2 





Figure 4.70 – Network plot highlighting core members of the red gene co-
expression module associated with the development of tau pathology. 
Shown are the top 50 nodes (i.e. genes) with the strongest edges (representing 
individual connections with other genes) for the red module (all genes with decreased 
expression). Stronger colours reflect higher absolute log2 fold change (8 months 
against 2 months). Total n = 58 animals (6-8 animals per group). 
 
 
4.3.8. Co-expression changes identified in rTg4510 mice 
overlap with AD-associated co-expression changes from 
human studies 
We next compared the significant rTg4510 co-expression modules to AD-
associated co-expression modules reported in a recent human post-mortem 
RNA-seq meta-analysis, focusing on modules identified in dorsolateral prefrontal 
cortex (DLPFC) and temporal cortex (TCX) (Logsdon et al., 2019). Briefly, we 
used a hypergeometric test to identify overlaps between the six rTg4510-
associated co-expression modules (“salmon”, “turquoise”, “purple”, “yellow”, 
“light-cyan”, and “red”) and four DLPFC (Supplementary Table 20) and five TCX 
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(Supplementary Table 21) AD-associated human co-expression modules, 
restricting our analysis to mouse-human homologs (see Section 4.2.6.1). After 
controlling for the number of comparisons performed for each of the human brain 
regions (DLPFC: Bonferroni-corrected P < 0.0021; TCX: Bonferroni-corrected P 
< 0.0017), each of the rTg4510-associated modules was found to significantly 
overlap with at least one AD-associated module in both human cortical regions. 
For example, genes in the turquoise rTg4510 module (enriched for pathways 
involved in activation of the immune system (Supplementary Table 13)), were 
found to overlap significantly with two human DLPFC modules (“DLPFC-blue” 
and “DLPFC-brown” from Logsdon et al.) and three TCX modules (“TCX-blue”, 
“TCX-turquoise” and “TCX-yellow” from Logsdon et al.) associated with AD; for 
this module the largest proportion of overlaps in genes were found with the 
“DLPFC-blue” module (n = 658 genes, 40.82% of the human module gene list, P 
< 2.2E-16) and the “TCX-turquoise” module (n = 389 genes, 39.1% of the human 
module gene list, P < 2.2E-16). Interestingly, GOseq analysis (see Section 4.2.6) 
highlighted a strong enrichment for immune response processes amongst the 
rTg4510 turquoise module genes overlapping with those in both the “DLPFC-
blue” module (Supplementary Table 22) and the “TCX-turquoise” module 
(Supplementary Table 23). Reflecting the similarities between these two human 
cortex modules, the list of overlapping genes includes many of the core hub 
transcripts identified in the turquoise rTg4510 turquoise module for both the 
“DLPFC-blue” module (e.g. CD63, ABCA1, CLU, APOE, ITGAX, CLEC7A, 
C1QB, TYROBP, and TREM2) and “TCX-turquoise” module (e.g. CD63, ITGAX, 
CLEC7A, C1QB, TYROBP, and TREM2). Together, these results indicate that 
the transcriptional networks associated with tau pathology in rTg4510 mice 
overlap considerably with those identified in human AD cortex and are involved 





4.4.1 Overview of results 
In this study, I quantified transcript read counts and profiled gene expression in 
TG and WT animals in a model of tau (rTg4510) and a model of amyloid (J20) 
pathology. To my knowledge, this represents the most extensive gene expression 
dataset generated on rodent models of AD pathology, providing excellent power 
to identify transcriptional variation associated with mutations in MAPT and APP, 
and the progressive changes in gene expression accompanying the development 
of AD pathology in TG mice. I identified transcriptional changes in the entorhinal 
cortex associated with the progression of AD-associated pathology in the two 
transgenic models. I found robust genotype-associated differences in entorhinal 
cortex gene expression in both models and identified widespread changes in 
gene expression paralleling the development of tau pathology in rTg4510 mice 
and reflecting alterations observed in other models of tau pathology. Of note, the 
list of transcripts progressively altered in rTg4510 mice includes genes robustly 
associated with familial AD from genetic studies of human patients, including App 
which is a key driver of amyloid pathology. It also includes genes annotated to 
both common and rare variants identified in GWAS and exome-sequencing 
studies of late-onset sporadic AD. Systems-level analyses identified discrete co-
expression networks associated with the progressive accumulation of tau, with 
these also being enriched for genes and pathways previously implicated in 
neuroimmune and neurodegenerative processes driving AD pathology. Further 
support for upregulation of immune system genes in response to tau pathology 
comes from our finding of increased expression of complement pathway genes 
including C1qa, C1qb, and C1qc. Finally, we compared these tau-associated 
networks to those identified in human post-mortem tissue from AD individuals, 
finding considerable overlap with disease-associated co-expression modules. 
To our knowledge, our study represents the most systematic analysis of 
transcriptional variation in mouse models of tau and amyloid pathology, and is 
the first to focus specifically on changes in the entorhinal cortex, a key region of 
the brain implicated early in the pathogenesis of AD (Braak and Braak, 1991). 
Compared to previous studies of transcriptional variation in transgenic mouse 
models of AD we profiled a relatively large number of samples spanning multiple 
222 
 
time-points selected to encompass the development of pathology; my study was 
therefore well powered to identify gene expression differences associated with 
both genotype and the progression of AD pathology. Furthermore, we 
implemented a statistical approach that enabled us to detect progressive 
changes in gene expression across age between the TG and WT samples, not 
only identifying stable differences induced by the transgene at each time-point, 
but also assessing temporal transcriptional changes relative to baseline within 
mutant mice. Our detailed immunohistochemical analyses (described in Chapter 
3) also allowed me to directly compare transcriptional variation with measures of 
tau and amyloid pathology measured in the same individual mice. 
Together my results reflect the dramatic upregulation of microglial genes 
observed in studies of other AD rodent models (Kamphuis et al., 2016, Kan et al., 
2015, Keren-Shaul et al., 2017, Landel et al., 2014, Matarin et al., 2015, Rothman 
et al., 2018), and also support a role – either causal or consequential – for 
dysregulation of the central nervous system (CNS) immune system in the 
development of AD pathology. In line with other studies using murine models of 
AD, mostly of amyloid pathology, Cst7 and Itgax (Cd11c) showed increased 
expression both in rTg4510 and J20 entorhinal cortex as a result of accumulation 
of neuropathology. These two genes are markers for activated microglia; 
therefore, this observation is most probably microglia-associated, as shown in the 
single-cell gene expression studies discussed previously (Chapter 1, Section 
1.5.2), suggesting an important role for microglia in the presence of pathological 
tau and amyloid. 
 
In summary, this study provides compelling evidence for widespread 
transcriptional changes in the entorhinal cortex paralleling the progression of AD 
pathology. Our data suggest that the altered expression of multiple genes, 
including several known AD risk genes is robustly associated with the 
accumulation of tau, with tau-associated co-expression networks overlapping 
those altered in human AD cortex. Our data provide further support for an 
immune-response component in the accumulation of tau, and reveal novel 





The work presented in this chapter has a number of important limitations that 
should be considered when interpreting my results. 
First, to minimise the heterogeneity in our analysis we only profiled female mice. 
However, a number of sex differences have been previously reported for these 
models, with females demonstrating elevated and more progressive pathology 
than males (Blackmore et al., 2017, Yue et al., 2011). Future work should focus 
on examining the extent to which the transcriptional profiles identified here are 
consistent between male and female mice. Second, our analysis was performed 
on bulk entorhinal cortex tissue, comprising a mix of different neural cell-types; 
consequently, changes in the fractional contribution of any given cell type to the 
total cellular population will contribute to the observed outcomes at each time-
point. Given the compelling evidence in our data for an enrichment of microglial 
markers, previously shown to be upregulated in AD (Hopperton et al., 2018, 
Keren-Shaul et al., 2017), as well as increased expression of canonical markers 
of astrocytes, future work should focus on identifying changes that occur within 
these and other brain cell-types. Of note, immunocytochemistry analyses of 
tissue sections from the left-brain hemisphere of these mice revealed a 
progressive increase in the microglia/macrophage marker Iba1, indicating that 
our bulk-tissue RNA-seq measurements reflect real underlying cellular changes. 
In rTg4510 mice it is also interesting to consider neuron-specific genes of which 
expression is not decreased, in what is a falling total neuronal population; these 
might represent transcripts which expression is increased in response to 
neuropathology in neuronal cells. Third, compared to the rTg4510 model, 
relatively few transcriptional changes were observed in J20 mice, potentially 
reflecting the slower and later accumulation of pathology (Harris et al., 2010), as 
well as the potential absence of neurodegeneration, in the entorhinal cortex in 
this model; future work should focus on the analysis of other brain regions more 
directly affected in the early stages of amyloid pathology. Interestingly, however, 
we found that effect sizes for the transcripts identified as being progressively 
dysregulated in rTg4510 mice were significantly correlated across both models, 
suggesting some common transcriptional mechanisms are involved in both tau 




Chapter 5.  Global DNA modifications profiling 
in the brain of tau and amyloid mouse 
models 
5.1. Introduction 
Despite global changes in DNA modifications being robustly reported in cancer, 
only limited work has been done in AD, with inconclusive results (see Section 
1.4.1.1 in Chapter 1). Even less studies have been done in rodent models of AD 
(see Section 1.5.2.2 in Chapter 1), looking at a very low number of samples, 
with no studies conducted in mouse models of tau pathology to date. One study 
in particular included brain samples from J20 mice and reported an age-related 
(4, 8, 16, and 34 months) decrease in 5mC in the dentate gyrus (DG) 
hippocampal sub-region in J20 transgenic mice compared to controls, as well as 
a negative correlation between plaque load and 5mC in the DG (Lardenoije et al., 
2018). A decrease in 5mC/5hmC ratio in J20 transgenic mice compared to 
controls in the DG and CA3 hippocampal sub-regions was also reported in this 
study. 
 
This chapter describes my analysis of global DNA modification levels in brain 
tissue from rTg4510 and J20 mice, using two independent approaches. First, I 
quantified global DNA methylation in the hippocampus (see Section 2.4.1 and 
Section 2.5.2 in Chapter 2 for details about brain dissections and isolation of 
DNA) from rTg4510 and J20 transgenic (TG) and wild-type (WT) littermate control 
mice (described in Chapter 2) using a modified version of the Luminometric 
Methylation Assay (LUMA). Second, using immunohistochemistry, I directly 
quantified levels of both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine 
(5hmC) in multiple brain regions (Figure 5.11) in rTg4510 and J20 mice, using 
right hemisphere tissue sections from transgenic (TG) and wild-type (WT) 





LUMA involves the use of differential methylation sensitive restriction enzymes 
followed by polymerase extension assay by pyrosequencing to produce an 
estimation (percentage) of global methylation (Karimi et al., 2006, Karimi et al., 
2011, Luttropp et al., 2015).The LUMA experiments described here were 
performed in conjunction with an undergraduate student (Hedley Baulf) who I was 
directly supervising during his Professional Training Year (PTY) placement in our 
lab. 
 
As explained in Chapter 3, immunohistochemistry relies on the selective 
identification of antigens within tissue sections by means of specific antibodies. 
Antigen-antibody binding is then visualised using a coloured histochemical 
reaction, visible by light microscopy (Ramos-Vara and Miller, 2014). All 
immunohistochemistry experiments for this chapter were performed at Eli Lilly & 
Co. Ltd. (Windlesham, United Kingdom), where I spent about 3.5 months during 
my PhD (from May 2017 to August 2017). I prepared the sections with the help 
of Mark Ward (Eli Lilly) and performed the immunostaining procedures. Josh 
Harvey (Eli Lilly) helped me with the visualisation  and quantification. 
 
5.2. Methods 
In this section the experimental procedures used for i) the evaluation of global 
DNA modification levels in hippocampus samples dissected from rTg4510 and 
J20 mice (described in Chapter 2, Section 2.4 and Section 2.5) using LUMA, 
and ii) the evaluation of DNA methylation and DNA hydroxymethylation levels in 
brain tissue sections (described in Chapter 2, Section 2.4, and in Chapter 3) 
using immunohistochemistry from rTg4510 and J20 mice (Chapter 2, Section 




5.2.1. Assessment of DNA quality and integrity 
DNA samples used for LUMA were quantified and assessed for purity using a 
NanoDrop 8000 spectrophotometer (Thermo Scientific), as described in Section 
2.5.3.1. One rTg4510 sample had a DNA concentration below the required 
minimum and was therefore excluded, leaving a total of 75 rTg4510 samples 
(initial mean concentration = 40.29 ng/µL (SD = 11.58 ng/µL)), and 77 J20 
samples (initial mean concentration = 53.40 ng/µL (SD = 13.94 ng/µL)).  
 
5.2.2. Sample dilutions for LUMA 
To ensure consistency in DNA concentrations across all samples, original DNA 
samples were diluted to 30 ng/µL in Elution Buffer (Qiagen). 5 µL of each dilution 
(150 ng) was then transferred into a 96-well plate to be used for LUMA. 
 
5.2.3. LUMA 
We used a modified version of LUMA (introduced in Section 5.1), using HpaII 
(Thermo Scientific) and MspI (Thermo Scientific) as the differential methylation 
sensitive restriction enzymes as originally described (Karimi et al., 2006, Karimi 
et al., 2011) and MunI (Thermo Scientific) as internal reference (Luttropp et al., 
2015). Both HpaII and MspI cleave the sequence 5’-CCGG-3’ resulting in 5’-CG 
overhangs; however, HpaII is methylation sensitive and therefore only cleaves at 
unmethylated sites, whilst MspI is methylation insensitive and cleaves at both 
methylated and unmethylated sites (Karimi et al., 2006, Karimi et al., 2011). MunI 
is unaffected by DNA methylation status and recognises the sequence 5’-
GAATTC-3’, producing 5’-AATT overhangs which can be distinguished from the 
5’-CG overhangs generated by from HpaII and MspI and therefore used for 
normalisation. We used MunI as an alternative to EcoRI – the enzyme used in 
the original protocol (Karimi et al., 2006, Karimi et al., 2011) – because of its 
similar action and lack of altered specificity at suboptimal conditions (“STAR 
activity”) which is a characteristic of EcoRI (Lisanti et al., 2013). 
An overview of the modified version of LUMA, including the four-step 
pyrosequencing reaction, is given in Figure 5.1. Samples from each mouse 
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model were processed separately and individual samples were randomised to 
ensure that each group was equally represented in each processing batch. 
Moreover, samples were run in duplicates and each duplicate was run on different 
days to control for batch effects. A fully methylated DNA control sample (Thermo 
Scientific) was included in each assay and used as a positive control. All 






Figure 5.1 – An overview of LUMA. 
Genomic DNA from each sample is digested with two combinations of restriction enzymes (MunI + HpaII or MunI + MspI), followed by a polymerase extension 
assay based on a four-step pyrosequencing reaction. In the pyrosequencer, after each nucleotide dispensation, inorganic pyrophosphate (PPi) is released and 
converted to ATP by ATP-sulfurylase. The resulting ATP is then used by luciferase to activate luciferin. The amount of luciferin activation produces a 
proportional amount of visible light, which is detected by a charge coupled device camera. The amount of light is directly proportional to the number of 
overhangs produced by the respective restriction enzymes with each step in the pyrosequencing reaction correlating to a peak in the resulting pyrogram via 
light capture by the camera: 1) the A and T peaks correspond to pyrosequencing Step 1 and Step 3, reflecting the MunI cleavage and should be equal; 2) the 
C + G peak resulting from pyrosequencing Step 2 illustrates HpaII or MspI cleavage; 3) the second C + G peak originating from Step 4 is an internal control 




5.2.3.1. Restriction enzymatic digestion of genomic DNA 
Digestion reactions containing MunI + Hpall (Mix A) or MunI + MspI (Mix B) were 
run in parallel on the same DNA sample (Figure 5.1). Preparation of the master 
mixes (Mix A and Mix B) for restriction enzymatic digestion per 5µL of diluted 
DNA Sample (30 ng/µl) were prepared for each restriction enzyme digestion as 
follows: 
MunI + Hpall (Mix A) MunI + MspI (Mix B) 
12 µL DNAse-Free Water 12 µL DNAse-Free Water 
2 µL 10 x Tango Buffer 2 µL 10 x Tango Buffer 
0.5 µL MunI (10U/µL) 0.5 µL MunI (10U/µL) 
0.5 µL HpaII (10U/µL) 0.5 µL MspI (10U/µL) 
 
15 µL of Mix A (MunI + Hpall) or Mix B (MunI + MspI) were added to 5 µL of 
diluted DNA samples (30 ng/µl) and mixed by pipetting. The plates were then 
sealed and incubated at 37ºC overnight in a thermocycler. Following the 
incubation period, 20 µL of Pyrosequencing Annealing Buffer (Qiagen) was 
added to each well of the pyrosequencing plate and mixed by pipetting. 40 µL of 
the annealing buffer/restriction digest solution was transferred to a 
pyrosequencing plate and placed within the pyrosequencer. 
 
5.2.3.2. Evaluation of enzymatic reactions by agarose gel electrophoresis 
To evaluate the success of the LUMA enzymatic digestions, two ‘test’ digested 
DNA samples were run on a 0.8% agarose gel. Agarose gel electrophoresis is 
explained in detail in Chapter 2 (Section 2.5.3.2). For this experiment we used 
the fluorescent nucleic acid stain SYTO 60 (Thermo Scientific) for visualisation 
(10 µL of SYTO 60 in 100 mL of agarose powder dissolved in 1X TBE). 
5 µL of the digested DNA sample, as well as the original diluted DNA test samples 
(30 ng/µL), were mixed with 2 µL of loading buffer (Orange G, Sigma-Aldrich) in 
a sterile 96-well PCR plate. 5 µL of each sample-loading buffer solution were 
loaded into an individual well in the agarose gel, and 5 µL of a molecular-weight 
size marker (1kb DNA ladder, New England BioLabs) were loaded into the first 
and last wells of the gel. The gel was left to run at 120 v for 40 mins. The LI-COR 
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Odyssey CLx scanner and LI-COR Image Studio Lite software were used to 
visualise the presence, size and intensity of each DNA fragment. The resulting 
gel highlighting digestion of genomic DNA is shown in Figure 5.2. 
 
Figure 5.2 – Agarose gel obtained for the evaluation of enzymatic reactions in test 
samples. 
LH3: original sample, showing one band corresponding to the genomic DNA; Mix A: 
genomic DNA treated with MunI + Hpall; Mix B: genomic DNA treated with MunI + 
MspI; Ladder: molecular weight marker. Smears indicate enzymatically digested DNA. 
 
5.2.3.3. Pyrosequencing 
The ratio of 5’-CG overhangs resulting from the two enzymatic reactions was 
quantified via the integration of nucleotides (dNTPs) into restriction sites using 
pyrosequencing. The pyrosequencing reaction involves the addition of dNTPs in 
four consecutive steps in a predetermined order, discriminating the 5’-CG 
(HpaII/MspI) from the 5’-AATT (MunI) overhangs. The incorporation of the 
nucleotides with DNA polymerase results in release of inorganic pyrophosphate 
(PPi), followed by its conversion into ATP by ATP-sulfurylase and adenosine-5’-
phosphosulfate. The newly formed ATP is then used for the conversion of luciferin 
into oxyluciferin by luciferase, which produces visible light (Figure 5.1). The light, 
proportional to dNTP incorporation in the original 5’-overhang produced by the 
restriction enzyme, is then detected by a charge coupled device camera and 
displayed as peaks in the pyrosequencer software. The resulting ratio of 
overhangs produced from each enzyme digestion reaction can then be used to 
calculate the percentage of global DNA methylation in each sample. 
Pyrosequencing assays were created using the PyroMark Q24 2.0.6 software 
(Qiagen) using the ‘AQ Assay’ (SNP) setup. The pyrosequencing cartridge 
231 
 
(Figure 5.3) was loaded using Pyromark Gold Q96 Reagents (Qiagen) as 




Figure 5.3 Schematic representation of the PyroMark Q24 cartridge. 




Table 5.1 – Pyrosequencing cartridge loading details for a 24-well pyrosequencing 
plate. 
 
Position in cartridge Reagent Volume 
E Pyrosequencing Enzyme 90 µL 
S Pyrosequencing Substrate 90 µL 
A dATP + dH2O 50 µL + 50 µL 
C dCTP + dGTP 50 µL + 50 µL 
G dH2O 100 µL 
T dTTP + dH2O 50 µL + 50 µL 





5.2.3.4. Data analysis 
Pyrograms produced from each assay were analysed using the PyroMark Q24 
2.0.6 software (Qiagen) as shown in Figure 5.4. 
 
Figure 5.4 – Typical pyrograms for LUMA for each enzyme restriction reaction 
(HpaII or MspI) from the same DNA sample. 
Numbers located on the x-axis correspond to the dispensation steps in Figure 5.1. 
Image and legend adapted from Karimi et al. (2006). 
 
Peak heights were extracted and global DNA methylation levels (%) were 
determined using the following equation: 















HpaII (C+G) = Mean peak height for dispensation 2 (Mix A) 
MunI (Aa) = Mean peak height for dispensation 1 (Mix A) 
MspI (C+G) = Mean peak height for dispensation 2 (Mix B) 
MunI (Ab) = Mean peak height for dispensation 1 (Mix B) 
 
All samples were run in duplicate (Section 5.2.3), and an average of the two 
global methylation values from both duplicates was calculated for each sample. 
 
5.2.4. Tissue preparation for immunohistochemistry 
A general overview of the immunohistochemistry procedures for the 
quantification of 5mC and 5hmC, from tissue preparation to visualisation  and 










As described in Chapter 3, right hemisphere brain tissue from each individual 
mouse was processed at Eli Lilly (in the Molecular Pathology department) using 
the Tissue TEK® VIP processor (GMI Inc), embedded in paraffin wax and stored 
for sectioning. During my placement at Eli Lilly, I prepared 6 μm serial sagittal 
sections (from bregma 0.84 to 1.08) using rotary microtomes (HM 200 from 
Ergostar and HM 355S from Thermo Scientific), which were mounted on glass 
slides (two sections per slide) for immunohistochemistry assessments. 
 
5.2.5. Deparaffinisation of the tissue for immunohistochemistry 
As described previously in Chapter 3 (see Section 3.2.2), deparaffinisation of 
the tissue was achieved by washing with xylene (Fisher Scientific), followed by 
70% ethanol (industrial methylated spirit, Fisher Scientific) and deionised water 
for rehydration of the sections. 
 
5.2.6. Immunohistochemistry 
Because we have not previously assessed 5mC and 5hmC levels in the mouse 
brain using immunohistochemistry in our lab, the first step of this study was to 
optimise the immunostaining experimental procedures. Before starting, I 
performed a comprehensive search for potential adequate antibodies; despite not 
finding many options available, according to information from the manufacturer, 
the antibodies used in this chapter looked promising for use in paraffin-embedded 
mouse brain tissue sections. Optimisation steps, which gave rise to satisfactory 
results to move forward with the stains for my rTg4510 and J20 samples, and the 
final protocol are described below. 
All experiments were performed in a blinded and randomised fashion. One slide 
containing no primary antibody and one slide containing no secondary antibody 




5.2.6.1. Antigen retrieval and blocking 
During the optimisation steps I initially performed heat-induced epitope retrieval 
in a PT Module (Thermo Scientific) containing citrate buffer (dilution 1:100), as 
described previously (‘Standard protocol’, described in section 3.2.3.2 in Chapter 
3) (Figure 5.7, Figure 5.8, Figure 5.9 and Figure 5.10). However, we noticed 
considerable background staining and decided to test if performing heat-induced 
antigen retrieval in an electric steamer containing deionised water as an 
alternative (‘Alternative protocol’) to citrate buffer would give more optimal results. 
Indeed, this slight modification dramatically improved the background staining 
(Figure 5.6), and therefore was the method that I used for antigen retrieval in the 
brain sections from rTg4510 and J20 mice used in this study. Samples were 




Figure 5.6 – Two methods for antigen retrieval were tested. 
(a) Immunostain for the quantification of 5mC (primary antibody: anti-5mC (1:4000); 
secondary antibody: biotinylated goat anti-mouse (1:200)) showing the two methods 
tested for antigen retrieval. (b) Immunostain for the quantification of 5hmC. (primary 
antibody: anti-5hmC (1:4000); secondary antibody: biotinylated goat anti-rabbit (1:200)) 
showing the two methods tested for antigen retrieval. Standard protocol: PT Module 




5.2.6.2. Antigen-antibody labelling 
For 5mC, we used mouse monoclonal anti-5-hydroxymethylcytosine (5hmC) 
antibody [RM236] (Abcam, catalogue number ab10805, lot number GR302463-
15) as the primary antibody, which discriminates between the modified base 5mC 
and unmethylated cytosine, and biotinylated goat anti-mouse IgG (Vector labs, 
catalogue number BA-9200, lot number ZB0304) as the secondary antibody 
(1:200). 
For 5hmC, we used rabbit monoclonal anti-5-methylcytosine (5mC) antibody 
[33D3] (Abcam, catalogue number ab214728, lot number GR284756-2) as the 
primary antibody, which reacts with 5-hydroxymethylcytosine in both single-
stranded and double-stranded DNA with no cross reactivity with non-methylated 
cytosine and methylcytosine in DNA, and biotinylated goat anti-rabbit IgG (Vector 
labs, catalogue number BA-1000, lot number ZB1007) as the secondary antibody 
(1:200). 
Considering the dilutions recommended by the manufacturer as a reference, I 
tested a range of dilutions (anti-5mC: 1:1000, 1:2000, 1:4000, 1:8000; anti-5hmC: 
1:500, 1:1000, 1:2000, 1:4000) to determine the optimal concentration for the 
primary antibodies for our experiments (Figure 5.7, Figure 5.8, Figure 5.9 and 
Figure 5.10). The 1:4000 dilution looked optimal for both stains, therefore we 
decided to proceed with a 1:4000 dilution for both anti-5mC and anti-5hmC 
quantifications in our rTg4510 and J20 brain tissue samples. 
Optimisation experiments were performed manually; all samples for each of the 
final 5mC or 5hmC experiments were immunostained together in an autostainer 






Figure 5.7 – Representative immunohistochemistry images for the different concentrations of anti-5mC primary antibody that were tested. 
Sagittal mouse brain sections showing a general view of the stained tissue with the different concentrations (1:1000, 1:2000, 1:4000, 1:8000) of anti-5mC 







Figure 5.8 – Representative hippocampi immunohistochemistry images for the different concentrations of anti-5mC primary antibody that were 
tested. 
The DG sub-region of the hippocampus is showed in detail. Primary antibody: anti-5mC (serial dilutions); secondary antibody: biotinylated goat anti-mouse 





Figure 5.9 – Representative immunohistochemistry images for the different concentrations of anti-5mhC primary antibody that were tested. 
Sagittal mouse brain sections showing a general view of the stained tissue with the different concentrations (1:500, 1:1000, 1:2000, 1:4000) of anti-5hmC 








Figure 5.10 – Representative hippocampi immunohistochemistry images for the different concentrations of anti-5hmC primary antibody that were 
tested. 
The DG sub-region of the hippocampus is showed in detail. Primary antibody: anti-5hmC (serial dilutions); secondary antibody: biotinylated goat anti-rabbit 





For detection we undertook enzymatic labelling using peroxidase (Vectastain 
Elite ABC HRP Reagent, Vector Laboratories) and DAB substrate (Vector 
Laboratories). 
5.2.6.4. Counterstain 
Tissues were counterstained with haematoxylin to provide contrast and 
dehydrated with ethanol and xylene to prepare for mounting. 
 
5.2.7. Mounting and image capture 
Immunohistochemistry samples were mounted in an automated coverslipper 
(ClearVue Coverslipper from Thermo Scientific) using ClearVue mountant. 
Images were digitised with Scanscope AT slide scanner (Aperio) at 20x 
magnification, and saved in svs (ScanScope Virtual Slide) format on an Eli Lilly 
network server. Images were subsequently accessed using the eSlide Manager 
system (Aperio). 
 
5.2.8. Visualisation and quantification 
Visualisation of the digitised tissue sections stored in the network server and 
delineation of a representative area of the anatomical brain regions of interest 
(ROI) was achieved using the software Imagescope (version 12.2.1.5005; 
Aperio). ROI were selected to reflect the known progression of amyloid and tau 
pathology in the two models (see Chapter 3) and to overlap with previous and 
ongoing studies at Eli Lilly in the same mouse models. 
For both mouse models, the ROI defined and quantified were the hippocampi 
sub-regions CA1, CA3 and dentate gyrus (DG); rostral cortex and caudal cortex; 
and thalamus (Figure 5.11), which exhibits very low levels of tau pathology in 
rTg4510 mice and no amyloid pathology in J20 mice (see Chapter 3). For each 
sample, ROI showing experimentally-related damaged tissue or staining artefacts 






Figure 5.11 – Anatomical regions of the brain analysed. 




Positivity was quantified automatically using the Aperio Positive Pixel Count 
Algorithm (Aperio), which was applied to the images using ImageScope (Aperio) 
as described in detail in Chapter 3 (Section 3.2.5). The values for the algorithm 
input parameters (Table 5.2 and Table 5.3, see Section 3.2.5 for details), 
calibrated to ignore non-specific staining, were based on optimisations from other 
experiments using similar (nuclear) stains from previous and ongoing studies 
conducted by my collaborators at Eli Lilly. Representative images depicting how 
the algorithm distinguished 5mC and 5hmC positivity in my samples are shown 
in Figure 5.12. The quantification of 5mC or 5hmC positivity was expressed as 
number of positive cells divided by the total number of cells (as a percentage). 
 
Table 5.2 – Algorithm inputs for anti-5mC 
 
Version 9.1 
View Width (Pixels) 1000 
View Height (Pixels) 1000 
Overlap Size 0 
Image Zoom 1 
Classifier None 
Classifier Neighbourhood 0 
Pixel Area (mm2) 2.46E-07 
Hue Value (Centre) 0.1 
Hue Width 0.5 
Colour Saturation Threshold 0.1 
Intensity Threshold WEAK (Upper Limit) 255 
Intensity Threshold WEAK (Lower Limit) 145 
Intensity Threshold MEDIUM (Upper Limit) 145 
Intensity Threshold MEDIUM (Lower Limit) 100 
Intensity Threshold STRONG (Upper Limit) 100 
Intensity Threshold STRONG (Lower Limit) 0 





Table 5.3 – Algorithm inputs for anti-5hmC 
 
Version 9.1 
View Width (Pixels) 1000 
View Height (Pixels) 1000 
Overlap Size 0 
Image Zoom 1 
Classifier None 
Classifier Neighbourhood 0 
Pixel Area (mm2) 2.46E-07 
Hue Value (Centre) 0.1 
Hue Width 0.5 
Colour Saturation Threshold 0.1 
Intensity Threshold WEAK (Upper Limit) 255 
Intensity Threshold WEAK (Lower Limit) 145 
Intensity Threshold MEDIUM (Upper Limit) 145 
Intensity Threshold MEDIUM (Lower Limit) 100 
Intensity Threshold STRONG (Upper Limit) 100 
Intensity Threshold STRONG (Lower Limit) 0 





Figure 5.12 – Representative immunohistochemistry images showing how the 
positive pixel count algorithm recognised the positive stain for quantification of 
5mC and 5hmC pathology. 
(a) Anti-5mC stain. (b) Anti-5hmC stain. Both images are from caudal cortex of a WT 
mouse. Bar = 50 µm. 
 
5.2.9. Statistical analysis 
R (version 3.4.3) was used for all statistical analysis, as well as to plot the data. 
Two-way factorial ANOVA was used, implementing the following statistical 
model: 





No differences in global DNA methylation assessed by LUMA were identified in 
the hippocampus of rTg4510 (Figure 5.13 and Table 5.4) or J20 (Figure 5.15 
and Table 5.4) when comparing TG to WT littermate mice. Furthermore, there 
was no significant correlation between global DNA methylation and levels of 
pathology in the hippocampus in the same mice for both rTg4510 (Figure 5.14) 





Figure 5.13 – Global DNA methylation in hippocampus from rTg4510 female mice 
quantified by LUMA. 
No significant differences were identified between rTg4510 transgenic (TG, blue) mice 
compared to wild-type (WT, black) littermate controls, associated with (a) genotype or 
(b) interaction between genotype and age (see Table 5.4). Total n = 72 animals, 7-10 
animals per group. Dashed lines represent mean paths of pathological burden across 
the four age groups. 
 
 
Figure 5.14 – No correlation was identified between global DNA methylation 
measured by LUMA and tau pathology in the hippocampus in rTg4510 mice. 
Pearson correlation r = 0.10, P = 0.41. Blue circles represent rTg4510 transgenic (TG) 





Figure 5.15 – Global DNA methylation in hippocampus from J20 female mice 
quantified by LUMA. 
No differences were identified between J20 transgenic (TG, red) mice compared to 
wild-type (WT, black) littermate controls, associated with (a) genotype or (b) interaction 
between genotype and age (see Table 5.4). Total n = 77 animals, 9-10 animals per 




Figure 5.16 – No correlation was identified between global DNA methylation 
measured by LUMA and amyloid pathology in the hippocampus in J20 mice. 
Pearson correlation r = 0.14, P = 0.22. Red circles represent J20 transgenic (TG) mice, 






Table 5.4 – Results for LUMA experiments in hippocampal tissue from rTg4510 and J20 mice. 
Statistical results (two-way ANOVA) are shown. 
 
Mouse model 
Genotype Age Genotype*Age 
N 
F-value P-value F-value P-value F-value P-value 
rTg4510 F(1,64) = 1.22 0.27 F(3,64) = 0.48 0.70 F(3,64) = 1.30 0.28 72 







My analysis of 5mC and 5hmc levels in tissue sections using 
immunohistochemistry revealed both genotype-associated and progressive 
changes (interaction between genotype and age) in rTg4510 TG mice compared 
to WT littermate controls in several brain regions (5mc: Figure 5.17 and Table 
5.5; 5hmC: Figure 5.21 and Table 5.6). Genotype-associated differences were 
identified for both 5mC and 5hmC in the hippocampal sub-regions CA1 (Figure 
5.17a and Figure 5.21a) and DG (Figure 5.17c and Figure 5.21c), with rTg4510 
TG mice showing significantly (P < 0.05) lower levels for both DNA modifications 
in both brain regions compare to WT. Levels of 5hmC in the caudal cortex were 
also lower in rTg4510 TG compared to WT mice (Figure 5.21e). Changes in 5mC 
associated with the progression of tau were identified in CA1 (Figure 5.17a, with 
5mC decreasing with age in TG mice only), CA3 (Figure 5.17b, with 5mC 
decreasing more intensely with age in TG mice compared to WT controls), and 
caudal cortex (Figure 5.17e). Changes in 5hmC associated with progression of 
tau were identified only in CA1 (Figure 5.21a, with 5hmC decreasing with age in 
TG mice only), with a similar profile to 5mC in the same hippocampal sub-region 
(Figure 5.17a). Representative immunohistochemistry images for the anti-5mC 
stain are shown in Figure 5.18 and Figure 5.19, and for the anti-5hmC stain in 
Figure 5.22 and Figure 5.23. 
Levels of both 5mC and 5hmc were also negatively correlated with levels of tau 
pathology in all hippocampal sub-regions (CA1, CA3, DG) (Figure 5.20a-c and 
Figure 5.24a-c). No correlation between DNA modifications and pathology was 
observed in any of the other brain regions assessed (Figure 5.20d-f and Figure 
5.24d-f). 
Age-associated changes were also identified in the CA1, CA3, DG, and caudal 






Figure 5.17 – Levels of 5mC in rTg4510 mice. 
Quantification of anti-5mC immunoreactivity for each of the tested brain regions: (a) 
CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Dashed lines 
represent mean paths of positivity across the four age groups. Blue circles represent 








Table 5.5 – Results for anti-5mC quantification in brains from rTg4510 mice. 
Statistical results (two-way ANOVA) are shown. Significant (α < 0.05) P values are underlined. 
 
Brain region N 
Genotype Age Genotype*Age 
F-value P-value F-value P-value F-value P-value 
CA1 69 F(1,61) = 96.26 3.68E-14 F(3,61) = 14.68 2.65E-07 F(3,61) = 21.25 1.52E-09 
CA3 73 F(1,65) = 1.55 0.22 F(3,65) = 8.51 7.56E-05 F(3,65) = 2.84 0.045 
DG 73 F(1,65) = 194.17 3.41E-21 F(3,65) = 8.82 5.48E-05 F(3,65) = 1.95 0.13 
Rostral cortex 57 F(1,49) = 0.27 0.60 F(3,49) = 2.80 0.050 F(3,49) = 0.51 0.68 
Caudal cortex 73 F(1,65) = 1.55 0.22 F(3,65) = 8.51 7.56E-05 F(3,65) = 2.84 0.045 







Figure 5.18 – Representative immunohistochemistry images for 5mC staining in rTg4510 mice. 
Sagittal sections showing the distribution of anti-5mC in the brains of rTg4510 transgenic (TG) mice (second row) compared to wild-type control (WT) mice 






Figure 5.19 – Representative immunohistochemistry images for 5mC staining in rTg4510 mice showing the hippocampal sub-region CA1 in detail. 





Figure 5.20 – Correlations between levels of 5mC and tau pathology in rTg4510 mice. 
(a) CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Shown is the Pearson correlation statistic for each comparison. Blue circles 




Figure 5.21 – Levels of 5hmC in rTg4510 mice. 
Quantification of anti-5hmC immunoreactivity for each of the tested brain regions: (a) 
CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Dashed lines 
represent mean paths of positivity across the four age groups. Blue circles represent 






Table 5.6 – Results for anti-5hmC quantification in brains from rTg4510 mice. 
Statistical results (two-way ANOVA) are shown. Significant (α < 0.05) P values are underlined. 
 
Brain region N 
Genotype Age Genotype*Age 
F-value P-value F-value P-value F-value P-value 
CA1 70 F(1,62) = 69.94 9.30E-12 F(3,62) = 8.48 8.38E-05 F(3,62) = 6.19 0.00095 
CA3 73 F(1,65) = 2.59 0.11 F(3,65) = 6.00 0.0011 F(3,65) = 1.79 0.16 
DG 73 F(1,65) = 185.70 1.01E-20 F(3,65) = 1.09 0.36 F(3,65) = 2.69 0.053 
Rostral cortex 56 F(1,48) = 0.0056 0.94 F(3,48) = 4.94 0.0045 F(3,48) = 1.35 0.27 
Caudal cortex 66 F(1,58) = 12.82 0.00070 F(3,58) = 1.023 0.39 F(3,58) = 0.51 0.68 







Figure 5.22 – Representative immunohistochemistry images for 5hmC stain in rTg4510 mice. 
Sagittal sections showing the distribution of anti-5hmC in the brains of rTg4510 transgenic (TG) mice (second row) compared to wild-type control (WT) mice 






Figure 5.23 – Representative immunohistochemistry images for 5hmC stain in rTg4510 mice showing the hippocampal sub-region CA1 in detail. 





Figure 5.24 – Correlations between levels of 5hmC and tau pathology in rTg4510 mice. 
(a) CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Shown is the Pearson correlation statistic for each comparison. Blue circles 




In tissue sections from J20 mice I identified more subtle changes in the levels of 
the DNA modifications 5mC (Figure 5.25 and Table 5.7) and 5hmC (Figure 5.29 
and Table 5.8) compared to those observed in rTg4510 mice. Genotype-
associated differences were identified in the hippocampal sub-regions CA1 and 
CA3 for both 5mC (Figure 5.25a-b) and 5hmC (Figure 5.29 a-b), with J20 TG 
mice exhibiting lower levels compared to WT controls for both DNA modifications. 
No statistically significant (P < 0.05) differences for the interaction between 
genotype and age were detected in any brain region. Representative 
immunohistochemistry images for the anti-5mC stain are shown in Figure 5.26 
and Figure 5.27 and for the anti-5hmC stain in Figure 5.30 and Figure 5.31. 
Interestingly, both levels of 5mC and 5hmc were negatively correlated with levels 
of amyloid pathology in the hippocampus in the CA1 and CA3 sub-regions 
(Figure 5.28a-b and Figure 5.32a-b). Levels of 5mC and 5hmc were also 
negatively correlated with cortical levels of amyloid pathology for the two cortical 
(rostral and caudal cortex) sub-regions quantified (Figure 5.28d-e and Figure 
5.32d-e). Age-associated changes were identified in all regions for 5mC (Table 




Figure 5.25 – Levels of 5mC in J20 mice. 
Quantification of anti-5mC immunoreactivity for each of the tested brain regions: (a) 
CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Dashed lines 
represent mean paths of positivity across the four age groups. Red circles represent 






Table 5.7 – Results for anti-5mC quantification in brains from J20 mice. 
Statistical results (two-way ANOVA) are shown. Significant (α < 0.05) P values are underlined. 
 
Brain region N 
Genotype Age Genotype*Age 
F-value P-value F-value P-value F-value P-value 
CA1 77 F(1,69) = 14.40 0.00031 F(3,69) = 3.17 0.03 F(3,69) = 0.87 0.46 
CA3 75 F(1,67) = 11.91 0.00097 F(3,67) = 12.00 2.23E-06 F(3,67) = 2.02 0.12 
DG 77 F(1,69) = 1.40 0.24 F(3,69) = 4.63 0.01 F(3,69) = 0.66 0.58 
Rostral cortex 54 F(1,46) = 0.44 0.51 F(3,46) = 7.66 0.00030 F(3,46) = 1.58 0.21 
Caudal cortex 62 
F(1,54) = 
0.00059 
0.98 F(3,54) = 7.16 0.00039 F(3,54) = 0.28 0.84 







Figure 5.26 – Representative immunohistochemistry images for 5mC stain in J20 mice. 
Sagittal sections showing the distribution of anti-5mC in the brains of J20 transgenic (TG) mice (second row) compared to wild-type control (WT) mice (top) at 







Figure 5.27 – Representative immunohistochemistry images for 5mC staining in J20 mice showing the hippocampal sub-region CA1 in detail. 




Figure 5.28 – Correlations between levels of 5mC and amyloid pathology in J20 mice. 
(a) CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Shown is the Pearson correlation statistic for each comparison. Red circles 




Figure 5.29 – Levels of 5hmC in J20 mice. 
Quantification of anti-5mC immunoreactivity for each of the tested brain regions: (a) 
CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Dashed lines 
represent mean paths of positivity across the four age groups. Red circles represent 






Table 5.8 – Results for anti-5hmC quantification in brains from J20 mice. 
Statistical results (two-way ANOVA) are shown. Significant (α < 0.05) P values are underlined. 
 
Brain region N 
Genotype Age Genotype*Age 
F-value P-value F-value P-value F-value P-value 
CA1 76 F(1,68) = 15.11 0.00023 F(3,68) = 4.21 0.0086 F(3,68) = 0.57 0.64 
CA3 73 F(1,65) = 15.51 0.00020 F(3,65) = 17.57 1.84E-08 F(3,65) = 0.28 0.84 
DG 75 F(1,67) = 0.082 0.78 F(3,67) = 11.49 3.62E-06 F(3,67) = 0.14 0.94 
Rostral cortex 72 F(1,64) = 0.16 0.69 F(3,64) = 10.25 1.34E-05 F(3,64) = 0.88 0.45 
Caudal cortex 71 F(1,63) = 2.11 0.15 F(3,63) = 8.82 5.75E-05 F(3,63) = 0.89 0.45 







Figure 5.30 – Representative immunohistochemistry images for 5hmC staining in J20 mice. 
Sagittal sections showing the distribution of anti-5hmC in the brains of J20 transgenic (TG) mice (second row) compared to wild-type control (WT) mice (top) 






Figure 5.31 – Representative immunohistochemistry images for 5hmC stain in J20 mice showing the hippocampal sub-region CA1 in detail. 





Figure 5.32 – Correlations between levels of 5hmC and amyloid pathology in J20 mice. 
(a) CA1, (b) CA3, (c) DG, (d) rostral cortex, (e) caudal cortex, (f) thalamus. Shown is the Pearson correlation statistic for each comparison. Red circles 




In this chapter I identified that decreased levels of two DNA modifications (5mC 
and 5hmC) are associated with accumulation of tau (in rTg4510 mice) and 
amyloid (in J20 mice) pathology. Both genotype-associated and progressive 
changes measured by immunohistochemistry were observed, with these 
changes notably stronger in rTg4510 TG relatively to J20 TG mice, particularly in 
the hippocampus. Notably, some of our findings in the J20 mice showed a similar 
profile to results from a previous study that reported a negative correlation 
between plaque load and 5mC in the DG hippocampal sub-region in J20 mice as 
well (Lardenoije et al., 2018). In contrast to my results, an age-related (4, 8, 16, 
and 34 months) decrease in 5mC in the DG in J20 TG mice compared to controls 
was also reported in this study, perhaps because it covered a larger aging interval 
compared to my analysis. 
Quantification of 5mC or 5hmC positivity was normalised to cell number in each 
region quantified (see Section 5.2.9). However, given that the rTg4510 mouse 
model exhibits neuronal cell loss, I cannot exclude the possibility that my 
observations may, at least partially, reflect the neurodegeneration (and this 
overall cell number) observed in this mouse model. This might also explain the 
negative correlation between tau pathology and the levels of both DNA 
modifications. Interestingly, a negative correlation between amyloid pathology 
and both DNA modifications was also observed in hippocampal and cortical 
regions in the J20 mice. The J20 mouse model, previously believed to have 
absent neurodegeneration, has been shown to exhibit limited age-dependent 
neuronal cell loss, varying by brain region, with neurodegeneration in CA1 
present from 12 weeks of age, but no neuronal cell deficits observed in CA3 at 
any age (up to 36 weeks of age) (Wright et al., 2013). 
In contrast to my immunohistochemistry data, no differences were identified in 
the LUMA experiments, when comparing rTg4510 TG and J20 TG mice to their 
respecting controls. This might be due to LUMA not being sensitive enough to 
detect small differences, or because we looked at DNA from the whole 
hippocampus; in the immunohistochemistry experiments I quantified specific 
hippocampal sub-regions. Furthermore, LUMA does not distinguish between 
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5mC and 5mC, and only quantified DNA modifications across informative CpG 
sites. 
Looking forward, potential complimentary assays for future follow-up studies to 
evaluate global changes in DNA modifications in AD mouse models could include 
high performance liquid chromatography (HPLC) and liquid chromatography 
mass spectrometry (LC-MS/M). However, these have high costs associated to 
them, and enzyme-linked immunosorbent assay (ELISA)-based methods have 
also been developed in recent years, in the form of commercialised kits, which 





Chapter 6.  Genome-wide methylation profiling 
of tau and amyloid mice 
6.1. Introduction 
Building on the dramatic changes in gene expression identified in Chapter 4, and 
the global DNA modification changes identified in Chapter 5, this chapter 
describes my analysis of genome-wide patterns of DNA methylation at single-
base resolution in the entorhinal cortex (ECX) from rTg4510 and J20 mice. 
 
As discussed in Section 1.4.1 (Chapter 1), DNA methylation is the most widely 
studied epigenetic modification in human disease, with several studies robustly 
linking methylomic variation to AD and other neurodegenerative disorders. A very 
limited number of studies assessing DNA methylation in AD mouse models have 
been performed, profiling a very low number of mice (see Section 1.5.2.2 in 
Chapter 1 for details), and no study to date has used sequencing-based 
technology to achieve this. 
 
Methods to profile DNA methylation have undergone significant improvements in 
the last decade due to the development of array- and sequencing-based 
technologies that have allowed the efficient quantification of DNA methylation at 
individual sites across the genome (Yong et al., 2016). Commonly used 






Figure 6.1 – Commonly used methods for genome-wide DNA methylation analysis. 
(a) The procedures may involve fragmentation of genomic DNA by restriction enzyme digestion or sonication. The genomic DNA can be subjected to methyl-
CpG-binding domain (MBD) enrichment, antibody enrichment, bisulfite conversion or oxidation by ten eleven translocation (TET) enzymes, before being 
analysed by microarray or next-generation sequencing (NGS) platforms. Figure and legend adapted from Yong et al. (2016). 
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Bisulfite-based approaches coupled with high-throughput sequencing, such as 
reduced representation bisulfite sequencing (RRBS) and whole-genome bisulfite 
sequencing (WGBS), allow for quantitative, genome-wide, site-specific 
methylation assessments (Doherty and Couldrey, 2014). Bisulfite conversion 
involves treating genomic DNA with sodium bisulfite, which reacts differently with 
unmethylated versus methylated cytosine, resulting in a positive display of 
methylation (Fouse et al., 2010). Sodium bisulfite promotes the conversion of 
unmethylated cytosine (C) to uracil (U), which is then replaced by thymine (T) by 
polymerase chain reaction (PCR) amplification. Methylated cytosines are 
unaffected by the bisulfite conversion, therefore remaining as cytosine after the 
bisulfite treatment reaction (Fouse et al., 2010, Yong et al., 2016). PCR clones 
derived from a single genomic DNA fragment can then be sequenced, allowing 
methylation status to be quantified at single-nucleotide resolution (Fouse et al., 
2010, Gu et al., 2011) using second-generation sequencing (discussed in more 
detail in Chapter 4). Bisulfite sequencing comes, however, with its challenges, 
particularly for studies in mammals: 1) repetitive elements (or repeated 
sequences), which occur in multiple copies throughout the genome and are 
usually highly methylated, make the alignment of short-read sequencing reads 
difficult; 2) the conversion of unmethylated cytosine to uracil/thymidine reduces 
genomic complexity to three bases in unmethylated regions, further complicating 
the alignment of sequencing reads; and 3) the costs associated with sequencing 
large genomes are relatively high, making large studies unfeasible (Fouse et al., 
2010). 
RRBS, introduced in 2005 by Meissner et al., combines the use of a CpG-specific 
restriction enzyme and bisulfite sequencing in order to enrich for regions of the 
genome with high CpG content, i.e., only a small proportion of the bisulfite-treated 
genome is interrogated (‘reduced representation’), emerging as a cost-efficient 
alternative to WGBS (Meissner et al., 2005). An overview of the RRBS workflow 
is given in Figure 6.2. In this approach genomic DNA is fragmented using the 
methylation-insensitive restriction enzyme MspI, which recognises and cleaves 
5'-CCGG-3' (Lee et al., 2014). Sequencing libraries are then constructed from 
size-selected MspI DNA fragments; in total only about 1% of the genome is 
sequenced, with the ‘reduced genome’ still including the majority of promoters 
and repeat sequences. This decreases the amount of sequencing required, 
reducing cost significantly and making this a relatively efficient method for large 
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studies (Gu et al., 2011). Despite being very cost-effect and characterised by very 
low input requirements (10-300 ng) (Gu et al., 2011, Yong et al., 2016), RRBS 
also has some limitations. An obvious disadvantage of RRBS, compared to other 
approaches such as WGBS, is the fact that only CpG-rich regions of the genome 
are sequenced, with RRBS failing to capture DNA methylation across all 
functionally-relevant domains. Furthermore, because the library is size-selected 
after enzymatic digestion with MspI, but before adapter ligation, any MspI 
fragments outside of the size-selection range (~40-250 bp) will not be sequenced 
(Doherty and Couldrey, 2014), i.e., since coverage is limited to regions in 
proximity to the restriction enzyme’s recognition sites, intergenic and distal 
regulatory elements exhibit low coverage (Yong et al., 2016). Another limitation 
of any method based on sodium bisulfte conversion, including RRBS, is the 
inability to distinguish between 5-methycytosine (5mC, ‘true methylation’) and 
other DNA modifications such as 5hmC; with RRBS or WGBS we can only 
determine if a particular cytosine residue contains a DNA modification or not. As 
mentioned in Section 1.4.1.4, 5hmC is particularly enriched in the central 
nervous system. 
Despite the described limitations, their advantages make targeted approaches 
such as RRBS the methods of choice for sequencing-based genome-wide 
studies in mammals, particularly in studies with a high number of samples (Fouse 
et al., 2010, Yong et al., 2016). Because methods for profiling DNA methylation 
using RRBS are still in development, I fully-optimised both laboratory and 







Figure 6.2 – Flowchart of the experimental procedures for RRBS. 





In this section the experimental procedures used for the evaluation of genome-
wide DNA methylation profiles using RRBS in samples from the ECX (described 
in Chapter 2, Section 2.4 and Section 2.5) dissected from rTg4510 and J20 
mice (Chapter 2, Section 2.1) are described in detail. 
When I started this work, the RRBS method had not been optimised to profile 
DNA methylation in a large number of samples, and the original protocol required 
certain modifications (see Sections 6.2.2.6 and 6.2.2.7). Therefore, my first step 
in this study was to optimise the method by performing a pilot experiment with 
eight test/control samples. After carefully checking the quality of the pilot data, I 
processed the rTg4510 and J20 samples. These were separated into two 
batches, with the two mouse models processed independently – 64 samples were 
processed in each batch (64 samples for the rTg4510 model, and 63 samples 
plus a negative control for the J20 model). All RRBS libraries were sequenced 
together (total number of samples = 128 samples), and this study represents one 
of the largest analyses of RRBS data – and the first in transgenic models of AD 
pathology – yet undertaken. 
 
6.2.1. Assessment of DNA quality and concentration 
All DNA samples used for my RRBS experiments were quantified and checked 
for purity using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific), 
as described in Section 2.5.3.1. 
Before RRBS library preparation, the concentration of each sample was 
determined using a fluorescence-based assay for double-stranded DNA (dsDNA) 
– the Qubit high sensitivity assay (Qubit dsDNA HS Assay, Thermo Fisher 
Scientific) – that utilises target-selective dyes that emit fluorescence when bound 
to DNA. Briefly, following the manufacturer’s instructions, a working reagent (WR) 
was freshly prepared by mixing HS Reagent and HS Buffer (both provided with 
the kit) in a 1:200 proportion. ‘Standard’ samples 1 and 2 (provided with the kit) 
were prepared by adding 10µL of each to 190 µL of WR in their respective Qubit 
Assay Tubes (Thermo Fisher Scientific). ‘Test’ samples were prepared by adding 
1 µL of the original DNA sample to 199 µL of WR in individual Qubit Assay Tubes. 
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All tubes containing a final volume of 200 µL were mixed by vortexing for 2-3 
seconds and left to incubate at room temperature for 2 minutes. Following 
incubation, standards and samples were read in a Qubit 3.0 Fluorometer (Thermo 
Fisher Scientific) and the concentration of each sample was recorded. 
 
6.2.2. Library preparation 
RRBS libraries were prepared using the Premium RRBS kit (Diagenode) with 
some modifications. An overview of the kit is given in Figure 6.3. 
All reagents were provided with the kit unless otherwise stated, with all reagents 
and consumables being sterile and DNase and RNase free. All experimental 
procedures were performed manually (in a PCR workstation, or PCR hood) as 
automation has not yet been established for this protocol by the manufacturer. 
The full protocol for the 64 samples from each batch (each mouse model 
processed separately, as described above) took 6 days, with the protocol 
repeated twice (total number of samples = 128 samples, 64 samples for each 
mouse model / batch). All volume calculations (e.g. for the digestion master mix) 
were performed in advance. On the first day, all reagents, except 80% ethanol, 
were prepared as indicated in the manufacturer’s instructions. 80% ethanol was 
prepared fresh from 100% ethanol (molecular biology grade, Sigma-Aldrich) on 
each day. On each day, before starting, every surface and all equipment were 








Figure 6.3 – Modified premium RRBS kit (Diagenode) workflow. 
The red asterisk indicates the key step modified in our study – an absolute 
quantification of the libraries was used instead of the relative quantification from the kit. 
The number of samples pooled together was also different than recommended in the 





6.2.2.1. Sample dilutions (day 1) 
After determining the concentration of each sample using the fluorescence-based 
Qubit High Sensitivity assay (see section 6.2.1), samples were diluted (100 ng of 
DNA from each sample in a total volume of 26 μL of buffer EB (Qiagen, see 
section 2.5.2.3)) and aliquoted into a 96-well plate, starting at well A01 and 
proceeding in columns. 
 
6.2.2.2. Enzymatic digestion (day 2) 
The Digestion Mix was prepared in a 1.5 mL tube as described below: 
Components Volume / reaction (x1) 
Enzyme Buffer 3 μL 
Restriction Enzyme 1 μL 
Total 4 μL 
 
4 μL of the Digestion Mix was added to each sample in the 96-well plate and 
mixed by pipetting 10 times (total volume = 30 μL). The plate was placed in a 
thermocycler and left to run using the following program overnight: 






6.2.2.3. Ends preparation (day 3) 
After digestion, the ends of the DNA fragments need to be filled-in with dGTP and 
methylated dCTP, followed by the addition of an A overhang to enable adaptor 
ligation (Fouse et al., 2010). The Ends Preparation Mix was prepared in a 1.5 mL 
tube as described below: 
Components Volume / reaction (x1) 
Ends Preparation Enzyme 1 μL 
dNTP mix 1 μL 
Unmethylated spike-in control 1 μL 
Methylated spike-in control 1 μL 
Total 4 μL 
 
A fully methylated control DNA fragment and an unmethylated control DNA 
fragment were added to each sample to control for conversion efficiency during 
sodium bisulfite treatment 
4 μL of the Ends Preparation Mix was distributed to each sample in the 96-well 
plate and mixed by pipetting 10 times (total volume = 34 μL). The plate was 
placed in a thermocycler and left to run using the following program: 
30°C 20 minutes 
37°C 20 minutes 






6.2.2.4. Adaptor ligation (day 3) 
5 μL of the adaptors was added to each sample, using a multichannel pipette to 
pipette 8 adaptors at a time, alternating between the different sets (strips A-F) of 
adaptors (this is important for sample pooling, as described in Section 6.2.2.6). 
As described in Chapter 4 (Section 4.2.2.6), chemically synthesised adaptors 
are short oligonucleotides that can be added to the ends of DNA molecules. In 
the Premium RRBS kit, the adaptors include indexes (or "barcodes", described 
in Figure 6.4) that allow several samples (or libraries) to be pooled and 
sequenced simultaneously (multiplex sequencing). RRBS adaptors are 
methylated at cytosine residues to prevent conversion during sodium bisulfite 
treatment (Fouse et al., 2010). 
 
 
Figure 6.4 – Distribution of the 24 adaptors in the tube strips and sequences of the 
24 corresponding indexes used in my RRBS experiments. 
Figure taken from the Premium RRBS kit manual (Diagenode, 2016). 
 
 
The Ligation Mix was subsequently prepared in a 15 mL tube as described below: 
Components Volume / reaction (x1) 
Ligation Buffer 40 μL 
Ligase 1 μL 




41 μL of the Ligation Mix was distributed to each sample in the 96-well plate and 
mixed by pipetting 10 times (total volume = 80 μL). The plate was placed in a 
thermocycler and left to run using the following program: 
25°C 20 minutes 
65°C 10 minutes 
8°C ∞ 
 
6.2.2.5. Size selection 
60 μL of AMPure XP Beads (Beckman Coulter) was added to each well of the 
96-well plate using a multichannel pipette, mixed by pipetting at least 10 times, 
and left to incubate for 15 minutes. The plate was then placed on a 96-well 
magnet for at least 5 minutes (until the supernatant was clear). 
Working column by column, the supernatant was removed using a multichannel 
pipette (taking care not to touch the beads) and the pellets were washed for 5 
seconds with 100 μL of freshly prepared 80% ethanol twice. The pellets from 
each column were left to air-dry for at least three minutes. The 96-well plate was 
taken from the magnet and 25 μL of Resuspension Buffer was added to each well 
using a multichannel pipette. Samples were then vortexed to resuspend the 
beads and left to incubate for 5 minutes out of the magnet to elute the DNA. The 
96-well plate was placed on the magnet again for 5 minutes and the supernatant 
transferred to a new 96-well plate, discarding the beads. 2 μL of each sample 
was taken from this new plate and added to another 96-well plate containing 118 
µL of NEB dilution buffer (New England Biolabs) 1x (1/60 dilution, optimised as 
the ideal dilution to bring the libraries’ concentrations to the interval of the 
standards’ concentrations and therefore accurately quantify the libraries), for 
quantification using qPCR (6.2.2.6). The remainder of the libraries were stored at 





6.2.2.6. Quantification (day 4) 
Previous RRBS experiments in our lab using the Premium RRBS kit (Diagenode) 
had highlighted considerable variability in the number of sequencing reads 
between samples within and between pools (Figure 6.5). To overcome this issue, 
I decided to replace the relative quantification step described in the official 
Premium RRBS kit protocol with an absolute quantification approach (Figure 
6.3), using the NEBNext Library Quant Kit (New England Biolabs) with 
modifications to quantify the libraries. My pilot experiment to test this approach 
revealed notably reduced variation in the number of reads obtained after 
sequencing (Figure 6.9). 
 
 
Figure 6.5 – Number of sequencing reads obtained from a previous experiment 
using the Premium RRBS kit. 
The number of raw sequencing reads from previous experiments in our group looking 
at DNA methylation in the mouse hippocampus exhibited high variability between and 
within pools. Each column represents a sample and each colour represents a pool. 
 
 
All reagents for quantification were provided with the NEBNext Library Quant Kit, 
with the Quantification Mix prepared according to the manufacturers’ instructions 
in advance and stored ‘ready to use’. Four standards (NEBNext Library Quant 
DNA Standards 10 pM, 1 pM, 0.1 pM, and 0.01 pM, provided with the kit) and 
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one negative control (no template control or NTC, containing dilution buffer only) 
were included. Diluted samples (1/60 dilution, see 6.2.2.5), standards and the 
negative control were prepared in triplicate in 96-well qPCR optical plates as 
described below, using a multichannel pipette: 
Components Volume / reaction (x1) 
NEB Quant Master Mix 
(containing primers & ROX) 
8 μL 
Diluted sample, standard, 
or negative control 
2 μL 
Total 10 μL 
 
The plate was sealed with a qPCR-specific adhesive plate seal, mixed by 
vortexing, centrifuged briefly and placed in a qPCR thermocycler using the 
following program (the second plate was kept at 4°C during the first run): 
Cycle step Temperature Time Cycles 
Initial Denaturation 95°C 3 minutes 1 
Denaturation 95°C 15 seconds 
35 
Annealing 63°C 45 seconds 
Hold 4°C ∞  
 
Using the standard curve generated for each plate (Figure 6.6a), sample 
concentrations were calculated with the qPCR instrument software (StepOnePlus 
Real-Time PCR System, Thermo Fisher Scientific). The concentrations of the 
diluted libraries were within the range of interval of the standards (Figure 6.6b), 




Figure 6.6 – Representative amplification plot and corresponding standard curve 
from qPCR quantification of an RRBS library. 
(a) Amplification plot showing that the diluted samples were within the range of the 
NEBNext Library Quant DNA standards. (b) Standard curve showing data generated 
from the four (10 pM, 1 pM, 0.1 pM, and 0.01 pM) NEBNext Library Quant DNA 
standards (red) and samples (blue and green). Samples in green were flagged by the 




6.2.2.7. Sample pooling (day 5) 
Making sure that there were no duplicate indexes (described in 6.2.2.4.) in the 
same pool, pools of 8 samples (pool concentration between 15 nM and 30 nM) 
were prepared in 1.5 mL tubes. Sample volumes for each pool were calculated 
using the next-generation sequencing (NGS) Laboratory Information 
Management System (LIMS) software (Illumina), adding Resuspension Buffer 
(from 6.2.2.5) to reach a volume of 120 μL per pool. 
Despite the original protocol being optimised for pools of six samples, our 
previous experiments using the Premium RRBS kit (Diagenode) revealed lower 
than optimal sequencing depth when running six samples in a single sequencing 
lane. Sequencing depth is a key parameter when evaluating DNA methylation 
profiles, with a greater depth providing higher statistical power to identify 
differentially methylated sites (Yong et al., 2016). Therefore, we decided that 
sequencing four samples on each Illumina lane (see Section 6.2.3) would likely 
provide more optimal output per sample. To maximise read depth per sample and 
to avoid batch effects, we pooled eight samples together and distributed each 
pool of eight samples across two sequencing lanes (Section 6.2.3). The 
concentration for each pool was determined using the Qubit dsDNA HS Assay 
(Thermo Fisher Scientific) as described in 6.2.1. 
240 μL of AMPure XP Beads (Beckman Coulter) were added to each pool, mixed 
well by pipetting, and incubated for 15 minutes at room temperature to allow DNA 
binding to the beads. After incubation, the tubes were placed in a magnetic 1.5 
mL tube rack for at least 5 minutes (until the supernatant appeared clear), and 
the supernatant was subsequently discarded. Pools were washed twice with 500 
μL of freshly prepared 80% ethanol for 5 seconds, and the tubes were left opened 
in the magnet, to enable the beads to air-dry for at least 25 minutes (until beads 
were dry). Tubes were taken off the magnet and 36 μL of Resuspension Buffer 
was added to each tube. Each tube was mixed by pipetting 10 times, centrifuged 
quickly and incubated for 5 minutes out of the magnet to elute DNA. The tubes 
were then place on the magnet once again for at least 5 minutes (until the 




6.2.2.8. Bisulfite conversion (days 5 and 6) 
BS Conversion Reagent was prepared by adding 790 μL of BS Solubilization 
Buffer and 300 μL of BS Dilution Buffer to a tube of BS Conversion Reagent, 
vortexing for 10 minutes at room temperature, adding 160 μL of BS Reaction 
Buffer, and mixing for an additional 1 minute.  
33 μL of each library pool was transferred to a new 96-well plate and 117 μL of 
BS Conversion reagent was added (total volume = 150 μL), followed by mixing 
and brief centrifuging. The 96-well plate was then left to incubate overnight in a 
thermocycler, as indicated below: 
Cycle step Temperature Time Cycles 
Denaturation 95°C 1 minute 
20 
Conversion 60°C 10 minutes 
Hold 4°C ∞  
 
On the subsequent morning, BS Spin columns were placed into the provided BS 
Collection Tubes, and 600 μL of BS Binding Buffer were added into each BS Spin 
Column. Bisulfite-converted library pools were loaded into the BS Spin Columns 
containing the BS Binding Buffer, mixed by inverting the column several times, 
and centrifuged at 12,000 x g for 30 seconds. The flow-through was discarded, 
and 100 μL of BS Wash Buffer was added to each column, followed by 
centrifuging at 12,000 x g for 30 seconds. 200 μL of BS Desulphonation Buffer 
was added to each column and let stand at room temperature (20-30°C) for 
exactly 30 minutes. After incubation, columns were centrifuged at 12,000 x g for 
30 seconds, 200 μL of BS Wash Buffer was added to each column followed by 
centrifugation at 12,000 x g for 30 seconds, and the flow-through was discarded. 
Another 200 μL of BS Wash Buffer was added to each column, followed by 
centrifugation for an additional 30 seconds. Each column was then placed into a 
new 1.5 mL tube, and 22 μL of BS Elution Buffer were added directly to the centre 
of the column matrix. After incubation for 2 minutes, columns were centrifuged 
for 30 seconds at 12,000 x g and the bisulfite-converted DNA was kept on ice 
during the qPCR step (6.2.2.9) to determine the optimal cycle number for the 
enrichment PCR (6.2.10).  
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6.2.2.9. Determination of the optimal cycle number for the enrichment PCR 
(day 6) 
Bisulfite-converted pools were quantified using the NEBNext Library Quant Kit 
(New England Biolabs) with modifications, as described in section 6.2.2.6. A 
single qPCR per library was performed instead of triplicates, as recommended in 
the Premium RRBS kit manual (Diagenode, 2016), and the pools were not diluted 
but quantified directly. The remainder of the pooled samples were kept at 4°C (or 
on ice) during the quantification as mentioned in 6.2.2.8. A standard curve was 
generated for each plate (Figure 6.7a), and the concentrations of the libraries 
were observed to be within the range of intervals for the standards and very close 
to each other (Figure 6.7b). Ct values for each pool were used to determine the 




Figure 6.7 –Representative amplification plot and corresponding standard curve 
from one of the qPCR runs to calculate the Ct value for each RRBS pool. 
(a) Amplification plot showing that the RRBS pools (indicated with the red arrow had 
very similar Ct values). NEBNext Library Quant DNA Standards. (b) Standard curve 
showing the four (10 pM, 1 pM, 0.1 pM, and 0.01 pM) NEBNext Library Quant DNA 




6.2.2.10. Enrichment PCR (day 6) 
The Amplification Mix was prepared in a 1.5 mL tube as described below: 
Components Volume / reaction (x1) 
2X MethylTaq Plus Master Mix 25 μL 
Primer mix 2.5 μL 
Water 3.5 μL 
Total 31 μL 
 
In a new 96-well PCR plate, 31 μL of Amplification Mix and 19 μL of each bisulfite 
converted RRBS pool (final volume = 50 μL) were added to each well and 
incubated in a thermocycler as indicated below: 
Cycle step Temperature Time Cycles 
Denaturation 95°C 5 minutes 1 
Denaturation 98°C 20 seconds 
Ct – 1 
 
(6.2.2.9) 
Annealing 60°C 15 seconds 
Extension 72°C 45 seconds 
Final extension 72°C 7 minutes 1 
Hold 4°C ∞  
 
6.2.2.11. Clean up (day 6) 
50 μL of AMPure XP Beads were added to the samples, mixed by pipetting at 
least 10 times, and left to incubate for 15 minutes at room temperature to allow 
DNA binding to the beads. After incubation, the plate was placed on a 96-well 
magnet for at least 5 minutes (until the supernatant appeared clear), and the 
supernatant was removed and discarded. Libraries were sequentially washed 
twice for 5 seconds with 100 μL of freshly prepared 80% ethanol and the beads 
were left to air-dry for at least 10 minutes (until the beads appeared dry). Beads 
were then resuspended in 15 μL of Resuspension Buffer and incubated for 5 
minutes to elute the DNA from the beads. The 96-well plate was placed on a 96-
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well magnet for at least 5 minutes (until the supernatant appeared clear), and the 
clear supernatant was transferred to a new 0.6 mL tube for each pool. 
 
6.2.2.12. Quality control (day 6) 
Libraries were checked using the High Sensitivity D1000 Screentape and 2200 
TapeStation System (Agilent Technologies). The TapeStation System is 
described in detail in Section 2.5.3.4, and the protocol for the High Sensitivity 
D1000 Screentape is described in Section 4.2.2.8. When the run was finished, I 
checked the profile of each RRBS library using the TapeStation Software. An 
example is given in Figure 6.8, where the area observed between the lower and 
upper peaks represents the RRBS library. 
 
 
Figure 6.8 – Example of a TapeStation gel electrophoresis and corresponding 
electropherograms for one representative RRBS library pool. 
Each pool was checked using High Sensitivity D1000 Screentapes and 2200 
TapeStation System (Agilent Technologies). The area observed between the lower and 
upper peaks represents the library. 
 
6.2.3. Sequencing 
After I prepared the libraries, they were sequenced at the University of Exeter 
Sequencing Service. The library pool from the pilot experiment was subjected to 
150 bp single-end sequencing using a MiSeq sequencer (Illumina). Final library 
pools (eight pools per mouse model) were distributed across thirty-two 
HiSeq2500 (Illumina) lanes (16 lanes for samples from each mouse model, with 
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each pool of eight samples distributed in two lanes) and subjected to 50 bp single-
end sequencing, as recommended by others (Gu et al., 2011). 
 
6.2.4. Sequencing data processing 
All sequencing data processing was performed on a Unix-based operating 
system server. 
 
6.2.4.1. Data pre-processing 
Initial demultiplexing of the raw sequencing files into FASTQ files, contamination 
checks and methylated spike-in control quality checks were performed in 
collaboration with Paul O’Neill at the University of Exeter Sequencing Service. 
 
6.2.4.2. Quality control of raw data using FastQC 
The randomised FASTQ files underwent quality control (QC) assessments using 
FastQC (Andrews, 2010) (version 0.11.7). Read coverage for each sample from 
the pilot experiment is shown in Figure 6.9, and read coverage for all rTg4510 
and J20 samples can be seen in Figure 6.10 and Figure 6.11, respectively. A 
mean coverage of 40.67 (SD = 6.65) million sequencing reads per sample was 
obtained for the rTg4510 dataset, and a mean coverage of 42.36 (SD = 7.24) 





Figure 6.9 – Number of sequencing reads obtained from the pilot experiment using 
the Premium RRBS kit with modifications. 
We observed much less variability between samples in the same pool than before. 
Each column represents a sample. 
 
A representative example of the quality measures reported graphically by FastQC 
(explained in more detail in Chapter 4, Section 4.2.4.2) for one sample is shown 
in Figure 6.12 to Figure 6.17. Quality measures for all samples looked as 











Figure 6.11 – Number of raw RRBS reads for each sample in the J20 dataset. 





Figure 6.12 – Per base sequence quality from the FastQC report for raw RRBS 
reads. 
Results for one representative sample, showing high quality per base sequencing 





Figure 6.13 – Per sequencing quality scores from the FastQC report for raw RRBS 
reads. 
Results for one representative sample, showing high quality score distribution over all 
sequences measured by Phred (Q) quality score (Phred score > 30, where a quality 






Figure 6.14 – Per base sequence content from the FastQC report for raw RRBS 
reads. 
Results for one representative sample, showing the expected pattern of bases for 
RRBS as a result of bisulfite conversion. 
 
 
Figure 6.15 – Per sequence GC content from the FastQC report for raw RRBS 
reads. 




Figure 6.16 – Sequence length distribution from the FastQC report for raw RRBS 
reads. 
Results for one sample are shown as an example. 
 
 
Figure 6.17 – Sequence duplication levels from the FastQC report for raw RRBS 
reads. 
Results for one sample are shown as an example.  
304 
 
6.2.4.3. Trimming and quality filtering 
Trimming (quality threshold 20, error rate 0.2) was performed with Trim Galore 
(Krueger, 2017) (version 0.4.5). A Phred score of 20 was used as the quality cut-
off value, as previously recommended (Doherty and Couldrey, 2014), which 
relates to a 1/100 chance of the assigned nucleotide being incorrect. This 
represents a balance between using high quality data without discarding too 
many sequencing reads. Trimmed FASTQ files underwent QC assessments 
using FastQC (Andrews, 2010) (version 0.11.7) once again, with very little 
changes in most quality measures for each sample. All samples passed these 
stringent QC measures. At this stage, however, two samples were removed from 
the rTg4510 dataset as neuropathology observations using 
immunohistochemistry (Chapter 3) identified these samples to be incorrectly 
assigned to their experimental groups. 
The number of RRBS reads after filtering for all samples is shown in Figure 6.18 
and Figure 6.19. A mean output of 40.19 (SD = 6.12) million filtered sequencing 
reads per sample was obtained for the rTg4510 dataset, and a mean output of 
42.20 (SD = 7.23) million filtered sequencing reads per sample was obtained for 
the J20 dataset. A representative example of the quality measures reported by 















Figure 6.20 – Per base sequence quality from the FastQC report for trimmed RRBS 
reads. 






Figure 6.21 - Per sequencing quality scores from the FastQC report for trimmed 
RRBS reads. 






Figure 6.22 – Per base sequence content from the FastQC report for trimmed 
RRBS reads. 




Figure 6.23 – Per sequence GC content from the FastQC report for trimmed RRBS 
reads. 




Figure 6.24 – Sequence length distribution from the FastQC report for trimmed 
RRBS reads. 
Results for one sample (same sample as Figure 6.16) are shown as an example. 
 
 
Figure 6.25 – Sequence duplication levels from the FastQC report for trimmed 
RRBS reads. 




6.2.4.4. Alignment to reference genome and methylation calling 
Trimmed samples were aligned to the mm10 (GRCm38.p4) reference mouse 
(Mus musculus) genome with Bismark (Krueger and Andrews, 2011, Krueger et 
al., 2012) (version 0.19.0), which uses Bowtie2 (Langmead et al., 2009) (version 
2.3.4.1) and SAMtools (Li et al., 2009) (version 1.8). Running Bismark involves 
five individual steps: (1) genome preparation, (2) alignment, (3) methylation 
extraction, (4) generating a Bismark processing report, and (5) generating a 
Bismark summary report. Step 1 includes bisulfite conversion of the genome of 
interest and indexing, to allow the alignments. In step 2, Bismark produces a 
combined alignment/methylation call output and a run statistics report. In step 3, 
methylation information is extracted from the Bismark alignment output. This 
methylation information can be split into different genomic contexts (CpG, CHG, 
and CHH), and can be strand-specific. Optional additional filtering is also possible 
during this step. In step 4, a graphical HTML report is produced for each sample, 
containing alignment statistics, deduplication, methylation extraction (CpG, CHG 
and CHH), and a methylation bias plot showing the methylation proportion across 
each possible position in the read. The Bismark summary report from step 5 
corresponds to a graphical summary HTML report, containing alignment statistics 
and methylation extraction (CpG, CHG and CHH) for all samples. Both reports 
were used to further assess the quality of the samples and their respective 
alignment. Quality measures reported by Bismark for one representative sample 
are shown from Figure 6.26 to Figure 6.28. For all samples, we obtained unique 
alignments ≥ 60% – a graphical summary for alignment statistics for the rTg4510 
and J20 datasets is shown in Figure 6.29 and Figure 6.30, respectively. All ECX 
samples (rTg4510 and J20, described in Chapter 2, sections 2.4 and 2.5) passed 





Figure 6.26 – Alignment statistics from Bismark report. 






Figure 6.27 – Bismark report statistics for cytosine methylation after extraction. 








Figure 6.28 – M-bias plot from Bismark report, showing methylation levels averaged per position in the reads. 
Results for one sample (same sample as shown in the previous figures) are shown as an example. Left axis: methylation (%) for CpG (dark blue), CHG (dark 








Figure 6.29 – Alignment statistics from Bismark summary report for rTg4510 samples. 
The top panel shows the total number of reads per sample, and the panel on the bottom shows the percentage of reads per sample. Green corresponds to 








Figure 6.30 – Alignment statistics from Bismark summary report for J20 samples. 
The top panel shows the total number of reads per sample, and the panel on the bottom shows the percentage of reads per sample. Green corresponds to 
unique alignments; dark blue represents reads that did not align; and purple corresponds to reads that aligned ambiguously. The sample in the 9th position 




6.2.5. Differential DNA methylation analysis 
All analyses were performed in R (version 3.4.3) unless otherwise stated. 
Dorothea Seiler Vellame (University of Exeter) provided assistance with data 
filtering (Section 6.2.5.1) and initial steps of the statistical analysis (Section 
6.2.5.2). 
 
6.2.5.1. Data filtering 
RRBS data was filtered to exclude sites with 1) low read depth (i.e. those with a 
minimum of 10 reads per DNA methylation site) and 2) low standard deviation in 
DNA methylation values (because DNA methylation at most cytosine sites is 
invariable, sites that did not have a standard deviation greater than 5% of 
methylation were removed). Sites with DNA methylation data for fewer than five 
samples within each genotype (WT/TG) group were removed to ensure high 
quality data and maximise statistical power. The distribution of DNA methylation 
values across all sites for each sample was inspected by plotting the distribution 
of the data before and after filtering (Figure 6.31), revealing the expected 






Figure 6.31 – Methylation distribution. 
Distribution of methylation (%) for one sample (same representative sample shown 
from Figure 6.19 to Figure 6.28) before (a) and after (b) filtering is shown as an 
example. 
 
6.2.5.1. Statistical analysis 
Given the complexity of DNA methylation data, the relatively small individual 
group sizes, and the large number of DNA methylation sites across the genome 
profiled by RRBS, I decided to focus my analyses on identifying genotype-
associated differentially methylated sites. To achieve this, a t-test was used 
(using the R function anova), comparing all transgenic (TG) mice to all wild type 
(WT) controls for each DNA methylation site in both mouse models (rTg4510 (n 
= 62) and J20 (n = 63)) datasets. P values were adjusted for multiple testing, 
using the false discovery rate (FDR) method (also known as Benjamini and 
Hochberg correction (Benjamini and Hochberg, 1995)) implemented with the R 
function p.adjust; FDR-values < 0.05 were defined as ‘significant’. Sites were 
annotated to the nearest gene with the R package Granges using the biomaRt 
(Durinck et al., 2005, Durinck et al., 2009) gene annotation database from 
Ensembl for mouse mm10 (GRCm38.p4) gene sets. Enrichr (Chen et al., 2013, 
Kuleshov et al., 2016) was used for gene ontology (GO) analysis of genes 




6.3.1. Sequencing metrics 
There was no significant (P > 0.05) difference in RRBS read-depth between TG 
and WT controls for either the rTg4510 (Table 6.1 and Figure 6.32) or J20 (Table 
6.2 and Figure 6.33) datasets. 
 
Table 6.1 – Statistical results for RRBS read-depth in rTg4510 mice. 
 
Mean ± SD 
(million reads) 
t-value P-value N 
WT TG 




Figure 6.32 –Average number of raw RRBS reads for rTg4510 samples. 
The number of raw sequencing reads did not differ between WT and TG mice (n = 62 





Table 6.2 – Statistical results for RRBS read-depth in J20 mice. 
 
Mean ± SD 
(million reads) 
t-value P-value N 
WT TG 




Figure 6.33 – Average number of raw RRBS reads for J20 samples. 
The number of raw sequencing reads did not differ between WT and TG mice (n = 63 
animals, two-tailed unpaired t-test, t(62)= -0.76, P = 0.45). Bar plots represent mean 
and SD. 
 
6.3.2. Genotype-associated epigenetic wide methylation 
changes 
In total, our filtered RRBS datasets included DNA methylation values for 
1,066,467 sites in the rTg4510 model and 1,145,020 sites in the J20 model. 
In the rTg4510 dataset, 20,070 (1.88%) sites were characterised by genotype-
associated differential DNA methylation (FDR < 0.05) (Figure 6.34). Clusters of 
DMPs, seen as peaks (highlighted by pink arrows) in the Manhattan plot depicted 
in Figure 6.34, were annotated to major prion protein (Prnp) and protein tyrosine 
phosphatase, receptor type, N polypeptide 2 (Ptprn2). These differences likely 
reflect the effect of the transgene insertion and parallel the results of our RNA-
seq analysis (see Chapter 4, Section 4.3.2). We therefore decided to remove all 
DMPs that could potentially reflect direct effects of the transgene insertion before 
running further analysis, with all sites annotated to regions spanning Wdr60, 
Esyt2, Ncapg2, Ptprn2 or Fgf14 being removed from further analyses. After 
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filtering for potentially transgene-associated sites, 20,023 (1.87%) sites were 
found to be differentially methylated between TG and WT mice (FDR <0.05). A 
filtered version of the Manhattan plot for rTg4510 genotype-associated 
methylation changes is shown in Figure 6.35; of note, we still observe 
differentially methylation in the proximity of the transgene-disrupted genes (black 
arrow in Figure 6.35), potentially reflecting cis effects on DNA methylation of the 
inserted transgene. Quantile-quantile (QQ) plots were used to assess the 
normality of distribution of test statistics from rTg4510 samples (Figure 6.37 and 
Figure 6.38). Quantification of the extent of P-value inflation and the excess false 
positive rate was achieved by calculating the genomic inflation factor (lambda gc 
or λgc) (Yang et al., 2011) from FDR values. Λgc, which corresponds to the ratio 
of the median of the empirically observed distribution of the test statistic to the 
expected median (i.e., the median of the resulting chi-squared test statistics 
divided by the expected median of the chi-squared distribution), indicated very 
limited inflation in both the unfiltered (λgc = 1.05) and filtered data (λgc = 1.04) 
suggesting no major stratification in my results. 
 
In the J20 dataset, 16,473 (1.44%) of profiled sites were found to be differentially 
methylated (FDR < 0.05) between TG and WT mice (Figure 6.36). A quantile-
quantile plot to evaluate the normality of distribution of methylation data from J20 
samples is shown in Figure 6.39; calculation of the genomic inflation factor from 








Figure 6.34 – Manhattan plot showing rTg4510 genotype-associated epigenetic wide methylation changes. 
Pink arrows highlight changes likely to reflect transgene integration sites. N = 1,066,467 sites, 62 animals (WT = 31, TG = 31). The red line corresponds to 








Figure 6.35 – Manhattan plot showing rTg4510 genotype-associated epigenetic wide methylation changes after removal of sites potentially reflecting 
transgene integration. 
The two top differentially methylated sites are highlighted by the name of the gene that they were annotated to. The black arrow indicates a peak of 
methylation changes in several sites in the proximity of the genes disrupted by the insertion of the transgene. N = 1,066,420 sites, 62 animals (WT = 31, TG = 







Figure 6.36 – Manhattan plot showing J20 genotype-associated epigenetic wide methylation changes. 
The top differentially methylated site is highlighted by the name of the gene that it was annotated to N = 1,145,020 sites, 63 animals (WT = 32, TG = 31). The 





Figure 6.37 – Quantile-quantile (Q-Q) plot for rTg4510 RRBS samples before 
removal of transgene-associated sites. 
N = 1,066,467 sites, 62 animals (WT = 31, TG = 31). 
 
 
Figure 6.38 – Quantile-quantile (Q-Q) plot for rTg4510 RRBS samples after removal 
of transgene-associated sites. 




Figure 6.39 – Quantile-quantile (Q-Q) plot for J20 RRBS samples. 




6.3.3. DNA methylation at genotype-associated sites robustly 
distinguishes between TG and WT mice for both rTg4510 and 
J20 models 
Across sites with DNA methylation data for all samples, hierarchical clustering of 
individual mouse samples based on methylation levels for genotype-associated 
sites was found to robustly discriminate between TG and WT groups for both 
Tg4510 (Figure 6.40) and J20 (Figure 6.41) models. In contrast to clustering 
between genotype groups using RNA-seq data (Chapter 4) – where samples 
also clustered by age within the rTg4510 TG group (Figure 4.39) – no such 
temporal clustering was seen for DMPs suggesting that temporal changes in DNA 
methylation are less pronounced. In rTg4510, there was a significant (exact 
binomial test, n = 20,023 DMPs, P ≤ 4.94E-324) enrichment of hypermethylated 
DMPs (n = 15,558 (77%) DMPs showing increased methylation in TG versus WT 
mice, compared to n = 4,465 (33%) of hypomethylated DMPs). In J20 mice, there 
was also a significant (exact binomial test, n = 16,473 DMPs, P ≤ 4.94E-324) 
enrichment of hypermethylated DMPs (n = 11,672 (71%) of hypermethylated 
DMPs, compared to n= 4,801 (29%) of hypomethylated DMPs, in TG compared 




Figure 6.40 – Genotype-associated DNA methylation variation robustly 
discriminates between rTg4510 transgenic (TG) and wild type (WT) mice. 
N= 3,625 sites, 62 animals (WT = 31, TG = 31). Direction of methylation (%), relative to 
mean levels of methylation across all individual mice (“relative methylation”), is 




Figure 6.41 – Genotype-associated DNA methylation variation robustly 
discriminates between J20 transgenic (TG) and wild type (WT) mice. 
N= 3,226 sites, 63 animals (WT = 32, TG = 31). Direction of methylation (%), relative to 
mean levels of methylation across all individual mice (“relative methylation”), is 




6.3.4. Top genotype-associated differentially methylated sites 
The top rTg450 genotype-associated DMP was annotated to Ugt2b37 (Figure 
6.35, Table 6.3 and Figure 6.42a, hypermethylated in TG mice compared to WT), 
which encodes for the member 37 of UDP glucuronosyltransferases (UGTs) 
subfamily 2B (UGT2B37). UGTs are cytosolic glycosyltransferases that catalyse 
glucuronidation (i.e., the transfer of the glucuronic acid component of UDP-
glucuronic acid to a small hydrophobic molecule) and have a role in drug 
metabolism and detoxification (Kurita et al., 2017, Rowland et al., 2013). 
UGT2B37 in particular is involved in the metabolism of key endogenous 
compounds including bilirubin, bile acids, fatty acids, steroid hormones, thyroid 
hormones and fat soluble vitamins, and in glucuronidation of testosterone and 
dihydrotestosterone (Friedman et al., 2019, Zhou et al., 2015). Ugt2b37 is highly 
expressed in the adult mammalian kidney and liver, with only moderate 
expression in the brain when compared to kidney and liver (Bohmdorfer et al., 
2017, Sakamoto et al., 2015, Zhang et al., 2017). Ugt2b37 has been shown to be 
expressed in neurons (Friedman et al., 2019), however, information about its 
expression in other brain cell types is still unavailable. Three DMPs were 
annotated to Arsi (Figure 6.35, Table 6.3 and Figure 6.42b-d, all 
hypomethylated in TG mice compared to WT). This gene encodes arylsulfatase 
family member I (ARSI), which belongs to a large family of sulfatases involved in 
hormone biosynthesis, the modulation of cell signalling, and the degradation of 
macromolecules (Sardiello et al., 2005). Several sites located in chromosome 12 
were found to be differentially methylated (black arrow in Figure 6.35), including 
three sites annotated to Tmem212 (Table 6.3 and Figure 6.42e-g, 
hypermethylated in TG compared to WT mice) that encodes transmembrane 
protein 212, and one site annotated to Ighe (Table 6.3 and Figure 6.42h, 
hypermethylated in TG compared to WT) which encodes immunoglobulin heavy 
constant epsilon (constant region of heavy chain of immunoglobulin epsilon or 
IgE). As discussed in Section 6.3.2, these DMPs on chromosome 12 potentially 




Table 6.3 – Statistical results for top rTg4510 genotype-associated sites. 
Sites are ordered by FDR. Δβ refers to difference in methylation (%) between TG and 
WT. Underlined sites are plotted in Figure 6.42. 
 
Location Nearest gene t-value Δβ FDR N 
chr5:87231917 Ugt2b37 t(59) = 224.50 51.82 9.05E-21 58 
chr18:60917719 Arsi t(55) = 150.25 -47.78 9.44E-17 56 
chr18:60917731 Arsi t(55) = 131.59 -34.98 1.28E-15 56 
chr18:60917761 Arsi t(55) = 118.92 -40.60 8.74E-15 56 
chr12:113190326 Tmem121 t(58) = 98.15 43.63 1.59E-13 59 
chr12:113266015 Ighe t(28) = 188.52 78.98 3.22E-13 29 
chr7:103488891 Olfr609 t(37) = 82.59 -58.02 2.25E-10 38 
chr12:119325190 Gm6768 t(48) = 59.74 36.32 2.57E-09 47 
chr12:113199742 Tmem121 t(52) = 54.33 12.40 1.41E-09 53 
chr1:118279473 Tsn t(51) = 51.44 44.90 9.68E-09 52 
chr12:119752693 Gm25675 t(57) = 48.56 33.06 1.17E-08 58 





Figure 6.42 – Top rTg4510 genotype-associated sites. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 




The top J20 genotype-associated DMP was annotated to Tmprss7 (Figure 6.36, 
Table 6.4 and Figure 6.43a, hypomethylated in TG compared to WT) that 
encodes for transmembrane serine protease 7 (also known as matriptase 3) – a 
type-II serine proteinase (TMPRSS7, located in the plasma membrane) of the 
peptidase S1 family, which preferentially hydrolyses peptides with Arg at the P1 
position. In humans and in the mouse, expression of Tmprss7 has been detected 
in several tissues, including brain (Szabo et al., 2005). Its biochemical functions 
include hydrolase activity, peptidase activity, and protein binding. Tmprss7 was 
followed by Gm9578 (Table 6.4 and Figure 6.43b, hypermethylated in TG 
compared to WT) which encodes the glyceraldehyde-3-phosphate 
dehydrogenase pseudogene, i.e., non-coding, for which each function is yet to 
be uncovered. Another differentially methylated site was annotated to Prdm5 
(Table 6.4 and Figure 6.43c, hypermethylated in TG compared to WT), encoding 
PR domain zinc finger protein 5, a transcription factor of the PR-domain protein 
family highly expressed in mouse embryonic stem cells, and hypothesised to 
regulate gene expression of a subset of developmental regulators during cell 
differentiation by affecting chromatin organisation (Galli et al., 2013). Another 
J20-associated DMP was annotated to Mknk1 (Table 6.4 and Figure 6.43d, 
hypermethylated in TG compared to WT), a protein coding gene encoding 
mitogen-activated protein kinase (MAPK) interacting serine/threonine kinase 1 
(MKNK1), which belongs to a family of serine/threonine kinases, considered 
downstream effectors of MAPK signalling (Fukunaga and Hunter, 1997). MKNK1 
is a serine/threonine protein kinase that interacts with p38 and extracellular-
signal-regulated kinase (ERK) 1 and ERK2, suggesting a role in cellular stress 
responses (Waskiewicz et al., 1997). Mknk1 is highly expressed in the spleen 
and modestly expressed in the liver and muscle, with relatively low levels 
expressed in the brain (Ueda et al., 2004, Waskiewicz et al., 1997). Despite the 
growing research on the involvement of MKNK1 in carcinogenic processes, only 
a limited number of studies have explored its role in the brain (Genheden et al., 
2015, Moy et al., 2017), with Genheden et al. suggesting MNK1 as a key 
component of BDNF-mediated translational regulation in neurons (Genheden et 
al., 2015). A few brain-unrelated published studies have used mice in which the 
expression of MNK1 has been knocked out (Joshi et al., 2009, Moore et al., 2016, 
Moy et al., 2017) – research exploring the role of MNK1 in the mouse brain is 
certainly only one step away.  
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Table 6.4 – Statistical results for top J20 genotype-associated sites. 
Sites are ordered by FDR. Δβ refers to difference in methylation (%) between TG and 
WT. Underlined sites are plotted in Figure 6.43. 
 
Location Nearest gene t-value Δβ FDR N 
chr16:45667595 Tmprss7 t(33) = 89.22 -55.79 2.70E-10 34 
chr14:80916197 Gm9578 t(31) = 35.98 42.05 4.20E-06 32 
chr6:65870804 Prdm5 t(59) = 28.14 26.38 5.53E-06 60 
chr4:115869229 Mknk1 t(25) = 118.92 44.99 6.02E-06 26 
chr16:45740128 Abhd10 t(45) = 98.15 -46.16 9.53E-06 46 
chr18:75831039 Zbtb7c t(12) = 72.05 -69.67 1.11E-05 13 
chr13:54346100 Cplx2 t(62) = 25.16 20.14 1.46E-05 63 
chr16:43973665 Zdhhc23 t(53) = 25.52 -32.79 1.73E-05 54 
chr16:20701672 Fam131a t(61) = 24.26 24.39 2.08E-05 62 
chr12:105535344 Bdkrb2 t(41) = 25.93 42.59 2.65E-05 42 
chr12:51187188 Gm22088 t(50) = 24.57 28.46 2.69E-05 51 





Figure 6.43 – Top J20 genotype-associated sites. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 




6.3.5. Several genotype-associated differentially methylated 
positions are located in the vicinity of Mapt and App 
Interestingly, two rTg4510 genotype-associated differentially methylated sites 
were annotated to Mapt (Table 6.5 and Figure 6.44), with both sites located in 
the gene body; one DMP was characterised by decreased methylation in TG mice 
compared to WT mice, and the other DMP was characterised by increased 
methylation in TG mice compared to WT mice. Furthermore, two genotype-
associated differentially methylated sites in J20 mice were also located in the 
gene body of Mapt; one DMP was characterised by decreased methylation and 
the other by increased methylation in TG compared to WT mice (Table 6.6 and 
Figure 6.45). Mapt DMPs identified in both models were located close to each 
other, suggesting potentially overlapping effects in both Tg4510 and J20 mice. 
 
 
Table 6.5 – Significant DNA methylation differences at sites annotated to Mapt in 
rTg4510 samples. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:104247451 Mapt t(24) = 8.12 -33.77 0.027 25 
chr11:104299117 Mapt t(50) = 6.82 17.70 0.036 51 
 
 
Table 6.6 – Significant DNA methylation differences at sites annotated to Mapt in 
J20 samples. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:104310400 Mapt t(56) = 6.61 -16.41 0.039 57 





Figure 6.44 – Two DMPs associated with rTg4510 genotype were annotated to 
Mapt. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 
controls (WT, black). 
 
 
Figure 6.45 – Two DMPs associated with J20 genotype were annotated to Mapt. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 




In J20 mice, six genotype-associated DMPs were annotated to App; all were 
characterised by hypermethylation in J20 TG mice compared to WT (Table 6.7 
and Figure 6.46), with one DMP (chr16:84922199) being located ~35kb 
upstream of App, and the other five DMPs being located in the gene body. 
Interestingly, six DMPs associated with rTg4510 genotype were also annotated 
to App, again all hypermethylated in rTg4510 TG mice compared to WT (Table 
6.8 and Figure 6.47); five DMPs were located in the gene body of App, with an 
additional DMP (chr16:85269100) located ~95 kb downstream of the gene. 
 
 
Table 6.7 – Significant DNA methylation differences at sites annotated to App in 
J20 samples. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr16:84922199 App t(41) = 7.13 18.78 0.033 42 
chr16:84995182 App t(48) = 9.38 21.86 0.011 49 
chr16:85084104 App t(14) = 8.18 42.48 0.040 15 
chr16:85086498 App t(58) = 6.95 16.03 0.032 59 
chr16:85087931 App t(61) = 7.28 9.72 0.027 62 





Table 6.8 – Significant DNA methylation differences at sites annotated to App in 
rTg4510 samples. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr16:85088148 App t(59) = 6.91 10.99 0.033 60 
chr16:85091216 App t(58) = 12.76 12.37 0.0022 59 
chr16:85091220 App t(58) = 16.67 12.72 0.00042 59 
chr16:85091240 App t(58) = 9.19 9.32 0.011 59 
chr16:85091540 App t(58) = 6.81 9.55 0.035 59 








Figure 6.46 – Six DMPs associated with J20 genotype were annotated to App. 
Annotated gene and chromosome positions are indicated in each individual plot. Shown are J20 transgenic (TG, red) female mice compared to wild 








Figure 6.47 – Six DMPs associated with rTg4510 genotype were annotated to App. 
Annotated gene and chromosome positions are indicated in each individual plot. Shown are rTg4510 transgenic (TG, blue) female mice compared to 




6.3.6. Annotated genes contain many genes associated with AD 
from EWAS 
Recent work by our group and others have found that DNA methylation 
differences in human cortex annotated to four loci - ANK1, RPL13, CDH23, and 
RHBDF2 – are robustly associated with AD neuropathology (Figure 6.48; see 
also Chapter 1, Section 1.4) (De Jager et al., 2014, Lunnon et al., 2014). Other 
loci annotated to AD-associated DMPs in these studies included TIMM22-ABR, 
ACTR3BP2, CLYBL-TM9SF2 (Lunnon et al., 2014), SLC2A1-FLJ32224, COQ7-
ITPRIPL2, HOXA region, FOXK1-AP5Z1-RADIL, DIP2A, SERPINF1, SERPINF2 
(De Jager et al., 2014) (Figure 6.48). I therefore explored whether DNA 
methylation differences in the mouse homologues of these genes were 
associated with either rTg4510 or J20 genotype. We identified genotype-
associated DMPs annotated to Ank1 (Table 6.9, Figure 6.49, Table 6.10, Figure 
6.50) and Cdh23 (Table 6.11, Table 6.12, Figure 6.51, Figure 6.52) in both 
rTg4510 and J20 ECX; of note, the vast majority of DMPs were found to be 
hypermethylated in TG mice compared to WT, with all DMPs located in the gene 
body, except one DMP (chr8:22974676) in J20 that was located 167 bp away 
from Ank1. In the rTg4510 mice, one genotype-associated DMP was annotated 
to Rpl13 (Figure 6.53; t(61) = 6.61, Δβ = -3.16, FDR = 0.038), and one DMP was 
annotated to Rhbdf2 (Figure 6.54; t(61) = 7.66, Δβ = -19.79, FDR = 0.038); no 
DMPs were annotated to Rpl13 or Rhbdf2 in J20 mice. Furthermore, several 
genotype-associated DMPs were annotated to Abr (Table 6.13, Table 6.14, 
Figure 6.55), Clybl (Table 6.15, Table 6.16, Figure 6.56, Figure 6.57), the Hoxa 
region (Table 6.17, Table 6.18, Figure 6.58, Figure 6.59), and a region spanning 
Foxk1-Ap5z1-Radil (Table 6.19, Table 6.20, Figure 6.60, Figure 6.61) in both 
the rTg4510 and J20 model. In the rTg4510 dataset, one DMP was annotated to 
Coq7 (Figure 6.62, t(56) = 6.50, Δβ = -4.13, FDR = 0.041), located 7665 bp from 
the gene. Furthermore, one DMP in each mouse model was annotated to Dip2a 
(Figure 6.63; rTg4510: t(24) = 8.40, Δβ = 6.04, FDR = 0.024; J20: t(12) = 13.27, 
Δβ = 24.97, FDR = 0.0039), and two DMPs in the rTg4510 mice and one DMP in 
J20 mice were annotated to Serpinf2 (Figure 6.64). These results are interesting 
because they highlight potential overlaps in differentially methylated loci between 





Figure 6.48 – Annotated genes for CpG sites shown to be associated with 
Alzheimer's disease pathology reported by Lunnon et al. (2014) and De Jager et al. 
(2014). 
Genes in red were validated by De Jager et al. (2014) as showing differential mRNA 




Table 6.9 – Significant DNA methylation differences at sites annotated to Ank1 in 
rTg4510 samples. 
Δβ corresponds to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr8:22978636 Ank1 t(44) = 7.78 23.86 0.024 45 
chr8:22978666 Ank1 t(44) = 11.04 27.56 0.0055 45 
chr8:23035040 Ank1 t(13) = 9.48 45.06 0.029 14 
chr8:23035042 Ank1 t(13) = 18.40 54.11 0.0032 14 
chr8:23045092 Ank1 t(28) = 9.75 13.96 0.013 29 
chr8:23058852 Ank1 t(56) = 6.18 3.37 0.048 57 
chr8:23143029 Ank1 t(45) = 8.08 19.15 0.020 46 







Figure 6.49 – Eight genotype-associated DMPs were annotated to Ank1 in rTg4510 
mice. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 





Table 6.10 – Significant DNA methylation differences at sites annotated to Ank1 in 
J20 samples. 
Δβ corresponds to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr8:22974676 Ank1 t(13) = 12.20 -7.02 0.013 14 
chr8:23034919 Ank1 t(61) = 9.67 8.82 0.0086 62 
chr8:23116360 Ank1 t(41) = 10.60 -18.17 0.0069 42 
chr8:23123856 Ank1 t(43) = 6.52 15.72 0.043 44 
chr8:23123864 Ank1 t(43) = 9.12 25.54 0.013 44 







Figure 6.50 – Six genotype-associated DMPs were annotated to Ank1 in J20 mice. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 





Table 6.11 – Significant DNA methylation differences at sites annotated to Cdh23 
in rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr10:60321298 Cdh23 t(46) = 7.58 15.54 0.025 47 
chr10:60346482 Cdh23 t(45) = 7.07 14.86 0.033 46 
chr10:60455760 Cdh23 t(54) = 10.84 12.92 0.0053 55 
chr10:60523066 Cdh23 t(16) = 7.83 10.04 0.040 17 
chr10:60634392 Cdh23 t(61) = 11.76 12.99 0.003 62 
chr10:60634564 Cdh23 t(42) = 6.29 21.50 0.049 43 





Figure 6.51 – Seven genotype-associated DMPs were annotated to Cdh23 in 
rTg4510 mice. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 





Table 6.12 – Significant DNA methylation differences at sites annotated to Cdh23 
in J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr10:60303537 Cdh23 t(50) = 7.69 20.90 0.024 51 
chr10:60334144 Cdh23 t(40) = 7.04 -7.14 0.034 41 
chr10:60346528 Cdh23 t(58) = 9.40 -19.40 0.010 59 
chr10:60411179 Cdh23 t(59) = 8.06 12.14 0.019 60 
chr10:60436753 Cdh23 t(61) = 8.44 12.81 0.015 62 
chr10:60495199 Cdh23 t(30) = 16.18 14.02 0.0011 31 
chr10:60495544 Cdh23 t(16) = 7.42 40.83 0.047 17 
chr10:60540255 Cdh23 t(62) = 6.45 9.74 0.041 63 
chr10:60595936 Cdh23 t(21) = 6.96 27.56 0.047 22 
chr10:60596311 Cdh23 t(47) = 6.73 -19.17 0.038 48 
chr10:60638890 Cdh23 t(60) = 7.49 9.24 0.025 61 
chr10:60638910 Cdh23 t(60) = 7.96 9.14 0.019 61 







Figure 6.52 – Thirteen genotype-associated DMPs were annotated to Cdh23 in J20 mice. 
Annotated gene and chromosome positions are indicated in each individual plot. Shown are J20 transgenic (TG, blue) female mice compared to wild type 




Figure 6.53 – One genotype-associated DMP was annotated to Rpl13 in rTg4510 
mice. 
Annotated gene and chromosome position are indicated. Shown are rTg4510 




Figure 6.54 – One genotype-associated DMP was annotated to Rhbdf2 in rTg4510 
mice. 
Annotated gene and chromosome position are indicated. Shown are rTg4510 






Table 6.13 – Significant DNA methylation differences at sites annotated to Abr in 
rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:76508111 Abr t(61) = 7.68 7.47 0.022 62 
chr11:76508178 Abr t(57) = 6.51 11.89 0.040 58 
chr11:76542804 Abr t(61) = 9.50 4.11 0.0092 62 
chr11:76570619 Abr t(61) = 6.43 6.99 0.041 62 
chr11:76577662 Abr t(46) = 6.84 13.56 0.036 47 
chr11:76624326 Abr t(52) = 7.13 16.64 0.030 53 
chr11:76624371 Abr t(52) = 9.14 19.43 0.012 53 
chr11:76639885 Abr t(55) = 7.71 11.66 0.023 56 
 
 
Table 6.14 – Significant DNA methylation differences at sites annotated to Abr in 
J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:76473889 Abr t(19) = 7.97 -14.47 0.034 20 





Figure 6.55 – Eight rTg4510 genotype-associated and two J20 genotype-
associated DMPs were annotated to Abr. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) or J20 TG (red) female mice compared to 




Table 6.15 – Significant DNA methylation differences at sites annotated to Clybl in 
rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr14:122172522 Clybl t(30) = 15.82 35.38 0.0013 31 
chr14:122172566 Clybl t(30) = 19.04 34.30 0.00044 31 
chr14:122257470 Clybl t(52) = 6.22 14.19 0.048 53 
chr14:122307062 Clybl t(50) = 7.47 14.26 0.026 51 
chr14:122406730 Clybl t(57) = 6.77 7.57 0.035 58 
 
 
Table 6.16 – Significant DNA methylation differences at sites annotated to Clybl in 
J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr14:122179634 Clybl t(18) = 8.91 -20.13 0.025 19 
chr14:122181645 Clybl t(59) = 6.38 5.15 0.043 60 
chr14:122200537 Clybl t(62) = 6.82 13.82 0.034 63 
chr14:122222613 Clybl t(62) = 6.66 12.81 0.037 63 
chr14:122222644 Clybl t(61) = 7.23 10.72 0.028 62 
chr14:122222740 Clybl t(62) = 9.91 11.22 0.0076 63 
chr14:122406878 Clybl t(62) = 8.55 5.38 0.015 63 





Figure 6.56 – Five genotype-associated DMPs were annotated to Clybl in rTg4510 
mice. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 





Figure 6.57 – Eight genotype-associated DMPs were annotated to Clybl in J20 
mice. 
Annotated gene and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 




Table 6.17 – Significant DNA methylation differences at sites annotated to the 
Hoxa region in rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr6:52199921 Hoxaas3 t(61) = 7.55 4.01 0.024 62 
chr6:52209539 Hoxaas3 t(61) = 9.76 9.34 0.0082 62 
chr6:52217163 Hoxa7 t(55) = 8.39 -4.08 0.016 56 
chr6:52224435 Hoxa9 t(59) = 6.49 -8.93 0.041 60 
chr6:52225800 Hoxa9 t(12) = 8.87 11.35 0.038 13 
chr6:52226299 Hoxa9 t(38) = 8.24 11.69 0.020 39 
chr6:52244601 Hoxa11os t(50) = 8.26 8.60 0.018 51 
chr6:52252901 Hoxa11os t(51) = 6.47 11.46 0.042 52 
chr6:52259995 Hoxa13 t(55) = 7.14 -4.52 0.030 56 





Table 6.18 – Significant DNA methylation differences at sites annotated to the 
Hoxa region in J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr6:52175647 Hoxaas3 t(61) = 7.04 3.50 0.030 62 
chr6:52176077 Hoxaas3 t(46) = 7.71 6.02 0.024 47 
chr6:52190581 Hoxaas3 t(62) = 7.77 3.65 0.021 63 
chr6:52205277 Hoxaas3 t(52) = 7.25 12.93 0.029 53 
chr6:52208860 Hoxaas3 t(62) = 6.22 -3.02 0.046 63 
chr6:52226257 Hoxa9 t(50) = 7.46 3.94 0.026 51 
chr6:52226267 Hoxa9 t(56) = 8.05 -9.87 0.019 57 
chr6:52233069 Hoxa10 t(62) = 6.61 4.96 0.038 63 
chr6:52244694 Hoxa11os t(62) = 9.61 5.78 0.0089 63 
chr6:52248587 Hoxa11os t(62) = 6.24 -4.28 0.046 63 
chr6:52252821 Hoxa11os t(59) = 6.29 6.83 0.045 60 





Figure 6.58 – Ten genotype-associated DMPs were annotated to the Hoxa region 
in rTg4510 mice. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 




Figure 6.59 – Twelve genotype-associated DMPs were annotated to the Hoxa 
region in J20 mice. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 
controls (WT, black).  
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Table 6.19 – Significant DNA methylation differences at sites annotated to the 
Foxk1-Ap5z1-Radil region in rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr5:142400345 Foxk1 t() = 6.60 6.67 0.038083 62 
chr5:142423143 Foxk1 t() = 7.37 26.19 0.034208 29 
chr5:142474921 Ap5z1 t(49) = 7.06 15.33 0.031942 50 
chr5:142477404 Ap5z1 t(57) = 8.15 -14.17 0.018051 58 
chr5:142485494 Radil t(34) = 9.29 8.92 0.013552 35 
chr5:142546740 Radil t(58) = 6.53 13.67 0.039903 59 
 
 
Table 6.20 – Significant DNA methylation differences at sites annotated to the 
Foxk1-Ap5z1-Radil region in J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr5:142435122 Foxk1 t(50) = 7.25 9.83 0.029 51 
chr5:142435276 Foxk1 t(55) = 7.05 13.49 0.031 56 
chr5:142466639 Ap5z1 t(46) = 11.53 20.52 0.0043 47 
chr5:142474598 Ap5z1 t(41) = 9.23 29.98 0.013 42 
chr5:142506674 Radil t(12) = 8.64 50.53 0.040 13 





Figure 6.60 – Six genotype-associated DMPs were annotated to the Foxk1-Ap5z1-
Radil region in rTg4510 mice. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 





Figure 6.61 – Five genotype-associated DMPs were annotated to the Foxk1-Ap5z1-
Radil region in J20 mice. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are J20 transgenic (TG, red) female mice compared to wild type littermate 





Figure 6.62 – One genotype-associated DMP was annotated to Coq7 in rTg4510 
mice. 
The annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) female mice compared to wild type littermate 




Figure 6.63 – One rTg4510 genotype-associated site and one J20 genotype-
associated differentially methylated site were annotated to Dip2a. 
The annotated gene and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) and J20 TG (red) female mice compared to 





Table 6.21 – Significant DNA methylation differences at sites annotated to Serpinf2 
in rTg4510 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:75431357 Serpinf2 t(57) = 10.74 11.47 0.0054 58 
chr11:75431375 Serpinf2 t(57) = 9.79 9.38 0.0083 58 
 
 
Table 6.22 – Significant DNA methylation differences at sites annotated to Serpinf2 
in J20 samples. 
Δβ corresponds to difference in DNA methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 




Figure 6.64 – Two rTg4510 genotype-associated DMPs and one J20 genotype-
associated DMP were annotated to Serpinf2. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) and J20 TG (red) female mice compared to 




6.3.7. Genotype-associated differentially methylated positions 
included sites annotated to genes nominated from genetic 
studies of AD 
A number of loci implicated in AD from GWAS and subsequent meta-analyses 
(discussed in detail in Section 1.2 in Chapter 1) were found to also harbour 
DMPs in rTg4510 and J20 mice (Table 6.23, Table 6.24, and Figure 6.65). Three 
DMPs in rTg4510 and one DMP in J20 were annotated to Abca7; all 
hypermethylated in TG mice compared to WT, and all located in the gene body. 
DMPs annotated to Clu and Bin1 were detected in the J20 model: from the three 
DMPs annotated to Clu, the two hypomethylated DMPs in TG compare to WT 
were located in the gene body, and the hypermethylated DMP in TG compared 
to WT was located 81 bp downstream of Clu; DMPs annotated to Bin1 showed 
increased methylation in J20 TG compared to WT and were located in the gene 
body. 
 
Table 6.23 – Significant DNA methylation differences at sites annotated to AD-
associated genes from GWAS in rTg4510. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr10:80003740 Abca7 t(48) = 7.86 19.90 0.022 49 
chr10:80013732 Abca7 t(16) =15.39 35.44 0.0041 17 





Table 6.24 – Significant DNA methylation differences at sites annotated to AD-
associated genes from GWAS in J20. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr10:80015045 Abca7 t(59) = 8.73 12.20 0.014 60 
chr14:65975708 Clu t(20) = 7.11 -20.38 0.046 21 
chr14:65981137 Clu t(59) = 6.35 -16.66 0.043 60 
chr14:65981630 Clu t(37) = 7.73 22.03 0.026 38 
chr18:32392554 Bin1 t(40) = 6.80 21.12 0.039 41 
chr18:32392717 Bin1 t(47) = 7.46 18.79 0.027 48 





Figure 6.65 –Genotype-associated DMPs in rTg4510 and J20 ECX annotated to 
genes implicated in AD from GWAS. 
Annotated genes and chromosome positions are indicated in each individual plot. 
Shown are rTg4510 transgenic (TG, blue) and J20 TG (red) female mice compared to 
their respective wild type littermate controls (WT, black).  
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6.3.8. Genotype-associated differentially methylated positions 
included sites annotated to genes differentially expressed in 
TG mice 
I next explored whether DMPs were annotated to top-ranked genotype-
associated DEGs identified in my RNA-seq analysis (Chapter 4, Section 4.3.2 
and Section 4.3.3). In rTg4510 mice, one DMP was annotated to Car4 (located 
about 18 kb upstream of Car4), the most significant rTg4510 genotype-
associated differentially-expressed transcript (Chapter 4, Figure 4.41). This 
DMP was hypermethylated in TG mice compared to WT (Figure 6.66a; t(59) = 
8.23, Δβ = 16.53, FDR = 0.017), and DNA methylation at this site was significantly 
positively correlated with Car4 gene expression (Figure 6.66b; Pearson 
correlation, r = 0.36, P = 0.0059). One DMP was annotated to Blnk (located in 
the gene body), and showed decreased methylation in rTg4510 TG compared to 
WT (Figure 6.67a; t(38) = 7.73, Δβ = -16.11, FDR = 0.025). At this site, there was 




Figure 6.66 – One rTg4510 genotype-associated DMP was annotated to the top 
rTg4510 genotype-associated DEG Car4. 
(a) Differential DNA methylation between rTg4510 WT (black) and TG (blue). (b) 
Significant (α < 0.05) positive correlation between DNA methylation at this site and 





Figure 6.67 – One rTg4510 genotype-associated DMP was annotated to the 
rTg4510 genotype-associated DEG Blnk. 
(a) Differential DNA methylation between rTg4510 WT (black) and TG (blue). (b) 
Correlation between DNA methylation at this site and expression of the Blnk gene. 
 
In the J20 model, DMPs annotated to three of the four genes found to be 
differentially expressed in TG mice (Chapter 4, Section 4.3.3) were identified. 
One DMP was annotated to Ccdc80 (located in the gene body), the most 
significant J20-associated differentially-expressed transcript (Chapter 4, Figure 
4.44). This DMP showed decreased methylation in J20 TG mice compared to WT 
(Figure 6.68a; t(53) = 18.39, Δβ = -31.19, FDR = 0.00024), and was significantly 
negatively correlated with Ccdc80 gene expression (Figure 6.68b; Pearson 
correlation, r = -0.31, P = 0.024). Two DMPs were annotated to Abca8a (Table 
6.25, Figure 6.69a, and Figure 6.69c), both located in the gene body, with no 
significant correlation with gene expression (Figure 6.69b and Figure 6.69d). 
Two DMPs were annotated to Htr1a (Table 6.26, Figure 6.70) – one located 
about 73 kb upstream (chr13:105371119) and one located 199 kb downstream 
(chr13:105647323) of Htr1a – both hypermethylated in TG compared to WT 
(Figure 6.70a and Figure 6.70c), with one site being significantly negatively 
correlated with Htr1a gene expression (Figure 6.70d; Pearson correlation, r = -




Figure 6.68 – One J20 genotype-associated DMP was annotated to the top J20 
genotype-associated DEG Ccdc80. 
(a) Differential DNA methylation between J20 WT (black) and TG (red). (b) Significant 
(α < 0.05) negative correlation between DNA methylation at this site and expression of 




Table 6.25 – Significant DNA methylation differences at sites annotated to Abca8a 
in J20. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr11:110056727 Abca8a t(10) = 12.88 -29.40 0.018 11 
chr11:110078353 Abca8a t(57) = 8.79 -11.90 0.013 58 
 
 
Figure 6.69 – Two J20 genotype-associated DMPs were annotated to the J20 
genotype-associated DEG Abca8a. 
(a, c) Differential DNA methylation between J20 WT (black) and TG (red). (b, d) 




Table 6.26 – Significant DNA methylation differences at sites annotated to Htr1a in 
J20. 
Δβ refers to difference in methylation (%) between TG and WT. 
 
Location Nearest gene t-value Δβ FDR N 
chr13:105371119 Htr1a t(62) = 8.08 5.92 0.018 63 
chr13:105647323 Htr1a t(27) = 6.73 7.44 0.046 28 
 
 
Figure 6.70 – Two J20 genotype-associated DMPs were annotated to the J20 
genotype-associated DEG Htr1a. 
(a, c) Differential DNA methylation between J20 WT (black) and TG (red). (b) No 
significant correlation between DNA methylation at this site and expression of the Htr1a 
gene. (d) Significant (α < 0.05) negative correlation between DNA methylation at this 
site and expression of the Htr1a gene.  
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6.3.9. Common differentially methylated positions and genes 
associated with both rTg4510 and J20 genotype 
Considering sites present in both the final rTg4510 and J20 filtered RRBS 
datasets (see Section 6.2.5.1) (n = 867,012 sites), I explored the presence of 
significant (FDR < 0.05) DMPs associated with genotype in both models, 
identifying 364 overlapping DMPs (Figure 6.71), annotated to 342 genes. GO 
analysis using Enrichr identified disruption of biological processes (Figure 6.72 
and Supplementary Table 24) and molecular processes (Figure 6.73 and 
Supplementary Table 25) including several relevant pathways related with 
ornithine transport, nervous system development, and lipid signalling (e.g. 
phosphatidylinositol). In parallel, from the DMPs identified associated with either 
the rTg4510 or J20 genotype, I explored common annotations and identified 5007 
genes annotated to sites differentially methylated in both mouse models (Figure 
6.74). Functional biological terms (Figure 6.75 and Supplementary Table 26) 
and molecular function terms (Figure 6.76 and Supplementary Table 27) from 
GO analysis using Enrich suggested disruption of axonal processes (e.g. axonal 







Figure 6.71 – Common sites differentially methylated associated with both rT4510 
and J20 genotype. 







Figure 6.72 – Functional biological terms for annotated genes from common DMPs associated with genotype in both rTg4510 and J20 mouse 
models. 
Gene ontology analysis performed using Enrichr. 
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Figure 6.73 – Molecular function terms for annotated genes from common DMPs associated with genotype in both rTg4510 and J20 mouse models. 
Gene ontology analysis performed using Enrichr. 
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Figure 6.74 – Common annotated genes associated with both rTg4510 and J20 
genotype. 








Figure 6.75 – Functional biological terms for common annotated genes associated with genotype in both rTg4510 and J20 mouse models. 
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Figure 6.76 – Molecular function terms for common annotated genes associated with genotype in both rTg4510 and J20 mouse models. 
Gene ontology analysis performed using Enrichr. 
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6.4.1 Overview of results 
In this chapter I have described the first sequencing-based analysis of genome-
wide changes in DNA methylation in mouse models of AD pathology. I identified 
widespread DNA methylation differences in the entorhinal cortex from TG mice 
compared to WT, in both mouse models. These were more dramatic in the 
rTg4510 model, following a common theme in all my results – from 
neuropathology (Chapter 3), to gene expression (Chapter 4), and global DNA 
methylation (Chapter 5). In both rTg4510 and J20 models, the majority of DMPs 
were hypermethylated in TG compared to WT mice. Although this might appear 
to contrast with my finding of progressive global hypomethylation identified in the 
hippocampus of rTg4510 and J20 TG mice using immunohistochemistry 
(Chapter 5), this potentially reflects distinct changes in different brain regions. 
Also, the use of immunohistochemistry does not enable the analysis of DNA 
methylation at specific sites, and it captures variation by regions not assessed by 
RRBS (e.g. in intergenic regions covering most of the genome); while RRBS 
assesses mostly promoters, my immunohistochemistry results capture global 
shifts across all genomic regions. It also reflects results from studies of other 
complex disorders known to involve epigenetic dysfunction. Cancer, for example, 
is characterised by global DNA hypomethylation in conjunction with 
hypermethylation of specific sites (such as promoters of tumour suppressor 
genes and homeobox genes) (Ehrlich, 2009). As discussed in detail in the 
previous sections, the list of TG-associated DMPs overlapped with regions 
nominated from human AD EWAS and genetic studies, and also with genes 
identified in my gene expression RNA-seq study (Chapter 4). 
The observation of hypomethylation in J20 TG mice compared to WT in the gene 
body of Tmprss7 – that encodes for the protease matriptase 3 (see Section 6.3.4 
for details) – might be a response to the accumulating Aβ in this mouse model. 
Matriptase 3 has 31% amino acid identity with matriptase, a protein that has been 
shown to interact with and cleave APP, reducing its proteolytic cleavage to Aβ 
(Lanchec et al., 2017). Complex proteolytic pathways responsible for the 
generation and clearance of the abnormally folded protein fragments 
characteristic of AD (i.e., Aβ and tau) have been widely described (De Strooper, 
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2010); however, despite the recognition that other classes of proteases besides 
secretases can cleave APP, their roles in AD are yet to be fully understood. 
Furthermore, proteases produced by neurons, microglia, and astrocytes, and 
involved in the proteolysis of Aβ, have been shown to be active players in the 
neuroinflammatory processes observed in AD (Newcombe et al., 2018). For 
those reasons, the investigation of a possible role for matriptase 3 in Aβ 
processing would be an important follow-up for this study, particularly in parallel 
with the amyloid-associated increase in expression of the microglia-associated 
genes (i.e. neuroinflammatory) observed in J20 TG mice (Chapter 4). 
The top DMP in the rTg4510 mouse model was located about 8kb upstream of 
the gene encoding the metabolic enzyme UGT2B37 (see Section 6.3.4 for 
details); this site was hypermethylated in TG mice compared to WT. Growing 
evidence from the last decades support a link between central and peripheral 
metabolic dysfunction and AD, and drugs that modulate cell metabolism are 
currently being investigated for the treatment of AD (Clarke et al., 2018). 
Furthermore, a connection between AD and type 2 diabetes and obesity has been 
extensively described in recent years (Shalev and Arbuckle, 2017), with chronic 
inflammation, oxidative stress, reduced neuronal sensitivity to insulin, as well as 
impaired glucose uptake observed in this context (Clarke et al., 2018). The 
potential change in the regulation of Ugt2b37 at the gene expression and protein 
levels as a result of the observed hypermethylated site may indicate a role for 
UGT2B37 in response to accumulation of tau and should be further investigated 
in the context of metabolic dysregulation. Interestingly, the transport of ornithine, 
a naturally occurring non-proteinogenic amino acid involved in the urea cycle, 
was the top functional biological term enriched amongst DMPs commonly 
identified in both mouse models (Section 6.3.9). Amino acids such as ornithine 
are involved in many crucial metabolic and signalling pathways in the cell; 
additionally, ornithine levels have been shown to be decreased in human AD 
brains, cerebrospinal fluid (CSF), and plasma (Griffin and Bradshaw, 2017, 
Fonteh et al., 2007, Shetty et al., 1996). Therefore, and given the limited literature 
available at this time, the study of the effects of altered amino acid metabolism in 
the context of AD is an area that requires additional research, particularly as it 
has been hypothesised as a potential compensatory response to the decreased 






At this stage, I focused solely on genotype effects as I did not consider my study 
to be adequately powered to look at progressive changes in DNA methylation at 
individual CpG sites using the same statistical model (𝑦 =  𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 +  𝐴𝑔𝑒 +
 𝐺𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ∗ 𝐴𝑔𝑒) employed in the other chapters. In contrast to gene expression, 
the evaluation of DNA methylation is much more complex: 1) more than one 
methylation site can be associated to the same gene, i.e., DNA methylation may 
operate over broader regions, which means that looking at individual sites only 
might not be appropriate; 2) the presence of DNA methylation in different genomic 
contexts (transcriptional start sites, in gene bodies, at regulatory elements and at 
repeated sequences) can have very different relationships with gene regulation 
(Jones, 2012) (e.g. the presence of DNA methylation on gene regulatory 
sequences, such as promoters or enhancers, typically represses expression (Dor 
and Cedar, 2018), whilst the presence of DNA methylation in the gene body often 
promotes gene expression (Jones, 2012)); 3) sites are usually annotated to 
genes considering the distance between them, which can be quite arbitrary as 
their relationship is still not fully understood. For all these reasons, analysis 
packages (preferentially specific for RRBS data) that take this into account are 
more suitable than a ‘simple’ straightforward statistical analysis, which will be 
investigated in detail for the next steps of the statistical analysis (Section 6.4.3). 
Other analysis-related limitations to consider are associated with how RRBS 
works (where only CpG-rich regions of the genome are sequenced), as well as 
the filtering that we have performed – not every site of every sample has 
methylation data, with some sites only having measures in a few samples. Given 
the high number of significant DMPs and respective annotated genes identified 
in both mouse models, it is possible that the FDR threshold used might not be 
stringent enough to accurately exclude false positives; although this issue has 
been explored in detail during the last decade for genome-wide studies in human 
(Fadista et al., 2016), it has not been done for genome-wide studies in mice yet. 
All these aspects need to be (re)considered for future analyses. As in our gene 
expression RNA-seq experiments, we have used bulk tissue for RRBS DNA 
methylation assessments, and DNA methylation changes can be cell-specific. 
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Future work should address these issues by profiling additional samples at 
enhanced depth in purified cell populations. 
 
6.4.3. Future directions 
Despite the acknowledged limitations of these data, our preliminary results seem 
promising. In the next year, I will focus on developing novel computational 
methods to assess progressive DNA methylation changes in rTg4510 and J20 
mouse models, as well as integrate these changes with gene expression changes 
(Chapter 4) and neuropathology data (Chapter 3) from the same individual mice 
(Figure 6.77). A few approaches have been described by others (Wreczycka et 
al., 2017, Yong et al., 2016), with a couple of methods showing encouraging 
strategies for systematic multi-omic data integration (Chen et al., 2018, Hansen 





Figure 6.77 – Computational pipeline for genome-wide bisulfite sequencing data 
analysis. 
Reads from bisulfite sequencing are first aligned to the reference genome. The 
alignment data may be visualised in different tracks for comparison. After methylation 
calling, the bulk methylation level and genome-wide methylation level can be calculated 
and plotted, and differentially methylated regions (DMRs) can be determined. DNA 
methylation data can be integrated with gene expression data (differentially expressed 
genes, DEGs) to delineate the regulatory role of DNA methylation. Figure and legend 





Chapter 7.  General discussion 
7.1. Summary of results 
In this PhD I have directly assessed transcriptomic and epigenomic variation 
associated with the progression of AD neuropathology in the mouse brain. I used 
cutting-edge genome-scale approaches to assess tissue dissected from two well 
validated transgenic mouse models – the rTg4510 line (to investigate genomic 
signatures of tau pathology) (Ramsden et al., 2005, Santacruz et al., 2005) and 
the J20 line (to investigate genomic signatures of amyloid pathology) (Mucke et 
al., 2000, Palop et al., 2007) – and related the identified genomic changes to 
histopathology information from the same mice. 
 
In Chapter 2 I outline the general methods common across the individual data 
chapters (Chapters 4-6) including all animal procedures, sample processing, and 
optimisation procedures for nucleic acid isolation and associated quality control. 
The experimental procedures specific to each individual chapter are described in 
detail in the methods sections of the corresponding chapter.  
In Chapter 3 I describe the progression of tau pathology in rTg4510 mice and of 
amyloid pathology in J20 mice, quantified using immunohistochemistry across 
multiple regions of the mouse brain. 
In Chapter 4 I describe an analysis of transcriptional variation in the entorhinal 
cortex associated with the development of both tau and amyloid pathology in 
rTg4510 and J20 mice, respectively. Using systems-level network analyses, I 
identified gene co-expression clusters of genes (or modules), related these to 
neuropathological burden from the same mice, and explored transcriptomic 
changes identified in the mouse models in datasets from human AD brains. 
In Chapter 5 I describe global changes in levels of two DNA modifications (5mC 
and 5mC) across multiple brain regions from tissue sections from rTg4510 and 
J20 mice using immunohistochemistry.  
Finally, in Chapter 6 I describe the quantification of genome-wide patterns of 
DNA methylation at single-base resolution in the entorhinal cortex from rTg4510 




Taking a global view of my results, a common theme is revealed across all the 
data modalities assessed (neuropathology (Chapter 3), gene expression 
(Chapter 4), global DNA modifications (Chapter 5), and genome-wide DNA 
methylation (Chapter 6)); I identified consistently larger changes in the rTg4510 
samples compared to samples from the J20 model. This potentially reflects the 
slower and later accumulation of pathology in J20 compared to rTg4510 mice 
(described in detail in Section 1.5.1.1 and Section 1.5.1.2 of Chapter 1 and 
discussed in Section 4.3.5 of Chapter 4). Moreover, these findings were 
expected to a certain degree given the potential absence of neuronal cell loss 
(particularly in the entorhinal cortex) in J20 mice (Wright et al., 2013), in contrast 
widely present in rTg4510 mice (Blackmore et al., 2017, Booth et al., 2016, 
Ramsden et al., 2005, Santacruz et al., 2005). 
My findings of altered gene expression in rTg4510 and J20 mice suggest 
upregulation of immune system genes with progressive AD pathology. In 
particular, I observed a common increase in expression of microglial genes – i.e. 
Cst7 and Itgax (Cd11c) (see Chapter 4, Section 4.3.5) – associated with both 
tau and amyloid pathology. The functional role of microglia in AD is not yet fully 
understood, with both detrimental and beneficial effects resulting from microglia 
activation reported (Hansen et al., 2018). Currently the most accepted hypothesis 
is that beneficial consequences of microglial activity are important in the early 
stages of disease, whilst detrimental effects may take over in later stages. 
Microglia can engulf and remove abnormal neurons and synapses, likely via a 
complement-dependent mechanism; they can also exacerbate tau pathology and 
secrete inflammatory factors that can injure neurons directly or via activation of 
neurotoxic astrocytes (Hansen et al., 2018). Interestingly, the extracellular 
amyloid deposits typical of AD, mainly composed of aggregated Aβ, have been 
shown to be surrounded by activated microglia that express activation markers 
and pro-inflammatory proteins (Kamphuis et al., 2016). The inflammatory 
environment created by activated microglia has been suggested to increase Aβ 
production; however, there is also evidence showing that microglia-mediated 
inflammation reduces amyloid plaque deposition via upregulation of phagocytic 
and degradation pathways (Zuroff et al., 2017). The increased amounts of soluble 
and insoluble Aβ observed in human AD are hypothesised to result from an 
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imbalance between Aβ production and clearance (Mawuenyega et al., 2010). 
Whilst the literature indicates that the rare forms of EOAD caused by genetic 
alterations involve an increase in the production of Aβ, increased Aβ in sporadic 
LOAD has been suggested to be due to impairments in its clearance (Baranello 
et al., 2015, Mawuenyega et al., 2010, Ries and Sastre, 2016). Although the 
mechanisms involved in impaired clearance of Aβ in AD are believed to occur 
through interactions with ApoE4, decreased catabolism of Aβ via reduced 
proteolytic enzymes, impaired transport across the blood-brain barrier and 
impaired CSF transport (Mawuenyega et al., 2010), growing evidence supports 
a key role of microglia and monocyte-derived macrophages in this process 
(Mawuenyega et al., 2010, Zuroff et al., 2017). The accumulation of misfolded Aβ 
as a result of an imbalance between its production and removal may in turn 
stimulate synaptic and neuronal loss, as well as neuroinflammation (Zuroff et al., 
2017). In fact, in addition to neuroinflammation, a large proportion of the risk 
genes for LOAD are associated with Aβ processing or trafficking, and with 
immunological processes related to myeloid cell-mediated Aβ clearance (Zuroff 
et al., 2017). For example, polymorphisms in the genes CD33 and TREM2, 
shown to increase susceptibility to AD (Chapter 1, Section 1.2), have been 
associated with impairments in microglial- and macrophage-mediated 
phagocytosis of Aβ. Nevertheless, the question of whether the inflammation and 
myeloid cell disruption observed in AD are drivers for the disease or are a 
consequence of the neuropathology remains unanswered. Interestingly, the 
expression of many of these genes (e.g. Cd33 and Trem2) was disrupted in my 
rTg4510 dataset, as a result of tau accumulation, which I did not observe in the 
J20 mice potentially due to the reasons stated elsewhere (Chapter 4, Section 
4.3.5). 
Together, my results suggest common pathways and mechanisms of response 
to the presence of tau and amyloid pathology. With the dramatic increase in 
cerebral Aβ beginning as early as twenty years prior to symptom manifestation 
(Zuroff et al., 2017), and the currently most accepted hypothesis stating tau 
pathology as downstream of amyloid (Selkoe and Hardy, 2016), targeting Aβ 
(aiming to reduce its levels) by promoting its clearance, for example, is a potential 
strategy for the treatment of AD. Currently, the study of the role(s) of microglia in 
AD is a hot topic within the scientific community, with a plethora of recent studies 
looking at sorted microglia or even single cells / nuclei; studies in the upcoming 
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years should clarify the role of these neural cells in Aβ and tau processing and 
clearance, as well as in overall AD toxicity. Building on the results of my thesis, it 
will be important to integrate the various layers of genomic regulation (e.g. DNA 
methylation and gene expression, as well as histone modifications), and protein 
levels, particularly in sorted microglia and this will be the focus of my ongoing 
research. 
Another (potentially related) reason for insufficient clearance, and consequential 
accumulation and spread of oligomeric forms of neurotoxic proteins in AD, is 
related to the deficient extracellular clearance by proteases (Boland et al., 2018). 
Curiously, I observed hypomethylation in a region annotated to the gene that 
encodes the protease TMPRSS7 (or matriptase 3) in J20 TG compared to WT 
(see Chapter 6, Section 6.3.4 and Section 6.4.1). It is important to perform 
functional follow-up studies (e.g. using cell culture approaches and/or knockout 
mouse models) aiming at exploring the role of matriptase 3 in Aβ processing. 
Additionally, the incorporation of CRISPR/Cas9 gene editing technology in these 
studies could be an interesting approach to take this further, with novel 
applications of this technology enabling the induction of epigenetic changes to 
facilitate the assessment of DNA methylation differences in this context (Liu et 
al., 2016, Liu et al., 2018). 
 
7.2. Limitations 
This study has a number of important limitations that should be considered when 
interpreting the results described in each of the data chapters. 
First, to minimise the heterogeneity in my analysis, I only profiled female mice. 
However, a number of sex differences have been previously reported for these 
models, with females demonstrating elevated and more progressive pathology 
than males (Blackmore et al., 2017, Yue et al., 2011). Future work should focus 
on examining the extent to which the genomic changes identified in my work are 
consistent between male and female mice. 
Second, my analysis was performed on bulk brain tissue, comprising a mix of 
different neural cell-types. Future work should focus on identifying changes 
specific to the different brain cell-types. Our laboratory, for example, has been 
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developing methods to purify nuclei from neurons and oligodendrocytes using the 
nuclear markers NeuN and Sox10, respectively, in conjunction with fluorescence-
activated nuclei sorting (FANS) (Jeffries and Mill, 2017).  
Third, compared to the rTg4510 model, relatively few changes were observed in 
J20 mice, potentially reflecting the slower and later accumulation of pathology 
(Harris et al., 2010), as well as the potential absence of neurodegeneration, in 
the entorhinal cortex in this model; future work looking at changes at the genomic 
level should focus on the additional analysis of other brain regions more directly 
affected in the early stages of amyloid pathology in J20 mice.  
Fourth, I cannot exclude the possibility that my analysis did not cover an 
appropriate aging interval in order to being able to identify such changes; future 
work covering a more expanded aging interval, with samples collected from 
earlier and later time points, should be considered. In particular, an earlier 
baseline sample would enable a more accurate temporal assessment of genomic 
changes across the life course to be determined. 
Finally, my PhD project only used two mouse models, and as discussed in 
Chapter 1 (Section 1.5.1) other models of AD pathology are currently available. 
In order to validate my findings, future work should include other mouse models 
of tau or amyloid pathology, as well as models with characterised by both types 
of AD-associated neuropathology. In addition, it will be important to profile 
samples from knock-in mouse models, which are characterised by the 





7.3. Current challenges and future directions 
Although studies of gene regulation in AD have demonstrated promising findings, 
more studies, particularly at the genome-wide level, are still required. There are 
however a number of challenges and caveats associated with performing such 
studies, and these need to be adequately addressed to allow the identification of 
novel genes, neurobiological pathways and pharmacological targets in AD. 
 
7.3.1. Limitations on the use of AD animal models 
A key issue with studying genomic variation in diseases of inaccessible tissues, 
such as the brain, is that human studies are restricted to post-mortem samples, 
which usually represent end-stage disease and so it is difficult to establish 
causality. Although murine models have utility for understanding disease 
progression, as discussed earlier (see Section 1.5), these also have their own 
caveats for studying a disease such as AD. For example, mouse models do not 
‘naturally’ develop Aβ plaques, nor do they normally display overt 
neurodegeneration. In addition, the transgenic models described to date (see 
Section 1.5.1) are based on mutations identified in FAD and are not therefore 
really accurate models of SAD, which has both polygenic and environmental 
contributions to disease aetiology (Alzheimer's-Association, 2018, Selkoe, 2011) 
(see Section 1.2 and Section 1.4 in Chapter 1). 
 
7.3.2. Cellular heterogeneity in the brain 
Different tissues and cell types exhibit unique transcriptomic and epigenetic 
profiles, and therefore discriminating between disease-specific changes in 
cellular composition in heterogeneous tissues can be quite challenging. As 
discussed previously (Chapter 1, Section 1.1), some regions of the brain are 
more affected than others by AD neuropathology, with specific genomic changes 
reported in distinct brain regions and for specific cell types (see Section 1.3, 
Section 1.4, and Section 1.5.2). In addition, AD is characterised by progressive 
changes in brain cell composition, including neuronal loss due to 
neurodegeneration, an increased number of activated microglia (microgliosis), 
and the abnormal hypertrophy of astrocytes (reactive astrogliosis), which is 
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particularly true in brain regions highly susceptible to neuropathology such as the 
hippocampus and entorhinal cortex (see Chapter 1, Section 1.1). The vast 
majority of AD genomic studies, including the studies performed for this thesis, 
have used ‘bulk’ brain tissue; therefore, it becomes difficult to draw conclusions 
about cell-specific AD-associated genomic changes. Furthermore, it is plausible 
that some important disease associated genomic variation is missed if genomic 
changes in one cell type might be masked by opposing changes in a different cell 
type. The optimal analysis approach would use single cell profiling to investigate 
epigenomic and transcriptomic changes in individual cells; however, the costs 
associated with performing such experiments with adequate power to detect 
disease-associated differences are still prohibitive. Nonetheless, studies utilising 
methods aimed at isolating specific cell populations, utilising LCM, FACS, 




7.3.3. Beyond DNA methylation: incorporating other epigenetic 
modifications 
An issue with current DNA methylation studies, including the published EWAS 
analyses of human AD and my RRBS analysis presented in this thesis (Chapter 
6), is that they have utilised sodium bisulfite conversion to enable quantification 
of DNA methylation across the genome. This method converts unmodified 
cytosines to uracil (explained in detail in Chapter 6, Section 6.1), whilst both 5-
methylcytosines (DNA methylation) and 5-hydroxymethylcytosines (DNA 
hydroxymethylation; see Chapter 1, Section 1.4.1 for details) are protected from 
the conversion; the presence of a DNA modification can be then determined in 
downstream analyses as a difference in the sequence between modified [C] and 
unmodified [T] DNA. In this way, these approaches cannot differentiate between 
DNA methylation and hydroxymethylation; given the relatively high abundance of 
5hmC in the brain this may represent a major confounder in current analyses. A 
recent adaptation to the bisulfite conversion protocol, where the DNA is oxidised 
prior to bisulfite treatment, converts 5hmC to 5-formylcytosine (5fC) (which is 
converted to uracil), meaning that data generated from oxidative bisulfite treated 
DNA gives a measure of ‘true’ DNA methylation (5mC). Furthermore, by running 
bisulfite and oxidative bisulfite treatment in parallel one can calculate 5hmC levels 
through the subtraction of 5mC from total modifications. In conjunction with array- 
or sequencing- based assays this allows for the evaluation of 5mC and 5hmC in 
a genome-wide fashion (Lunnon et al., 2016, Zhao et al., 2017). Although this 
method has not yet been applied to studies in AD, future analyses of DNA 
modifications in human and mouse brain tissue should employ these novel 
approaches. Other epigenetic processes other than DNA modifications, such as 
histone modifications, should also be profiled in future work; for example, 
H3K27ac – a robust mark of active enhancers/promoters (Creyghton et al., 2010, 
Wang et al., 2008) that is strongly correlated with gene expression and 
transcription factor binding (Kumar et al., 2013) has been shown to be 




7.3.4. Sequencing-based approaches as the way forward 
Many of the existing genomic studies of AD pathology have utilised microarray-
based technologies, particularly in transcriptomic studies (discussed in Section 
1.3 and Section 1.5.2 of Chapter 1). Although microarrays are a cost-effective 
method for analysing the transcriptome and epigenome, especially when profiling 
large numbers of samples, their content is relatively constrained, and they only 
cover a small proportion of known transcripts (or DNA modification sites). As 
such, pathology-associated genomic variation in other regions in the genome will 
not be detected. Sequencing-based technologies are likely to offer a more optimal 
approach for uncovering AD-associated genomic variation. For example, RNA 
sequencing (RNA-seq), the approach that I used to evaluate transcriptomic 
changes in this thesis (Chapter 4), enables the quantification of all expressed 
transcripts, without the limitations/assumptions associated with pre-designed 
arrays (Sahraeian et al., 2017). Likewise, whole genome bisulfite sequencing 
(WGBS-Seq), allows the identification of DNA methylation changes at single 
nucleotide resolution across the entire genome, including at non-CpG sites (Yong 
et al., 2016); however, the depth of sequencing required to accurately profile DNA 
methylation using this approach is still associated with prohibitively high costs to 
enable a large number of samples to be profiled (Ziller et al., 2015). In this study 
I used RRBS as a compromise approach to enable the cost-effective profiling of 
DNA methylation at single base resolution (Gu et al., 2011, Meissner et al., 2005) 
(Chapter 6). Looking to the future, third generation (or long-read) sequencing 
technologies, currently under active development, will enable the simultaneous 
identification of both genetic and epigenetic variation in the same sample (Hirst 
and Marra, 2010). 
 
7.3.5. The ‘big data’ era 
Our understanding of the role of altered gene regulation in AD pathology has 
expanded considerably in the last few years; novel technological advances and 
the reduction in the cost of genomic sequencing mean that even bigger datasets 
are likely to be on the horizon. The increase in “multi-omics” analyses, including 
the integration of different data types using network analyses will require 
extensive collaboration between multidisciplinary teams and the development of 
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novel analytical strategies. We are currently in the ‘big data’ era; where large 
‘omics’ data-sets with extensive clinical and demographic information have been 
amassed, which offers extraordinary possibilities to better understand AD 
aetiology. Although these studies are still in their infancy, the integration of 
genetic, epigenetic, transcriptomic, proteomic and clinical data, from the same 
individuals will enable a fully comprehensive analysis of dysfunctional 
mechanisms and pathways involved in AD. Further, by comparing similar data-
sets generated in mouse models to the human AD data-sets a more 
comprehensive analyses of disease mechanisms will be achievable. Mouse 
models will continue to be important as they overcome a number of caveats 
associated with studying human samples; the integration of human and mouse 
genomic data will allow the temporal/spatial analysis of disease loci and ultimately 
nominate novel targets for therapeutic intervention. A handful of recent papers 
have pioneered this approach, exploring findings from AD mouse models in 
human data (Gjoneska et al., 2015, Wang et al., 2017). 
 
7.3.6. Beyond AD 
It should be noted that many other diseases besides AD are characterised by the 
symptoms and pathology associated with dementia. Other forms of dementia 
include VaD, DLB, HD, PD dementia (PDD) and FTD. Although the field has 
mainly focused on AD, translational genomic studies in other dementias are also 
needed especially given the likely aetiological overlap between them. Moreover, 
most studies have focused on regions in the temporal lobe (particularly the 
hippocampus) and the frontal lobe (mostly the prefrontal cortex), and studies 
assessing other brain regions will also be important. Ultimately, if these cross-
region analyses were performed in the same individuals, it would allow the 




7.4. Future research directions 
The results presented in this PhD represent the foundation for a broader and 
larger follow-up study – recently funded by Alzheimer’s Research UK (ARUK) – 
in which we will expand the diversity of mouse models to be profiled. In addition 
to profiling gene expression and DNA methylation, we will include long read 
sequencing (to assess gene isoforms and splicing), other DNA modifications (i.e. 
DNA hydroxymethylation), as well as histone modifications (e.g. H3K27ac). As in 
this study, genomic profiling data (RNA-seq, DNA modifications and histone 
modifications) will be integrated with histopathological, biochemical and 
neurophysiological phenotypes across multiple brain regions through a systems-
level network analysis. Additionally, we will tackle some of the challenges 
described in the previous sections; for example, we will purify specific neural cell 
types to test the cellular specificity of pathology-associated genomic changes. 
Importantly, epigenetic and transcriptional modifications represent potential novel 
therapeutic targets, particularly considering that many are dynamic, modifiable 
and potentially reversible. Compounds that can target these modifications might 
potentially help reverse abnormal gene expression typical of disease. Given that 
there are currently no therapeutics in AD that can reverse, or slow, the 
development of pathology, the possibility of specifically targeting epigenetic 
modifications to treat AD is very promising. Together with our collaborators at Eli 
Lilly, our ultimate goal is the identification of pathways involved in AD-associated 
neuropathology that can be potential targets for treatment and we will undertake 





In conclusion, the work presented in my thesis represents a comprehensive study 
of neuropathology, transcriptomic changes and alterations to DNA modifications 
in two mouse models of AD pathology. My data represent an important 
contribution to the field of Alzheimer’s disease research. First, my neuropathology 
findings corroborate the extensive characterisation of tau pathology in the 
rTg4510 mouse model, and amyloid pathology in the J20 mouse model. Second, 
my transcriptomic data highlight widespread changes in gene expression 
paralleling the development of AD-associated neuropathology, particularly tau 
pathology in rTg4510 mice, and confirm alterations observed in other models of 
pathology. Additionally, these data provide further support for an immune-
response component in the progression of AD-associated accumulation, 
particularly of tau pathology, in addition to nominating novel molecular pathways 
associated with the progression of AD neuropathology. Finally, my DNA 
methylation data, representing the first analysis of genome-wide changes in DNA 
methylation in any mouse model of AD pathology, highlights changes in regions 
of the genome annotated to genes nominated from human AD EWAS and genetic 
studies, as well as genes identified in my gene expression study. This data 
provides an excellent foundation for follow-up investigations of genomic 
regulation involved in the progression of AD, which I am highly motivated to 






Raw RNA-seq data has been deposited in GEO under accession number 
GSE125957. 
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